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An increase in degenerative bone d isease in an ageing population, combined with 3 
a rise in the number of patients suffering from bone defects caused  by physical 4 
trauma, makes the repair of bone an issue of growing clinical relevance. Current 5 
treatments such as autografts and  allografts have major drawbacks, including 6 
donor site morbid ity, limited  availability, disease transmission and immune 7 
rejection. To overcome these issues synthetic bone grafts have been developed to 8 
mimic the mineral phase of bone. Given the significant roles of silicon in bone 9 
growth and development there has been great interest in introducing silicon into 10 
synthetic bone grafts to enhance their bioactivity. Calcium phosphate based 11 
silicate containing grafts have demonstrated  enhanced bioactivity, improved 12 
physical properties, enhanced protein adsorption and greater bone formation, 13 
when compared  to non-silicated  calcium phosphates such as hydroxyapatite. 14 
However, is not clear whether the increased  bone formation associated  with these 15 
materials is the result of greater osteoblast activity or a rise in numbers of 16 
osteoblasts resulting from activation and d ifferentiation of stem/ progenitor cells.  17 
To answer this question, multipotent stem cells were cultured  on silicate 18 
substituted  calcium phosphate (Si-CaP) and hydroxyapatite (HA). Si-CaP 19 
promoted  greater cell adhesion and enhanced proliferation when compared  to 20 
HA.  Cells differentiated  along the osteogenic lineage on both substrates as 21 
evidenced by up regulation of osteoblast specific genes and proteins. However, 22 
cells on Si-CaP showed earlier and  greater gene expression of all osteoblast genes 23 
examined, and  greater protein p roduction as detected  by immunohistochemistry.  24 
Integrin gene expression analysis revealed  up regulation of α and β subunits on 25 
both substrates during differentiation. Integrins α5 and β1 expression were greater 26 
on Si-CaP than on HA, suggesting preferentia l binding of fibronectin. The 27 
implication of these findings for tissue engineering is clear, suggesting these 28 
substrates may be utilized  to control stem cell fate in vivo and  in vitro without the 29 
need for osteogenic supplementation. Furthermore, the increa sed  rate of 30 
differentiation seen on Si-CaP may enable the development of novel substrates for 31 
osteogenic d ifferentiation of MSC, which may have significant impact in 32 
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CHAPTER ONE: GENERAL INTRODUCTION 2 
 3 
1.1 Regenerative medicine 4 
 5 
As a consequence of ageing in the overall population, the number of people 6 
with degenerative d iseases has increased  significantly  (Karen A Hing et al. 7 
2001; Anon n.d .) with d isease and  injury of the skeletal system becom ing a 8 
relevant and  demanding biomedical issue. The regeneration of damaged 9 
skeletal tissues is therefore a major challenge in the field  of regenerative 10 
medicine.  11 
Defined  as a ―therapeutic intervention which replaces or regene rates cells, 12 
tissues or organs, to restore or establish normal function‖ (Ducheyne & Qiu 13 
1999; Mason 2007) regenerative medicine is not one d iscipline alone, but 14 
instead  covers a number of fields or strategies.  Merging aspects of 15 
engineering and  biology, the goal of regenerative medicine is to encompass 16 
the use of biomaterials, growth factors, and  stem cells to restore function t o 17 
failing organs.  18 
Currently, many aspects of medicine are not truly ―regenerative‖, instead  19 
they offer repair of damaged tissue or organs through surgery, surgical 20 
implantation of artificial tissue, replacement of the organ function e.g. 21 
insulin injections in d iabetes or d ialysis in kidney failure, or replacement of 22 
the damaged organs themselves through transplantation. These strategies 23 
though are far from ideal.  For example, organ transplantation often 24 
involves immunosuppressant drugs, and  artificial metal hips can induce 25 
inflammation in addition to becoming loose. Furthermore the demand for 26 
organs required  for transplantation continues to outstrip  supply  (Fujita et 27 
al. 2003; NHS 2012a; Florence Barrère 2006). One method to replace the 28 
need  for transplanted organs is to utilise biomaterials either to prevent 29 
further damage or, in combination with cells, to replace organs entirely 30 
(Habraken et al. 2007; Barrère et al. 2008). 31 
Biomaterial scaffolds are being developed to provide mechanical support, 32 
serve as cell carriers, and  also to actively influence cellular responses such 33 
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 2 
as cell attachment, proliferation and d ifferentiation. Chemical 1 
modifications can be used  to enhance the physical and  biological properties 2 
of biomaterials (Nair et al. 2008; Zippel et al. 2010; Pietak & Sayer 2006; 3 
Fujita et al. 2003; Langstaff et al. 2001). Through the use of such 4 
biomaterials, it is hoped that damaged or d iseased  organs could  be restored 5 
and  allow the tissue to return to normal function. 6 
 7 
1.2 Normal tissue homeostasis 8 
 9 
Multiple cellular processes, including cellular proliferation, d ifferentiation 10 
and  death, maintain healthy tissue function  in a process known as tissue 11 
homeostasis.  12 
One of the most important means of tissue homeostasis is the on going 13 
removal and  replacement of certain d ifferentiated  cells. This is described  as 14 
cell turnover and  is composed  of three key stages:- 15 
1. selected  d ifferentiated  cells are continually eliminated ,  16 
2. adult stem cells or their daughter cells d ivide to replace the eliminated  17 
cells,  18 
3. the new cells become functionally integrated  with the tissue 19 
(Ramaswamy et al. 2008; Robbins & Cotran 1974; Tamai et al. 2007). 20 
 21 
1.2.1 Bone homeostasis 22 
 23 
Bone is a perfect example of a tissue that appears to be homeostatic, yet  it is 24 
actually highly dynamic. In a process known as remodelling, bone is 25 
constantly resorbed  and  renewed in response to a variety of physical and  26 
chemical factors (Ponader et al. 2008; Wolff 1870; Atilgan et al. 2007). 27 
This dynamic process occurs throughout the many d ifferent types of bone, 28 
and  is coordinated  by osteoclasts (cells that destroy bone) and  osteoblasts 29 
(cells that form bone) as well as osteocytes within the bone matrix. This 30 





Figure 1: Illustration depicting bone remodelling. 3 
Osteoclast and osteoblast differentiation from precursor cells, bone resorption and bone 4 
formation over time. RANKL - Receptor activator of nuclear factor B ligand, OPG – 5 
osteeoprotegerin, RUNX2 - runt related transcription factor 2, OSX - osterix, COL1A1 - 6 
collagen type I, BGLAP - osteocalcin, ALP - alkaline phosphatase, DMP-1 - dentin matrix 7 
protein 1. Hand drawn image, annotated in Microsoft PowerPoint 2007. 8 
 9 
During bone remodelling the activity of these cell types are  matched , so 10 
that the amount of bone removed by osteoclasts is equal to the amount of 11 
bone formed by osteoblasts. This process occurs throughout adult life, 12 
maintaining the structure and  strength of bone (Hench et al. 1971; Sims & 13 
Gooi 2008). However, like any other organ or tissue, this process can be 14 
d isrupted  through d isease or injury. One of the most common and 15 
prevalent d iseases of bone is osteoporosis, affecting approximately 3 16 
million people in the UK (Shi 2004; NHS 2012b).  Osteoporosis is caused  by 17 
an imbalance in bone resorption and  bone formation, where too much bone 18 
is resorbed  and  not renewed (Kolf, Cho & Tuan 2007b; Chamberlain et al. 19 
2007; Crisan et al. 2008; Vodyanik et al. 2010; Haasters et al. 2009; San chez- 20 
Guijo et al. 2009; Yoshimura et al. 2006; Kozhevnikova et al. 2008; Jack et al. 21 
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 4 
2002; Dominici et al. 2006; Ohgushi et al. 2005; Orciani et al. 2010).  Paget‘s 1 
d isease of bone is also a result of over active bone resorption, but unlike 2 
osteoporosis, is followed by a compensatory increase in new bone 3 
formation, resulting in structurally d isorganised  bone (Kolf, Cho & Tuan 4 
2007b; Chamberlain et al. 2007; Crisan et al. 2008; Barry & J. M. Murphy 5 
2004; Boyd et al. 2009; Haasters et al. 2009; Kozhevnikova et al. 2008; 6 
Pittenger 1999; Jack et al. 2002; Dominici et al. 2006; Orciani et al. 2010). 7 
Osteopetrosis is an inherited  d isease affecting osteoclast d ifferentiation and 8 
is characterised  by an increase in skeletal mass, due to lack of resorption 9 
(Chamberlain et al. 2007; Kolf, Cho & Tuan 2007b; Crisan et al. 2008; Barry 10 
& J. M. Murphy 2004; Boyd et al. 2009; Haasters et al. 2009; Kozhevnikova 11 
et al. 2008; Pittenger 1999; Yoshimura et al. 2006; Blitterswijk et al. 2007; 12 
Foster et al. 2005; Jack et al. 2002; Dominici et al. 2006; Orciani et al. 2010). 13 
Non-bone specific d isorders, such as autoimmune d isease and  cancer can 14 
also affect bone. Although it is relatively uncommon for cancer to originate 15 
in bone, cancer can spread  from another part of the body- termed 16 
metastatic cancer (Kolf, Cho & Tuan 2007b; Vodyanik et al. 2010; Jack et al. 17 
2002; Tare et al. 2012).  Bone can also be damaged through injury; it can be 18 
broken or fractured , usually caused  by high force impact or stress. Being 19 
highly dynamic, in most cases bone can repair itself after minor fractures. 20 
Yet, in some cases bone cannot regenerate itself extensively or effectively 21 
enough, and  additional assistance is needed. Bone itself is a highly complex 22 
organ, containing a variety of cell types and  is composed  of organic and  23 
inorganic matter. In order to successfully repair/ regenerate bone, its 24 














1.3 Bone  1 
 2 
Bone achieves a variety of function through its complex structure:- 3 
1. provid ing protection for vital organs including bone marrow, 4 
2. serving mechanically as a support for soft tissue and  attachment 5 
sites for the muscles, 6 
3. being the major organ responsible for the maintenance of serum 7 
homeostasis (due to its ability to store several ions, especially 8 
calcium and  phosphate), also functioning as the most abundant site 9 
of haematopoiesis (Crisan et al. 2008; Boyd et al. 2009; Jack et al. 10 
2002). 11 
 12 
The structure of bone is complex, both externally and  internally, provid ing 13 
an extremely strong yet lightweight frame to keep the body supported .  It 14 
is a composite of mineral and  organic matrix, which confer structure and  15 
strength respectively.  The mineral phase of bone is composed  of calcium 16 
phosphate, largely in the form of hydroxyapatite (Ca 10(PO4)6OH 2) and  the 17 
organic matrix of bone consists of a highly organised  network of proteins, 18 
of which collagen type I is the main constituent.   19 
 20 
1.3.1 Bone development 21 
 22 
During embryonic development bone is formed via two separate processes, 23 
either intramembranous or endochondral ossification. 24 
In intramembranous bone formation, mesenchymal progenitors condense 25 
and  d ifferentiate d irectly into osteoblasts. This process is closely 26 
coordinated  by osteoclasts selectively resorbing bone, maintaining the 27 
proportions and  structure of the marrow cavity and  cortical bone as it 28 
grows  29 
Occurring simultaneously is endochondral ossification, where the same 30 
progenitor cells first form cartilage, which undergoes mineralisation, 31 
vascular and  osteoprogenitor invasion and  extensive apoptosis. This 32 
sequential coordination of growth leads to the longitudinal lengthening of 33 
the bone. 34 
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Both endochondral and  intramembranous ossification occur not only in 1 
long bones but also in the short, flat and  irregular varieties. Although 2 
derived  from a d ifferent embryonic origin (neural crest) the skull and  facial 3 
bones are formed by both endochondral and  intramembranous ossification  4 
in a similar manner (Chamberlain et al. 2007; Kolf, Cho & Tuan 2007b; 5 
Barry & J. M. Murphy 2004; Boyd et al. 2009; Haasters et al. 2009; 6 
Yoshimura et al. 2006; Pittenger 1999; Crisan et al. 2008). 7 
 8 
1.3.2 Bone structure 9 
 10 
Anatomically, long bones can be d ivided  into d ifferent zones, which are 11 
shown in Figure 2:- 12 
1. epiphysis (the rounded ends of long bones),  13 
2. diaphysis (or midshaft) and  the 14 
3. metaphysis (development zone). 15 
 16 
The epiphyses and  methaphyses are formed at two independent 17 
ossification centres, separated  by a layer of cartilage known as the 18 
epiphyseal plate or line. This layer is responsible for the longitudinal 19 
growth in long bones and  is produced by proliferative cells and  expanding 20 
cartilage.  Below the epiphyseal plate, immature bone grows in the 21 
methaphysis. Extending between the methaphyses is the d iaphysis, which 22 
provides mechanical stability. Within the d iaphysis is the medullary cavit y, 23 
filled  with bone marrow. This cavity has two surfaces: the periosteal 24 
surface (external surface) and  the endosteal surface (internal surface) 25 






Figure 2: Illustrated anatomy of a long bone.  3 
Anatomical depiction of a long bone structure and zones, highlighting the bone marrow 4 
filled medullary cavity, trabecular and cortical areas, the surrounding connective tissue 5 
layer (endosteum), vascular periosteum and articular cartilage. Hand drawn illustration 6 
annotated in Microsoft PowerPoint 2007. 7 
 8 
Bone exists in two d istinct forms, cortical and  trabecular. Cortical bone is 9 
denser (5-10% porosity) than trabecular bone (50-90% porosity); hence its 10 
function is mainly mechanical and  p rotective (Oishi & Ito-Dufros 2006). It 11 
exists in the outer shafts (d iaphyses) of the long bones, and  on the surface 12 
of small and  flat bones.  13 
Cortical bone is composed  of densely packed collagen fibers that form 14 
concentric lamellae around central spaces called  Haversian canals; each 15 
unit of Haversian canal and  surrounding concentric lamellae is termed an 16 
osteon, as shown in Figure 3. Within Haversian canals are blood vessels, 17 
lymphatics, nerves and  connective tissue (see Figure 3 inset). Between the 18 
lamellae and  canals are lacunae that contain osteocytes, which are 19 
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connected  to each other and  the central canal by many smaller canal-like 1 
structures termed caniculi (Banas et al. 2007; Mitchell et al. 2005).  2 
Trabecular or cancellous bone is less abundant but it is metabolically more 3 
active, being located near the epiphyses of long bones and  the interior 4 
structure of small bones. Within cancellous bone there are interconnecting 5 
plates and  bars called  trabeculae, interconnected  by marrow in a 6 
honeycomb like structure. The trabeculae are aligned  along the lines of 7 
stress or mechanical force, adding considerably to its strength. 8 
 9 
 10 
Figure 3: Illustrated cross section of compact and trabecular bone.  11 
Bone microstructure, indicating osteons blood supply and cell types.  Hand drawn figure 12 




1.3.3 Periosteum and Blood supply 2 
 3 
Surrounding most bones is a dense, fibrous, connective tissue called  the 4 
periosteum. Beneath the periosteum exists a network of capillaries and  5 
vessels, which supply blood to the bone. Blood vessels penetrate the bone, 6 
through Volkmann‘s canals, which supply both cortical and  trabecular bone 7 
forming a dense capillary network. Endothelial pericytes surround these 8 
vessels, these cells of mesenchymal origin are found throughout the 9 
microvasculature of connective tissue, nervous tissue and  the lungs. 10 
Pericytes have the ability to contract and  therefore regulate blood flow, but 11 
more recently it has been demonstrated  that these cells can d ifferentiate 12 
into a wide variety of cell types including bone-forming cells (osteoblasts) 13 
(Peister 2004). 14 
1.3.4 Bone composition 15 
 16 
Bone material itself is composed  of two d istinct phases: an organic matrix, 17 
mostly made of collagen, along with proteoglycan s and  several non- 18 
collagenous proteins, and  the mineral phase which strengthens the organic 19 
phase with calcium salts. 20 
1.3.4.1 Organic matrix 21 
 22 
The organic matrix or ‗osteoid‘ is composed  of collagenous (90%) and non- 23 
collagenous proteins, synthesised  by osteoblasts. The most abundant 24 
protein is collagen type I, which is characterized  by its fibrous nature, with 25 
the fibrils in bone generally about 80–100 nm in d iameter. Each fibril is made 26 
up of three polypeptide chains roughly 1000 amino acids long, wound  27 
together in a triple helix composed  by two α1 chains and  one α2 chain. 28 
Between these molecules there are small spaces (37.5nm) that are filled  29 
with hydroxyapatite crystals. The collagen fibrils are stabilised  by inter and 30 
intra-molecular crosslinks, and  the number and  d istribution of these 31 
crosslinks are thought to determine whether the tissue will mineralise 32 
(Chamberlain et al. 2007). In classic Ehlers-Danlos syndrome, mutations in 33 
the collagen type I gene COL1A1 results in d isruption of the stability of 34 
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triple helix formation, and  as consequence can cause osteopenia or bone 1 
fragility (Péault et al. 2007). 2 
Other constituents of the organic phase include proteoglycans and  non - 3 
collagenous bone matrix proteins such as osteocalcin, osteopontin , 4 
osteonectin and  fibronectin  (Bentmann et al. 2010).  Osteopontin and  bone 5 
sialoprotein have an RGD (Arginyl, glycyl, aspartic acid) sequence that can 6 
be recognized  by the αvβ3 integrin receptor, which is involved  in mediating 7 
cell attachment, activating cell signalling pathways and  also involved  in 8 
binding hydroxyapatite. In vitro, bone sialoprotein nucleates the formation 9 
of hydroxyapatite crystals whereas osteopontin inhibits the mineral growth 10 
(Pampena et al. 2004; Hunter et al. 1994). Osteocalcin is thought to play a 11 
role in mineralisation, is an inhibitor of osteoclast function, and  is highly 12 
expressed  by mature osteoblasts (Caetano-Lopes et al. 2007).  13 
1.3.4.2 Bone Mineral 14 
 15 
Several decades ago, De Jong demonstrated  the similarities between 16 
synthetic apatite (hydroxyapatite) and  mineral bone, using X-ray 17 
d iffraction (de Jong 1926). 18 
Since then, several d ifferences have been demonstrated  between 19 
hydroxyapatite (HA; Ca10 (PO4)6 OH 2), and  the biological apatite that is 20 
present in bone tissue including composition, crystallinity, stoichiometry, 21 
physical and  mechanical properties. Natural bone mineral incorporates 22 
numerous substitutions within the calcium ph osphate lattice, including 23 
carbonate (CO3
2-), sodium (Na+), magnesium (Mg2+), potassium (K+), 24 
fluoride (F-), chloride (Cl-) ions and , also some trace elements such as 25 
silicon (Si4-) strontium (Sr2+), lead  (Pb2+), and  barium (Ba2+). These 26 
substitutions appear to be crucial to the biological activity and  surface 27 
chemistry of bone (Pietak et al. 2007). In particular, trace levels of silicon in 28 
the form of silicate (SiO 4
4-) are known to be essential for normal growth and  29 
development of bone (Carlisle 1972; Schwarz & Milne 1972). The 30 
incorporation of these ions and  elements have considerable influence on 31 
the physical, chemical, and  physiological properties of bone (Kannan et al. 32 




1.3.4.3 Bone cells and their origin 1 
 2 
Three key cell types exist within bone: osteoblasts, osteocytes and  3 
osteoclasts, which are respectively involved  in bone formation, 4 
maintenance and  resorption. 5 
 6 
1.3.4.3.1  Osteoblasts 7 
 8 
Osteoblasts are responsible for producing the bone matr ix, during 9 
embryonic bone formation and  constantly facilitate the maintenance of new 10 
bone deposited  in adults. Osteoblasts arise from multipotent mesenchymal 11 
stem cells (MSC) (Caplan 1991; Owen 1988), which prior to commitment to 12 
the osteoblast lineage, are capable of d ifferentiation into other 13 
mesenchymal cells lineages such as ad ipocytes, and  chondrocytes 14 
(Pittenger 1999). In vivo, MSC are induced  to d ifferentiate into osteoblasts 15 
through a variety of factors, including bone morphogenic proteins and  16 
other supporting cytokines (Lavery et al. 2009; Maegawa et al. 2007). As 17 
MSC differentiate along the osteogenic lineage they express a range of 18 
stage specific genes, shown in Figure 4 19 
 20 
 21 
Figure 4: Diagram representing stages and markers of osteogenic differentiation.  22 
Schematic diagram of growth and differentiation of osteoblasts, created using Microsoft 23 
PowerPoint 2007. CD105 – endoglin RUNX2 – runt-related transcription factor 2, 24 
COL1A1 – collagen type I, PTH1R- parathyroid hormone 1 receptor, ALP - alkaline 25 




Over a decade ago RUNX2 (also known as Cbfa-1) was identified  as the 2 
key transcription factor controlling osteoblastogenesis. RUNX2, a member 3 
of the runt family of transcription factors, is expressed  at the onset of 4 
skeletal development and  is present in osteoblasts throughout their 5 
d ifferentiation. RUNX2 has been shown to be both necessary and sufficient 6 
to d irect MSC toward  the osteoblast lineage (Marie 2008). 7 
 8 
RUNX2 operates by bind ing to a Run consensus sequence; this sequence is 9 
present in the promoter of all major osteoblast genes (COL1A1, OPN , BSP 10 
and  BGLAP) and  regulates their expression (Yamaguchi et al. 2000). 11 
RUNX2 also inhibits the d ifferentiation of MSC into ad ipocytic and  12 
chondrocytic lineages and  also negatively controls osteoblast proliferation 13 
by acting upon the cell cycle by modulating expression of key kinases such 14 
as p85 PI3K (Caetano-Lopes et al. 2007; Komori 2006).  Osterix is a zinc 15 
finger transcription factor, that acts downstream of RUNX2. Critical for 16 
osteoblast d ifferentiation, osterix deficient mice show a complete absence of 17 
osteoblasts resulting in defective bone formation (Nakashima et al. 2002). 18 
Both RUNX2 and osterix act together to mediate the expression of collagen 19 
type I and  alkaline phosphatase (Marie 2008; Datta et al. 2008). Pre- 20 
osteoblast and  mature osteoblasts synthesise and  secrete bone matrix 21 
proteins of which collagen type I is the major component, constituting up 22 
to 90% of the organic matrix (Mackie 2003). Along with collagen, 23 
osteoblasts manufacture various non-collagenous proteins such as bone 24 
sialoprotein (BSP), osteopontin (OPN ) and  osteocalcin (BGLAP). 25 
Osteocalcin is an osteoblast-specific protein that is characterized  by 3- 26 
gammacarboxyglutamic acid  residues; 1,25 OH Vitamin D3 enhances its 27 
synthesis and  its expression reflects metabolic cellular activity. Of the de 28 
novo synthesized  osteocalcin, 60%–90% is incorporated  into the bone matrix 29 
where it binds to hydroxyapatite during matrix mineralisation. The 30 
remainder is released  into the circulation where it can be measured  as a 31 
sensitive marker of bone formation (Cantatore et al. 2004). 32 
Tissue non-specific alkaline phosphatase is produced by osteoblasts, and  is 33 
highly expressed  prior to mineralisation (Robison 1923). Alkaline 34 
phosphatase is activated  by several transcription factor s, including RUNX2 35 
and  osterix, and  is commonly used  to quantify osteoblast d ifferentiaton in 36 
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vitro (E. E. Golub & Boesze-Battaglia 2007). 1 
 2 
1.3.4.3.2 Osteoclasts 3 
 4 
Osteoclasts are large multinucleated  cells, uniquely capable of resorbing 5 
bone, and  remodeling its structure. Originating from circulating 6 
haematopoietic myelomonocytic precursors, which undergo 7 
d ifferentiation, multinucleation and  activation in a process termed 8 
osteoclastogenesis (Sims & Gooi 2008; Yavropoulou & Yovos 2008).  The 9 
process of osteoclastogenesis is a complex sequence of events, which 10 
cannot take place in the absence of osteoblasts (Civitelli 2008). In a similar 11 
manner to osteoblastogenesis, osteoclast d ifferentiation is regulated  by a 12 
number of both systemic and  locally produced hormones and  cytokines. 13 
Osteoclastogenesis is crucially dependent upon two key cytokines; RANKL 14 
(receptor activator of nuclear factor B ligand) and  M-CSF (monocyte- 15 
colony stimulation factor). M-CSF is critical for the proliferation of 16 
osteoclast progenitors, while RANKL directly controls the d ifferent iation 17 
process by binding to its receptor, RANK. The precise mechanism by which 18 
RANK induces osteoclastogenesis is not fully understood, but it  is known 19 
to trigger an internal cascade resu lting in the expression of new receptors 20 
(Katagiri & Takahashi 2002; Datta et al. 2008). Osteoblasts can produce a 21 
decoy receptor, osteoprotegerin (OPG), which blocks RANK/ RANKL 22 
interaction by binding RANKL, and  therefore prevents osteoclast 23 
d ifferentiation and  activation; th is negative feedback loop is essential in 24 
controlling bone remodelling (Theoleyre et al. 2004). In a further level of 25 
regulation, the osteoclast, can release its own cytokines, which then 26 
feedback to control its own activity, or control the activity of osteoblasts as 27 
they deposit new bone (Civitelli 2008). 28 
 29 
1.3.4.3.3 Osteocytes 30 
 31 
Until recently the role osteocytes has been enigmatic and  contentious, 32 
however the existing view is that the osteocytes are responsible for 33 
detecting and  responding to mechanical loading and  initiating the bone 34 
adaptation process (You et al. 2008). Osteocytes are non-proliferative, yet 35 
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are the most abundant cell type in bone, constituting 90% of all adult bone 1 
cells (Tate et al. 2004). 2 
Osteocytes are formed when terminally d ifferentiated  osteoblasts are left 3 
behind  during osteoid  production then encased  in the mineralised  osteoid , 4 
a process that occurs relatively infrequently (10-20%). As the osteocyte is 5 
entombed it maintains contact with advancing osteoblasts by extending 6 
cellular processes, whilst the osteoid  becomes min eralised  under the 7 
control of enzymes (Palumbo et al. 1990; Datta et al. 2008). Significant 8 
changes occur, as an osteoblast becomes an osteocyte. Initially its shape 9 
changes considerably, from a rounded cobblestone like cell into a stellate 10 
shape with multiple long processes. Despite being encased  in individual 11 
lacunae, osteocytes form an impressive network connected  to each other 12 
through these dendritic processes in canaliculi. These canaliculi are fluid  13 
filled  spaces containing a mesh of proteoglycans and  extra cellular proteins, 14 
and  are thought to permit signalling between osteocytes. This system of 15 
fluid  filled  canals allows the osteocytes to detect mechanical loading and 16 
respond to this external stimulus by sending signals to osteoclasts and  17 
osteoblasts, regulating bone remodelling (You et al. 2008; Noble 2008; 18 
Kurata et al. 2007). Osteocytes are thought to orchestrate local bone 19 
remodelling through the action of local and  systemic, stimulatory and 20 
inhibitory signals (Tate et al. 2004). A number of matrix proteins, including 21 
dentin matrix protein 1 (DMP1), increase in expression once the osteoblast 22 
begins to transform into an osteocyte (Mikami et al. 2008; Toyosawa et al. 23 
2001; Hao et al. 2004). DMP1 is an extracellular matrix protein member of 24 
the SIBLING family and  has been implicated  in osteocyte function and  25 
signalling. It is also critical for matrix mineralisation, and  mutations in the 26 
gene can lead  to rickets and  osteomalacia (Feng et al. 2006). 27 
 28 
1.4 Bone tissue engineering 29 
 30 
Successful tissue engineering must integrate principles of engineering and  31 
life sciences to develop functional biological substitutes that restor e, 32 
maintain or improve tissue functions (Zippel et al. 2010).  33 
The first documented  attempt at tissue engineering was bone grafting, 34 
described  by a Dutch surgeon in 1668 when a bone defect in a sold ier‘s 35 
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cranium was filled  with a piece of skull from a dog. The bone was removed 1 
2 years later at the patients request, so that he could  be allowed back to 2 
church, which had  denounced him because of the xenotransplant (van 3 
Meekeren 1730). 4 
 5 
1.5 Bone grafting 6 
 7 
Bone grafting is a surgical procedure where missing or damaged bone is 8 
repaired  or replaced  using natural or synthetic materials; from the patient‘s 9 
own body, from a donor, or using synthetic or natural substitutes such as 10 
hydroxyapatite, collagen or coral. Bone grafts can be used  to repair 11 
fractures that fail to heal properly or voids that are extremely complex. 12 
 13 
In order to critically evaluate bone grafts, biocompatibility must first be 14 
addressed . The biocompatibility of a bone graft or bone graft substitute 15 
refers to the ability to perform as a substrate that will support the 16 
appropriate cellular activity, including the facilitation of molecular and 17 
mechanical signalling systems, whilst allowing integration and  conduction 18 
of new bone growth, without eliciting any undesirable local or systemic 19 
responses in the eventual host (Williams 2008). 20 
The biocompatibility of any bone graft mater ial can be determined  by the 21 
following factors:- 22 
 23 
1. Osteogenic potential, or the presence of osteogenic cells, which have the 24 
unique potential to d ifferentiate and  form new bone. Graft materials that 25 
contain cells or act as cell carriers, contain the ability to form bone de novo. 26 
This new bone formation utilises the transplanted  cells‘ ability to initiate 27 
early healing uniting the graft and  existing bone. This osteogenic potential 28 
is commonly seen in autogenously transplanted  bone and  bone marrow 29 
(Lucarelli et al. 2004). 30 
 31 
2. Osteoinduction is the ability of a matrix or scaffold  to initiate new bone 32 
formation. Generally, this occurs through neovasculature ingrowth and 33 
infiltration of osteogenic precursor cells then the graft becomes completely 34 
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resorbed  in a process known as ‗creeping substitution‘ (Yaszemski et al. 1 
1996).  2 
Materials such as allograft bone, demineralised  bone matrix, collagen and 3 
calcium phosphate based  ceramics are all examples of osteoinductive bone 4 
substitutes that can be completely resorbed  (Giannoudis et al. 2005). 5 
 6 
3. Osteoconduction, an osteoconductive surface is one that permits bone 7 
growth on its surface or within pores or channels (Albrektsson & Johansson 8 
2001). 9 
Some bone and  cartilage graft substitutes encourage such ingrowth 10 
through the inclusion of factors or biochemical substances, such as bone 11 
morphogenic proteins (Giannoudis & Einhorn 2009), transforming growth 12 
factors (Nicoll et al. 1997), and   fibroblast growth factors (Joung et al. 2008). 13 
 14 
4. Structural integrity provides support for the bone as it encounters natural 15 
mechanical stresses. Biomechanical strength is a key element for bone 16 
grafts, due to the daily stresses, which the skeleton undergoes.  17 
Metal implants composed  of titanium, provide excellent structural integrity 18 
yet possess no osteogenic properties. Cancellous bone grafts provide initial 19 
poor structural strength, but th is changes as a result of osteointegration. 20 
Cortical bone grafts provide excellent initial structural integrity, which  21 
once remodelled  and  osteointegration occurs, can lose up  to one third  of its 22 
strength (Williams 2008; Schimandle & Boden 1997).  23 
 24 
1.5.1 Autografts 25 
 26 
Autografts are considered  the gold  standard  for bone grafting, due to their 27 
osteogenic potential, osteoconductivity, osteoinductivity and  if cortical 28 
bone is used , structural strength. Furthermore, there are minimal 29 
immunological issues associated  as a result of complete histo -compatibility 30 
(Marsh 2003). 31 
Autografts can be cancellous, cortical, cortico-cancellous or free 32 
vascularised  bone; each type of autograft can contain viable cells and  33 
proteins within the bone matrix.  34 
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Cancellous autografts are the most common bone grafts used  due to their 1 
superior osteoinduction and  osteoconduction. They promote rapid 2 
revascularisation and  incorporation, have a strong osteogenic potential due 3 
to viable cells and  bone inducing growth factors contained  within. 4 
Cancellous autografts also exhibit good moulding characteristics, but must 5 
be used  alongside either internal or external fixation as they are lacking in 6 
support (Drosse et al. 2008). 7 
Cortico-cancellous autografts, also harvested  from the iliac crest, but in 8 
strips or small chips, contain some cortical component. This element 9 
provides more support and  structure, often used  to bridge a small defect 10 
(Marsh 2003). 11 
Structural or cortical autografts, commonly from the fibula, are used  to fill 12 
d iscrete defects, provid ing immediate mechanical and  structural support 13 
until bone can regenerate, restoring structural integrity.  Despite the 14 
advantage of mechanical strength, cortical bone is biologically less 15 
desirable as it contains fewer osteogenic cells, due to the absence of bone 16 
marrow. Furthermore, the cells that are present are less likely to survive, as 17 
they are embedded in a more compact matrix and  are shielded  from factors 18 
and  nutrients (Dinopoulos et al. 2012). The lower surface area, per weight 19 
of cortical bone also limits the amount of new bone that can form, and  from 20 
which proteins can pass. Finally, cortical bone is more resistant to 21 
vascularisation and  remodelling, necessary factors for healing an d  22 
developing strength (Drosse et al. 2008; Marsh 2003; Schimandle & Boden 23 
1997). 24 
 25 
Despite the excellent success rate and  low risk of d isease transmission of 26 
autologous cancellous grafts, they have several d isadvantages: including 27 
issues of resorption and  viability, associated  donor -site morbid ity, limited  28 
availability, risk of infection and  fracture, the need  for a second procedure 29 
with potential increased  blood loss, prolonged operating time and poor 30 






1.5.2 Allografts 1 
 2 
Allografts, or bone grafts from a d ifferent patient, are most frequently used 3 
for spinal fusion surgery. In recent years the use of allograft has increased , 4 
due to improvements in the methods of procurement, preparation and 5 
storage, and  also through the desire to avoid  donor site morbid ity 6 
associated  with autogenous bone.  Often used  as large structural sections or 7 
smaller cortico-cancellous chips, allografts provide an osteoconductive 8 
scaffold  for new repair.  The abundant supply, varying shape and  volume 9 
has also fuelled  its recent increase in use, with larger allografts being 10 
possible where autografting would  not be considered . 11 
Unlike autografts, allografts do not contain osteogenic cells and  therefore 12 
undergo a much slower incorporation. Issues also exist concerning the 13 
possibility of infection and  even infectious d isease transmission  (Drosse et 14 
al. 2008; Marsh 2003; Schimandle & Boden 1997).  15 
Allogeneic bone is available in many forms including: demineralised  bone 16 
matrix, small cancellous fragments or chips, cortico-cancellous and  cortical 17 
grafts, and  osteochondral and  various bone segments. Due to the removal 18 
of live cells via irrad iation or freeze-drying processing, allografts have little 19 
or no osteogenicity. But they do have osteoconductive and  reduced  20 
osteoinductive properties (Keating & McQueen 2001). 21 
However, there are issues of transmission of viral, especially hu man 22 
immunodeficiency virus (HIV), hepatitis B and  C, bacterial infections, 23 
malignancy, immunogenicity and  rejections reactions, as well as high cost 24 
of harvesting, processing and  conservation of allogeneic grafts  (Dinopoulos 25 
et al. 2012).  The overall infection rates using structural allograft have been 26 
reported  to be as high as 12.8% (Dick & Strauch 1994). 27 
 28 
1.5.3 Demineralised bone matrix 29 
 30 
Demineralised  bone matrix (DBM), is a form of allograft in which the 31 
mineral phase has been extracted , leaving proteins, growth factors and 32 
collagen. Available widely as powders, pastes or putties and  can be 33 
moulded  into deficient areas: both within fractures and  non-union sites 34 
(areas of bone which have failed  to heal a significant time after injury). The 35 
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presence of low molecular weight glycoproteins such as bone morphogenic 1 
protein (BMP) underlies the osteoconductivity of demineralised  bone 2 
matrix. Resid ing in the extracellular matrix of bone and  constituting only 3 
0.1% by weight of all bone proteins, BMP is known to simulate the 4 
migration, d ifferentiation and  activity of osteoprogenitors. Along with 5 
BMP, demineralised  bone matrix also contains a number of other growth 6 
factors known to stimulate osteoprogenitors, such as transforming growth 7 
factor- (TGF-).  Numerous studies have shown TGF- is of significant 8 
importance in the control of d ifferentiation of marrow precursor cells, 9 
which are capable of forming chondrocytes, ad ipocytes and  osteoblasts 10 
(Drosse et al. 2008; Marsh 2003; Massagué 1998). However, demineralised 11 
bone matrix can be variable in osteoinductive and  osteoconductive 12 
properties due to donor variability and  also provides no structural support. 13 
1.5.4 Cell based strategies 14 
1.5.4.1  Bone marrow aspirate 15 
 16 
Bone marrow aspirate can be utilised  to stimulate bone formation alone, or 17 
in combination with a bone graft. Aspirate can be obtained  from the iliac 18 
crest in a minimally invasive process (Schade & Roukis 2008). 19 
Bone marrow aspirate contains osteogenic and  haematopoetic progenitor 20 
cells and  once transplanted  is capable of enhancing bone formation, and  21 
revascularisation respectively. However, concentration and  quality of 22 
progenitor cells vary significantly between individuals, especially in 23 
elderly patients (Huibregtse et al. 2000; D'Ippolito et al. 1999).  24 
 25 
1.5.4.2 Mesenchymal stem cells 26 
 27 
Bone marrow aspirate can be centrifuged  to separate cells from plasma, 28 
reducing the volume of material that is replaced . Within the fractionated 29 
aspirate are multiple cell types of the osteo-progenitor lineage and  all are 30 
implicated  in bone repair  (Drosse et al. 2008). Mesenchymal stem cells are 31 
the key stem cells involved  in bone regeneration and  can be readily isolated 32 
from bone marrow (Pittenger 1999). Once purified  these cells can be 33 
expanded, d ifferentiated  and  delivered together with a bone graft to 34 
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enhance repair. The process of MSC differentiation into osteoblasts and  1 
ultimately osteocytes, also known as osteogenesis, is activated  and  2 
regulated  by a variety of soluble factors and  physical environment in vivo.  3 
 4 
1.5.4.3 Soluble factor based osteogenesis 5 
 6 
Mesenchymal stem cells can be induced  to differentiate into osteoblasts in 7 
vitro through the addition of soluble factors such as; glucocorticoids, 8 
growth factors, hormones, and  vitamins (Pittenger. 1999). The most 9 
commonly used  combination of soluble factors to promote osteogenic 10 
d ifferentiation in vitro is dexamethasone, ascorbic acid  and  β- 11 
glycerophosphate. Each constituent stimulates or supports osteogenic 12 
d ifferentiation of mesenchymal stem cells in vitro. 13 
 14 
1.5.4.3.1  Dexamethasone 15 
 16 
Dexamethasone is a synthetic corticosteroid, although not found naturally 17 
in the body, imitates the actions of various glucocorticoids such as cortisol, 18 
oestrad iol, testosterone, vitamin D3 (B et al. 2001).  Glucocorticoids 19 
influence the expression of many genes, through binding to specific 20 
activator proteins. In the absence of a glucocorticoid , activator proteins are 21 
kept in the cytosol and  cannot bind  DNA. In vitro dexamethasone can 22 
stimulate osteogenic d ifferentiation of MSC and acts at multiple points in 23 
the d ifferentiation process to stimulate osteoblastic maturation; 24 
transforming MSC morphology from spindle-shaped to cuboidal, 25 
increasing alkaline phosphatase (ALP) activity and  enhancing 26 
mineralisation (R. M. Porter et al. 2003b). It was previously thought that 27 
dexamethasone was required  for MSC differentiation in vitro however; 28 
multiple studies have demonstrated  it enhances osteogenic d ifferentiation 29 
but is not essential (Bellows et al. 1990; Benayahu et al. 1989; Kamalia et al. 30 
1992). Long-term intake of dexamethasone in vivo can result in 31 
osteoporosis, through decreased  osteoblast activity  (Mazziotti et al. 2006). 32 
This contradictory effect is thought to be due to the anti-proliferative effects 33 
of this corticoid  (Jaiswal et al. 1998). 34 
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1.5.4.3.2  Ascorbic acid  1 
 2 
Ascorbic acid  is an essential component in the synthesis of hydroxyproline 3 
and  hydroxylysine, two key components required  to stabilize the collagen 4 
triple helix and  to form intermolecular crosslinks within collagen (Murad  et 5 
al. 1981). Several studies have shown that ascorbic acid  concentration is 6 
correlated with collagen production by osteoblasts (Aronow et al. 1990; 7 
Franceschi & Iyer 1992) and  also linked  to enhanced  ALP activity 8 
(Franceschi et al. 2009).  However, a contradictory study has found that 9 
ALP expression by MSC cultured  in  presence of ascorbic acid  was no 10 
d ifferent than the same cells cultured  in the absence of ascorbic acid  11 
(Gronthos et al. 1994). 12 
1.5.4.3.3  β-glycerophosphate 13 
 14 
β-glycerophosphate provides a source of organic phosphate ions that 15 
promote mineralisation in vitro (Chung et al. 1992). Despite several studies, 16 
the exact mechanism behind  this mineralisation remains unclear, but may 17 
be related  to the ability of ALP to hydrolyse organic phosphate and  release 18 
inorganic phosphate (Y. L. Chang et al. 2000). 19 
 20 
1.5.4.3.4  Other soluble factors 21 
 22 
Numerous soluble factors are also known to activate or have a significant 23 
effect on osteogenic d ifferentiation, a summary of the most commonly 24 

















A family of cytokines that stimulates proliferation of 
osteoblasts and  causes increased  matrix production and  have 
also been seen to induce MSC d ifferentiation to osteoblasts. 
Fibroblast growth 
factors 
A family of growth factors that stimulates proliferation of 
MSCs and  osteoblasts. 
Insulin-like growth 
factors 
A family of growth factors that stimulates proliferation of 
osteoblasts and  induces matrix production. 
Platelet-derived  
growth factor 
A growth factor, it stimulates proliferation osteoblasts, it has 
also been implicated  in bone resorption. 
Transforming growth 
factor-β 
A growth factor, can initiate d ifferentiation of MSCs to 
chondrocytes, and  may also induce chondrocyte and  
osteoblast proliferation. Since, like PDGF, it has been seen to 
enhance bone resorption at certain concentrations, it may 
play a role in coupling formation and  resorption activities. 
Epidermal growth 
factor  
A growth factor, it stimulates chondrocyte proliferation 
while decreasing the cells‘ ability to synthesise matrix 
components. 
Parathyroid  hormone 
A single chain polypeptid e, it causes the release of calcium 
from the bone matrix as well as induces osteoclast 
d ifferentiation from precursor cells. It is also thought to 
inhibit osteoblast function. 
Estrogen 
A hormone, it has a complex effect on bone, w ith the final 
outcome being decreased  bone resorp tion by osteoclasts. 
Vitamin D 
 
A vitamin that has a complex effect on bone formation, 
thought to regu late the synthesis of other molecules, and  has 
been reported  to influence both bone resorption and  matrix 
mineralisation. 









3.1.1.1 . Non-soluble factor driven osteogenesis 1 
 2 
A complex extracellular matrix (ECM) composed  of multiple proteins 3 
surrounds MSC and osteoblasts in vivo, and can modulate cellular 4 
interactions and  receptor binding (Mathews et al. 2012). The composition 5 
and  mechanics of this microenvironment also plays a vital role in MSC 6 
maintenance and  osteogenesis.  7 
 8 
1.5.4.3.5  Physical forces 9 
 10 
The skeleton is constantly exposed  to physical forces, including 11 
compression, strain and  shear stress. These physical stimuli have long 12 
known to play a role in bone remodelling. In 1982, Wolff found mechanical 13 
loading of bone ensures that the bone is constantly renewed and repaired  14 
(Wolff & Wessinghage 1991).  15 
Osteocytes are thought to be the m ajor cell type involved  in translating 16 
external mechanical strain into biochemical signals, and  are known to 17 
orchestrate bone remodelling (Bonewald  2006). However, osteoblasts are 18 
also mechanically receptive. Several studies have shown increased 19 
proliferation and  d ifferentiation of osteoblasts in response to mechanical 20 
strain and  shear stress (Sikavitsas et al. 2001). In the absence of mechanical 21 
loading, osteoblast proliferation and  matrix production decreases and  22 
osteoclast activity increases (Nabavi et al. 2011). Such studies in 23 
microgravity and  simulated  microgravity may explain the significant bone 24 
loss associated  with spaceflight (Vico et al. 1998).  25 
Electromagnetic fields and  u ltrasound have also been shown to enhance 26 
fracture repair, although the molecular mechanism responsible is not yet 27 
fully understood (Dyson 1983; Li et al. 2006). 28 
 29 
 30 
1.5.4.3.6  Engineered  substrates 31 
 32 
Recent advances in material synthesis and  processing have enabled  a wide 33 
range of synthetic and natural materials to examine the effect of physical  34 
forces on MSC and osteogenesis. Using a variety of techniques and 35 
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materials including; lithography, micro printing and  nano-tubes, 1 
researchers have investigated  the influence of patterned  surfaces on cell 2 
adhesion and  d ifferentiation. MSC on d isordered  patterned  surfaces 3 
d ifferentiated  into osteoblasts in the absence of soluble osteogenic factors 4 
(Dalby et al. 2007). The shapes of nano-islands were also shown to d irect 5 
cell fate (Kilian et al. 2010), through control over the cellular cytoskeleton; 6 
MSC attached  to larger islands of adhesive ligands, which permitted 7 
greater cell spreading preferentially d ifferentiated  into osteoblasts, whereas 8 
cells on smaller islands preventing cell spreading d ifferentiated  into 9 
ad ipocytes (McBeath et al. 2004). This work indicated  that lineage 10 
commitment was regulated  by RhoA-ERK-MAPK pathway. Altering the 11 
d imensions of cross-sectional nanotubes affected  osteogenic d ifferentiation 12 
of MSC, in the absence of osteogenic inducing media. Larger tubes induced  13 
cell spreading, cytoskeletal stress and  osteoblast d ifferentiation (S. Oh et al. 14 
2009). 15 
In a landmark study, MSC assumed d ifferential morphology and  gene 16 
expression when cultured  on polyacrylamide gels with varying moduli.  17 
MSC showed lineage specification depending on the substrate mechanics, 18 
in the absence of any known inducing solu ble factors. Reflecting the in vivo 19 
matrix elasticity - soft substrates supported  d ifferentiation along the neural 20 
lineage, intermediate substrates resulted  in cells of the myogenic lineage, 21 
and  stiffer substrates d ifferentiated  cells along the osteogenic lineage 22 
(Engler et al. 2006). Cues provided  by the matrix mechanics were thought 23 
to occur via the cells ability to sense the matr ix elasticity and  generatinon of 24 
intracellular signals based  on this force.  25 
Altering the surface chemistry of surfaces has been also shown to be 26 
sufficient to d irect MSC differentiation (Benoit et al. 2008). Unmodified  and  27 
methyl (–CH 3) modified  surfaces maintained  MSC multipotency, hydroxyl 28 
(–OH) and carboxyl (–COOH) modified  surfaces promoted  chondrogenic 29 
d ifferentiation, and  amino (–NH 2), silane (–SH 4) modified  surfaces 30 
promoted  ostegengenic d ifferentiation (Curran et al. 2006). These 31 
engineered  substrates that contain cues to facilitate MSC differentiation 32 
along the osteoblastic pathway provide insight into the molecular 33 
mechanisms controlling cell fate but also may enable the further 34 
development of novel substrates for tissue engineered  bone regeneration. 35 
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1.5.5 Bone graft substitutes  1 
 2 
Both synthetic materials and  alternative natural matrices have been utilised  3 
in the design and  manufacture of bone graft substitutes, making it largely 4 
possible to incorporate many properties of an ideal biomaterial. This has 5 
led  to a superior class of tissue-engineered  products, with enhanced  6 
biocompatibility. Manufactured  bone grafts represent a much more 7 
abundant source of graft materials that do not depend upon bone banks, 8 
and  are not limited by the volume of tissue that can be removed 9 
autonomously. Furthermore, this approach eliminates many of the 10 
problems associated  with trad itional bone grafts, such as infection, or 11 
d isease transmission.  12 
 13 
1.5.5.1 Natural materials 14 
 15 
Natural bone graft substitutes largely consist of compon ents found in bone, 16 
such as the extracellular matrix, collagen, hyaluronic acid  and  17 
hydroxyapatite. These biodegradable materials have the advantage of 18 
being bioactive, biocompatible and  represent natural body constituents 19 
provid ing adhesive surfaces for cells.  20 
Other natural materials are derived  from plants, animals or insects: 21 
cellulose, chitosan and  silk respectively (Muzzarelli 2009).  22 
Some d isadvantages of using natural materials over synthetic products 23 
include limited  control over physicochemical properties; degradation is 24 
d ifficult to control along with sterilisation and  purification. There is also 25 
the risk of pathogenic or viral infection when isolating from differing 26 
sources. Despite these d rawbacks, recently chitosan and  hyaluronic have 27 
become commercially available and  appear to possess well-characterised  28 
and  reproducible properties (Stoop2008; Daw son et al 2008).  29 
 30 
1.5.5.2 Collagen 31 
 32 
Bone is naturally very rich in collagen, known to contribute to 33 
mineralisation, vascular ingrowth and  has excellent growth factor binding 34 
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capacity. As a result, collagen has become one of the most exploited  natural 1 
polymers for orthopaedic applications and  combined  with hydroxyapatite, 2 
is clinically available under the trade names SunMax, Legato and  3 
Collagraft (SunMax n.d .; Legato n.d .; Zimmer n.d .). 4 
Collagen alone is a poor bone graft material; however, when combined  5 
with growth factors, hydroxyapatite, or osteoprogenitor precursors, it can 6 
significantly enhance the incorporation of grafts. These commercially 7 
available collagens are trad itionally extracted  from animal tissues and  can 8 
contain d ifferent types of collagen. Therefore, these products can be 9 
contaminated  with potential immunogenic and  infective agents (Xu et al. 10 
2011).  11 
1.5.5.3  Synthetic bone graft substitutes 12 
 13 
Synthetic bone graft substitutes represent a much larger class of 14 
biomaterials. This group encompasses metals, synthetic polymers and  15 
synthetically altered  ceramics. Major advantages include design flexibility 16 
and  elimination of d isease transmission. Moreover, synthetic materials can 17 
be processed  into many d ifferent forms to su it th eir use, such as scaffolds, 18 
fibers, sheets, blocks or even microspheres (Drosseet al. 2008; Marsh 2003).  19 
 20 
1.5.5.4  Synthetic polymer based bone graft substitutes 21 
 22 
Widely variable in design, structure and  composition, synthetic polymers 23 
represent a vast group of bone graft substitutes. The most commonly used  24 
synthetic polymers are the poly-hydroxyl acids; these include polylactic 25 
acid  (PLA), polyglycolic acid  (PGA) and polylactide-co-glycoride (PLGA). 26 
These materials gradually degrade by hydrolysis into water and soluble 27 
oligomers, both of which are removed from the implant site. 28 
PLA/ PGA/ PLGA scaffolds are currently used  in orthopaedics and  tissue 29 
engineering technologies. Several types of cells have been successfully 30 
grown on PLA/ PLGA scaffolds including MC3T3-E1 osteoprogenitor cells; 31 
osteoblasts, chondrocytes and  bone marrow derived  stromal cells. 32 
Nonetheless, synthetic polymers inherently have low bioactivity and  33 
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require biological, chemical or physical modification to achieve an 1 
appropriate cellular response (Dawson 2008).  2 
 3 
1.5.5.5 Drug Release Polymers 4 
 5 
Growth factors can be introduced  into polymers to improve their 6 
biocompatibility and  bioactivity. Growth factors can be delivered  either 7 
through d irect incorporation or through encapsulation.  A variety of 8 
scaffold  materials have been used  to deliver growth factors including 9 
natural and  synthetic polymers.  This approach has shown great promise, 10 
with increased  cell proliferation and  d ifferentiation leading to increased  11 
biocompatibility (Quaglia 2008; Sokolsky-Papkov et al. 2007; Habraken et 12 
al. 2007). Growth factors however, are expensive and  several doses may be 13 
required  to achieve any therapeutic effect (Kumada & Zhang 2010). 14 
Furthermore, the effects of long-term implantation of materials containing 15 
supra-physiologic doses of growth factors remain unknown  (Kretlow et al. 16 
2009). 17 
 18 
1.5.5.6  Calcium phosphate based synthetic ceramics 19 
 20 
Calcium phosphate based  ceramics are considered  to be one of the most 21 
promising materials for bone tissue engineering due to their bone-like 22 
composition and  mechanical properties. Synthetically manufactured  23 
calcium phosphate based  bone grafts provide an osteoconductive and 24 
inductive material without any of the d isadvantages associated  with 25 
autografts and  allografts. 26 
 27 
1.5.5.7  Hydroxyapatite 28 
 29 
Synthetic hydroxyapatite (HA) and  β-tricalcium phosphate (β -TCP) are two 30 
forms of calcium phosphate currently used  in fracture fixing, spinal 31 
fixation, the treatment of bone defects (Karin A Hing et al. 2007; Ogose et 32 
al. 2006) and  also as coatings on metallic and  polymeric substrates to 33 
promote osseointegration and  firm implant fixation (Shepperd  & Apthorp 34 
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2005). Both compounds can be artificially synthesised  through low 1 
temperature aqueous chemistry (Langstaff et al. 2001).  2 
In vitro, both HA and β -TCP have been shown to promote the proliferation 3 
and  d ifferentiation of osteoblasts (Huan & J. Chang 2009; K A Hing et al. 4 
1998), and  to encourage osteogenic d ifferentiation of bone marrow derived 5 
(Arinzeh et al. 2005) and  adipose derived  mesenchymal stem cells (Q. Liu  6 
et al. 2008). Both compounds have been shown to encourage new bone 7 
ingrowth in vivo (Anon n.d .; Karen A Hing et al. 2001), forming a strong 8 
bond with existing bone, a property that is unique to bioactive ceramics 9 
(Mason 2007; Ducheyne & Qiu 1999).  β -TCP is reported  to have greater 10 
bioactivity due to enhanced  biodegradation rates when compared  to 11 
stoichiometric HA, which has a more limited  reactivity (NHS 2012a; Fujita 12 
et al. 2003; Florence Barrère 2006). Without cellular or cortical support HA 13 
is naturally brittle, with low fracture resistance due to its chemical and  14 
structural, crystalline composition. This can make it inefficient in 15 
applications requiring significant impact, torsional, bending or shear stress. 16 
Furthermore, HA has an extremely low resorbability, which can affect 17 
stability in the long term, as it is not properly remodelled  (Barrère et al. 18 
2008; Habraken et al. 2007).  19 
Biological apatite is not stoichiometric, instead  it has multiple ionic 20 
substitutions (as described  previously in section 1.3.4.2) which d isrupt the 21 
lattice, making it unstable. HA‘s qualities can be improved through the 22 
addition of compounds or ionic substitution. These modifications have 23 
been the focus of many scientific stud ies (Zippel et al. 2010; Nair et al. 2008; 24 
Pietak & Sayer 2006; Fujita et al. 2003; Langstaff et al. 2001). 25 
The addition of ions, such as Niobium and Zinc has been shown to lower 26 
toxicity and  promotes calcification of hydroxyapatite-based  materials 27 
(Robbins & Cotran 1974; Ramaswamy et al. 2008; Tamai et al. 2007). Other 28 
stud ies have incorporated  compounds such as Pamidronate and  sulphate 29 
particles with some success (Wolff 1870; Ponader et al. 2008; Atilgan et al. 30 
2007). 31 
Bioactive glass ceramics are calcium phosphate based , and  contain specific 32 
proportions of SiO2 Na2O CaO and P2O5. The inclusion of these compounds 33 
results in a bioactive substrate, capable of forming intimate bonds to bone.  34 
Larry Hench originally developed Bioglass in 1971, as a bone graft 35 
substitute for Vietnam veterans (Sims & Gooi 2008; Hench et al. 1971).  36 
CHAPTER ONE 
 29 
Since then Bioglass is clinically used  in multiple forms, each containing 1 
varying proportions of ions (NHS 2012b; Shi 2004). These d ifferent 2 
compositions result in varying bioactivity, allowing degradation rates and  3 
bonding capabilities to be tightly controlled . In vitro studies of Bioglass 4 
have shown its d issolution products contain high levels of silicon, known 5 
to stimulate osteogenesis and  protein production  (Marie & Kassem 2011; 6 
Valerio et al. 2004; Xynos et al. 2001). The key d isadvantage of Bioglass is 7 
its mechanical weakness and  low bending strength. As a result Bioglass is 8 
not appropriate for load  bearing applications (Krane 1977; Shi 2004). 9 
1.5.5.8  Silicon  10 
 11 
After oxygen, silicon is the next most abundant element in the earth‘s crust. 12 
The presence of silicon in mammalian systems is relatively variable, yet 13 
essential for multiple organ functions (Tolar et al. 2004; Schwarz & Milne 14 
1972). In particular, silicon is present in high levels in extracellular 15 
components, implying a role in biological cross-linking that could  16 
contribute to the resilience and  structure of connective tissue (Theill et al. 17 
2002; Pietak et al. 2007; Bagi 2005). Silicon is essential in early bio- 18 
mineralisation and  calcification (Rodan 1992; Carlisle 1972; Yaszemski et al. 19 
1996). Silicon deficiencies in chicks and  rats showed deformities in skeletal 20 
development and  regulation (Shapiro 2008; Duivenvoorden et al. 2008; 21 
Gans & Northcutt 1983; Pietak et al. 2007). Furthermore, low dietary intake 22 
of silicon has been linked  to low bone mineral density, whilst d ietary 23 
supplementation of silicon shows stimulatory effects on cartilage and  24 
inhibits the physiological resorption process (Schulmerich 2008; 25 
Ramaswamy et al. 2008). Aqueous silicon has been demonstrated  to 26 
increase osteoblast proliferation, d ifferentiation and  protein production in 27 
vitro (Datta et al. 2008; Reffitt et al. 2003; Keeting et al. 1992). 28 
 29 
1.5.5.9  Silicate substituted calcium phosphate 30 
 31 
Given the significant roles of silicon in bone growth and  development there 32 
has been great interest in introducing silicon into synthetic bone grafts to 33 
enhance their bioactivity (Weiner & Traub 1986; Pietak et al. 2007). Silicon 34 
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in the form of silicate (SiO 4
4-) can be introduced  to these materials in a 1 
variety of concentrations. 2 
Wet chemical methods involve silicon as a chemical carrier, such as 3 
tetraethyl-, propyl- or ortho- silicate. Solid  state or hydrothermal methods 4 
apply extremely high temperatures, exceeding 700°C, sintering the 5 
materials together (Malfait et al. 2007; Tang et al. 2005; Reid  et al. 2006). 6 
Either of these processes can result in d iffering forms of silicon 7 
substitution, including octo-calcium phosphate, and  tri-calcium phosphate, 8 
either in  or  forms (Langstaff et al. 2001). The content can also be 9 
carefully regulated , resulting in reproducible and  accurate percentage 10 
weight.  11 
The biological performance of silicate-substituted  calcium phosphates has 12 
been well studied , in vivo and  in vitro.  13 
Actifuse is a commercially available and  clinically used  silicon substituted  14 
calcium phosphate (Si-CaP). It was specifically designed  to incorporate 15 
silicon at a similar level to that seen in bone (0.8% wt) (K A Hing et al. 16 
2004a). 17 
In vivo studies on Si-CaP demonstrated  (up to 14.5% compared to HA) 18 
greater, more dense (Wheeler et al. 2007) bone ingrowth (Patel et al. 2002; 19 
Patel et al. 2005), more stable (Karin A Hing et al. 2007) bone graft and  20 
enhanced  bone remodelling (A. E. Porter, Patel, et al. 2004b), no 21 
inflammatory response (Wheeler et al. 2007) 22 
In vitro studies have shown to enhance osteoblast adhesion, proliferation, 23 
protein production, and  enhanced  mineralisa tion (Thian et al. 2007; Bjerre 24 
et al. 2008; Zou et al. 2009; Ponader et al. 2008; Balamurugan et al. 2008). 25 
1.5.5.10  Biological reactivity of calcium phosphates 26 
 27 
When a calcium phosphate based  bone graft is implanted , a series of 28 
reactions occur at the graft–tissue interface that will determine the 29 
bioactivity and  ultimately how well the material is integrated into the 30 
surrounding bone. The dynamic reactions required  to result in successful 31 






Table 2: Stages of bone graft integration upon implantation 1 
Implantation 
Dissolution of ions 










Shortly after implantation, both HA and Si-CaP based  bone grafts lose 3 
calcium and phosphate ions from their structure in a process known as 4 
d issolution. This results in an enhanced  concentration of ions next to the 5 
graft-bone interface that react to form a biologically equivalent, carbonated 6 
HA layer on the graft materials surface, termed an apatite layer. The 7 
bioactivity of a substrate can be d irectly linked  to the rate and  composition 8 
of this biomimetic layer (Chou et al. 2004). Multiple in vitro and  in vivo 9 
studies, have examined d issolution rates and  apatite layer formation of 10 
both Si-CaP and HA (LeGeros et al. 2003; A. E. Porter, Botelho, et al. 2004a; 11 
A. E. Porter et al. 2003a). Stoichiometric HA has an extremely slow 12 
d issolution rate, the slowest of all calcium phosphates (Ducheyne et al. 13 
1993), and  as a result forms an apatite layer much later when compared  to 14 
substituted  calcium phosphates (Ducheyne & Qiu 1999). Substitution in the 15 
form of silicate, in particular (Si-CaP), decreases the time taken to form an 16 
apatite layer (Gibson et al. 2009). Studies have demonstrated  that the silicon 17 
ions released  form Si-CaP were capable of stimulating apatite precipita tion, 18 
even in the presence of bacterial inhibitors known to prevent calcium 19 
phosphate precipitation (Damen & Cate 1992). Dissolution of Si-CaP not 20 
only releases calcium and phosphate into the surrounding environment, 21 
but also silicate ions (Botelho et al. 2002). This release of silicate into the 22 
extracellular environment may play an additional role in promoting 23 
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biological activity. As d iscussed  previously, silicate has dose-dependent 1 
effects on osteoblast d ifferentiation, proliferation and  protein  synthesis, 2 
and  mineralisation. This silicate release, coupled  with an enhanced  apatite 3 
formation rate, may lead  to enhanced  binding of key proteins involved  in 4 
cell attachment. 5 
 6 
1.5.6 Protien adsorption 7 
 8 
Protein adsorption is the process of accumulation and  bin ding of protein to 9 
a surface. This occurs rapid ly in implanted  calcium phosphate bone grafts, 10 
which adsorb proteins from blood. Protein adsorption aids the recruitment 11 
and  osteoblastic d ifferentiation of MSC, which ultimately results in 12 
remodelling of newly synthesised  bone at the implant site. This biological 13 
response of a bone graft is dependent upon the species, quantity and  14 
conformation of the proteins adsorbed  (K A Hing 2005). A wide variety of 15 
proteins have been shown to adsorb onto biomaterials in vivo, including 16 
bone sialoprotein, collagens, fibrinogen, fibronectin, laminin, osteopontin, 17 
thrombin, thrombospondin and  vitronectin (Combes & Rey 2002; Alford  & 18 
Hankenson 2006).  19 
In order to examine the effect of proteins on MSC and osteoblast adhesion, 20 
proliferation and  d ifferentiation, experiments consisting of cell cultures on 21 
d ishes coated  with extracellular matrix proteins are currently used . Results 22 
have shown that cells adhere to p roteins with d iffering affinity; osteoblasts 23 
adhere preferentially to fibronectin, compared  to collagen type I and  24 
vitronectin (Gronthos et al. 1997).  Furthermore, studies have demonstrated 25 
that collagen; fibronectin and  vitronectin in particular are readily adsorbed 26 
onto Si-CaP and HA in vivo (Guth, Campion, Buckland & Hing 2010b; 27 
Blunn n.d .). Although both substrates adsorb proteins, studies have shown 28 
that a greater quantity of protein is adsorbed  in a preferential binding 29 
conformation on Si-CaP, compared  to HA (Pietak et al. 2007; Botelho 2005; 30 
Karin A Hing et al. 2006).  The adsorbed  protein layer will subsequently 31 
mediate the interaction of the implanted graft with local cells and  32 
migrating progenitor cells and  attachment of these cells are dependent 33 
upon adhesion molecules present on the cell surface. Integrins are the 34 
CHAPTER ONE 
 33 
predominant receptor involved  in cell adhesion to extracellular proteins 1 
(Siebers et al. 2005). 2 
1.6 Integrins 3 
 4 
Integrins are membrane-spanning proteins that couple the cell to its 5 
extracellular environment and  allow signalling across the cell membrane in 6 
both d irections. Integrins are composed  of two glycoprotein subunits, the α 7 
chain and  the β chain, which  are non-covalently bound. Each chain spans 8 
the cell membrane, containing cytoplasmic, transmembranous and 9 
intracellular domains. Each α and  β chain contains d isulfide bridges, but can 10 
differ vastly in length. The α chain is 1008-1152 amino acids long, and  the β 11 
chain 770, amino acids in length (Siebers et al. 2005). The basic structure of 12 
an integrin and  its subunits are depicted  in Figure 5. 13 
  14 
Figure 5: Integrin subunit structure and domains.  15 
Illustration depicting the extracelluar and intracellular areas of integrin subunits, 16 
highlighting calcium (Ca2+) binding domain, and extracelluar matrix (ECM) binding 17 
domain. Integrins allow bidirectional signalling, transducing information from the 18 
external environment into the cell and from within the cell to its surroundings. Figure was 19 
created using Microsoft PowerPoint 2007. 20 
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1.6.1 Integrin signalling 1 
 2 
Integrins bind  to specific recognition sequences in proteins, such as the 3 
arginine, glycine, aspartic acid  (RGD) binding domain  of fibronectin or the 4 
glycine-phenylalanine-hydroxyproline-glycine-glutamine-arginine 5 
(GFOGER) binding domain of collagen type I (García & Reyes 2005). These 6 
binding sites are also affected  by the proteins structure and  many integrins 7 
also require secondary binding sites to achieve maximum signal function 8 
(Danen et al. 1995).  Individually, integrin binding to the ECM is relatively 9 
weak however; ligand binding activates clustering of multiple integrins, 10 
forming a larger signalling complex. Within this complex, a variety of 11 



















Figure 6: Major signalling pathways involved in mechanical stimulation of 3 
osteogenic differentiation.  4 
Figure drawn using Microsoft powerpoint 2007, adapted from (Papachroni et al. 2009). 5 
Membrane-bound receptors including Ca2+ channels, G-proteins, integrins, IGF, TGF-β, 6 
BMP and Wntreceptors can be stimulated by extracellular forces, inducting activation of 7 
several transcription factors, which regulate osteoblast differentiation. AP-1 and RUNX2 8 
are induced mainly through MAPK and SMADs pathways. RUNX2 is also stimulated 9 
via the Wnt pathway, involving β-catenin and TCF or LEF factors. PLC–PKA pathway 10 
contributes to NF-κB, Cox-2 and CREB induction.  Abbreviations: IGF – insulin like 11 
growth factor receptor, AP-1- activator protein-1, FAK - focal adhesion kinase, IP3 - 12 
inositol (1,4,5)-trisphosphate, MEKK - MAPK kinase kinase, PKA - protein kinase A, 13 
PKC - protein kinase C, PLC - phospholipase C, PYK2 - proline-rich tyrosine kinase 2. 14 
 15 
Large clusters of integrins and  signalling molecules form focal adhesion 16 
complexes, which are essential to cell attachment (Eleniste & Bruzzaniti 17 
2012). Focal adhesions these are the contact points between cells and  the 18 
substrate and  dynamically link the ECM to intracellular actin, facilitating 19 
cell spreading and  migration. Figure 7shows an osteoblast attached  to Si- 20 
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CaP with mature focal adhesions d irectly connected  to actin filaments. In 1 
combination with other receptors, these adhesive clusters can activate 2 
intracellular pathways critical to proliferation, migration, and  3 




Figure 7: Osteoblast attached to Si-CaP with multiple focal adhesions.  8 
Immunostained osteoblast attached to silicate substituted calcium phosphate (Si-CaP), 9 
actin (red), Vinculin (green) DAPI (blue) scale bar represents 50 μm. 10 
 11 
 12 
Due to these multifunctional prop erties integrins have been extensively 13 
studied  and  as a result have become one of the best understood cell 14 
adhesion receptors since their recognition around 15 years ago (Hemler 15 
1999).  The mammalian set of integrins is composed  of 18 α and  8 β subunits, 16 








Table 3: Selected integrins, subunits, ligands and expression. 1 
Subunits Binds to  Expression 
β1 α1 Collagens, Laminins 
Bone cells, cultured  osteoblastic cells, activated  
T-cells, monocytes, melanoma cells and  smooth 
muscle cells 
 α2 Collagens, Laminins 
Bone cells, cultured  osteoblastic cells, B and  T 
lymphocytes, p latelets, fibroblasts, end othelial 




Cultured  osteoblastic cells, B- lymphocytes, 
kidney glomerulus and  most cultured  cell lines 
 α4 Fibronectin VCAM 
Cultured  osteoblastic cells, lymphocytes, 
monocytes, eosinophils, NK-cells and  
thymocytes 
 α5 Fibronectin  
Bone cells, cultured  osteoblastic cells, memory- 
T-cells, monocytes, p latelets and  fibroblasts 
 α6 Laminins 
Platelets, lymphocytes, monocytes, thymocytes 
and  epithelial cells 
 α7 Laminins 
Skeletal and  card iac muscle at specific stages 
during muscle development and  melanoma 
cells 
 α8 Fibronectin, Tenascin   
 α9 Tenascin 
Adult skeletal muscle, visceral smooth muscle, 
skin and  corneal epithelial cells, hepatocytes 
 α10 Collagens  





Bone cells, cu ltured  osteoblastic cells, 
endothelial cells, some B-cells, p latelets and  
monocytes 
β4 α6 Laminins 
Immature thymocytes, squamous epithelia, 
subsets of endothelial cells, Schwann cells and  
fibroblasts in the peripheral nervous system  
β5 αv Tenascin 
Cultured  osteoblastic cells, hepatoma cells, 
fibroblasts and  carcinoma cells 
β6 αv Vitronectin  Carcinoma cells 
β7 α4 Fibronectin, Tenascin  










1.7 Aims and Objectives 1 
 2 
Understanding the interaction between bone grafts and  stem cells has a key 3 
role in improving the success of orthopedic devices. Ideally, a substrate 4 
should  not only support, but actively drive osteogenic d ifferentiation. 5 
Silicon is known to play an essential role in bone formation and  can 6 
stimulate gene and  protein expression in osteoblasts. The inclusion of 7 
silicon into calcium phosphates, in particular  silicate substituted  calcium 8 
phosphate (Si-CaP), has shown enhanced  bone formation in vivo, when 9 
compared  to hydroxyapatite (HA).  10 
This thesis will therefore examine the hypothesis that the superior bone 11 
formation associated  with Si-CaP is a result of activating osteogenic 12 
d ifferentiation of mesenchymal stem cells. 13 
 14 
This will be achieved  by the following: 15 
 The optimisation of dense d isc manufacture of Si-CaP and HA for in 16 
vitro testing. 17 
 Characterisation of mesenchymal stem cells from three d ifferent 18 
sources. 19 
 An investigation into the effects of Si-CaP and HA upon these 20 
mesenchymal stem cells, compared  to soluble factors known to drive 21 
osteogenic d ifferentiation. 22 
 The evaluation of possible mechanisms behind  how stem cells 23 









CHAPTER TWO: MATERIALS AND METHODS 1 
 2 
Unless otherwise stated , all chemicals were purchased  from Sigma-Aldrich, 3 
UK. All tissue culture reagents were purchased  from Invitrogen, UK and all 4 
tissue culture plastics from Corning, UK. All tissue culture procedures were 5 
performed in a Class 2, HEPA filtered , laminar flow hood, using sterile 6 
equipment. 7 
 8 
2.1 General solutions 9 
 10 
All solutions are made in d istilled  water unless otherwise stated . 11 
 12 
50 X TAE:    24.2 % (w/ v) Tris base 13 
     5.71 % (v/ v) Glacial acetic acid  14 
     1.86 % (w/ v) EDTA 15 
 16 
10 X loading dye:   0.25% (w/ v) Bromophenol blue 17 
     0.25% (w/ v) Xylene cyanol 18 
     25% (v/ v) Ficoll 19 
 20 
Digestion solution:   1 mg/ ml Collagenase II 21 
      3.5 % BSA in un-supplemented  DMEM 22 
       23 
Red blood lysis buffer:   Solution A: 0.83 % (w/ v) ammonium 24 
chloride    Solution B: 2.059 % (w/ v) Tris base  25 
9 parts of solution A are added to 1 part 26 
of solution B and the pH is ad justed  pH 27 
to 7.65 with 1M hydrochloric acid  28 
 29 
EDTA solution:   37.2 % (w/ v) EDTA (pH 7.4)  30 
 31 







2.2 Cell Culture 1 
 2 
The media referred  to as ‗growth media‘ consists of Dulbecco‘s Modified 3 
Eagle‘s Medium – high glucose (DMEM), supplemented  with 10% (v/ v) 4 
Fetal bovine serum (FBS), L-glutamine (2 mM) (Gibco, UK), penicillin (100 5 
IU/ ml) and  streptomycin (100 µg/ ml) (Gibco, UK). 6 
 7 
2.2.1  Human Bone Marrow Derived Mesenchymal Stem Cell Isolation 8 
And Culture 9 
 10 
Following written consent from the patients and  approval from the local 11 
ethical committee, (study number: 2002/ R/ OST/ 02).  Human femoral head  12 
tissue was obtained  from a total of five patients who had  undergone 13 
elective arthroplasty, who d id  not have viral infections (Hepatitis or AIDS), 14 
and  where tissue was not suitable for bone banking. The tissue samples 15 
were allocated  an anonymous number based  on the chronological order of 16 
the sample collection, shown in Table 4. 17 
 18 
Table 4: Patient details and passage at which cells were used. 19 
Patient 
number 
Age at date 
of surgery 
Sex Passage 
559 50 Female P3 - P10 
582 79 Female P2 - P11 
596 74 Female P3 - P9 
623 57 Male P3 - P10 
633 70 Male P3 -P7 
 20 
Tissue samples were stored  in sterile phosphate buffered  saline (PBS) at 21 
4°C, d irectly after surgery. The MSC isolation protocol used  was as 22 
previously described  by (Tremoleda et al. 2008) with minor modifications 23 
from (Gronthos & Zannettino 2008) and  (Gundle & Joyner 1995) and  was 24 
started  within 4 hours post-surgery. 25 
 26 
Using bone cutters and  a blunt ended scalpel, the trabecular bone was 27 
removed from the femoral head  and  placed  in a 50 ml Falcon tube.  Then 9 28 
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ml of growth media was added to the bone chips, which were pipetted  up 1 
and  down for approximately 1 minute with a 5 ml p ipette (Corning, USA). 2 
Large bone fragments were allowed to settle to the bottom of the 50 ml 3 
Falcon tube and  the supernatant, containing cells, was transferred  to a 50 4 
ml Falcon tube.  This process was repeated  twice using 5 ml of growth 5 
media and  the supernatants combined . The tube containing the 6 
supernatants was allowed to settle and  the upper layer containing fat was 7 
removed. The remaining portion was transferred  to a 25 cm 2 tissue culture 8 
flask (Corning, USA). The cells were maintained  undisturbed  for 4 days, in 9 
a humidified  air incubator at 37°C with 5% (v/ v) carbon d ioxide (CO 2).  10 
After this time, non-adherent cells were removed by washing twice with 5 11 
ml of PBS, before 5 ml of fresh growth media was added. 12 
The growth media was refreshed  every two or three days. Once the cells 13 
reached approximately 80% confluence, they were washed  twice with PBS, 14 
and  passaged  by add ing 1 ml of trypsin solution (2.5 mg/ ml) in PBS 15 
(Invitrogen, UK).  After up to 15 minutes incubation with trypsin at 37°C, 9 16 
ml of growth media was added to the flasks. The flasks were tapped hard  17 
on each side to lift cells off the bottom of the flask, once in suspension the 18 
cells were centrifuged  at 1000 rpm for 5 minutes and  media removed. The 19 
cells were resuspended in 10 ml of growth media and  were added to new 20 
tissue culture flasks (75 cm 2).  The flasks were then incubated  and  refreshed  21 
with new growth media as before. 22 
 23 
2.2.2  Human Embryonic Derived Mesenchymal Progenitor Cells  24 
 25 
Human embryonic Stem Cell derived  Mesenchymal Progenitor cells (hES- 26 
MP) (Cellartis, UK) were cultured  according to methods provided  by 27 
Cellartis. Cells were cu ltured  on 0.1% gelatin coated  75 cm 2 flasks in growth 28 
media, with the addition of 1μg/ ml of basic fibroblast growth factor (bFGF) 29 
and incubated  at 37°C with 5% (v/ v) CO 2.  The media was changed with 30 
fresh growth media at regular intervals three times every 7 days.  When the 31 
cells were confluent, they were washed twice in PBS and  passaged  by 32 
adding 1 ml of 2.5 mg/ ml trypsin solution in PBS.  After 5 minutes 33 
incubation at 37°C, 9 ml of growth media was added to each of the flasks. 34 
The cell suspension was centrifuged  at 1000 rpm for 5 minutes and  media 35 
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removed. The cells were counted  and  resuspended in accordance with 1 
recommendations given by Cellartis, flasks were then incubated  and  media 2 
changed as before. 3 
 4 
2.2.3 Human adipose derived mesenchymal stem cell isolation and 5 
culture 6 
 7 
All human adipose derived  cells were extracted  and  processed  by Dr 8 
Christopher West, and were received  at P1 or P3.  9 
After written consent from the patients and  approval from the local ethical 10 
committee (South East Scotland  Research Ethics Committee 03 (SESREC03), 11 
Study number: 10/ S1103/ 45), human lipoaspirate or whole fat was 12 
obtained  from patients who had  undergone plastic surgery for cosmetic 13 
reasons. Tissue was collected  from two patients. The tissue samples were 14 
allocated  an anonymous number based  on the chronological order  of the 15 
sample collection, shown in Table 5. 16 
 17 
Table 5: Patient details and passage at which cells were used. 18 
 19 
All tissue samples were stored  at 4°C, d irectly after surgery and  processed  20 
within 24 hours.   21 
The growth media was refreshed  every two to three days.  Once the cells 22 
were approximately 80 % confluent, they were washed  twice with PBS, and 23 
passaged  by adding 1 ml of trypsin solution (2.5 mg/ ml) in PBS 24 
(Invitrogen, UK). After up to 15 minutes incubation at 37°C, 9 ml of growth 25 
media was added to the flasks. The cell suspension was centrifuged  at 1000 26 
rpm for 5 minutes and  the supernatant removed. The cells were 27 
resuspended in 10 ml of growth media and  were added to new tissue 28 
culture flasks (75 cm 2). The flasks were then incubated  and  refreshed  with 29 




Age at time 
of surgery 













2.2.4 Differentiation conditions 1 
 2 
All cell types were induced  along the ad ipogenic, osteogenic and  3 
chondrogenic lineages using the following d ifferentiation media. 4 
2.2.4.1 Adipogenic different iat ion 5 
DMEM supplemented  with 10% FBS, 1 μM dexamethasone, 100 μM 6 
indomethacin, 1 μg/ ml of insu lin, and  500 μM 3-isobutyl-l-methylxanthine. 7 
The cultures were maintained  for 3 weeks and  the culture medium was 8 
replaced  every two to three days. 9 
2.2.4.2 Osteogenic different iat ion 10 
DMEM containing 100 nM dexamethasone, 50 μg/ ml L-ascorbic acid  2- 11 
phosphate, and  10 mM β-glycerophosphate. The cultures were maintained  12 
for 3 weeks and  the culture medium was replaced  every two to three days. 13 
2.2.4.3 Chondrogenic different iat ion 14 
DMEM supplemented  with 10 ng/ ml of recombinant human TGF-β3, 15 
100 nM dexamethasone, 6 μg/ ml of insulin, 50 μg/ ml L- ascorbic acid  2- 16 
phosphate, 1 mM sodium pyruvate, 6 μg/ ml of transferrin, and  0.40 mM 17 
proline. The cultures were maintained  for 3 weeks and  the culture medium 18 
was replaced  every two to three days. 19 
 20 
2.3 Flow cytometry 21 
 22 
Cells were trypsinised , resuspended in PBS containing 1% FBS, and  23 
incubated  with the appropriate antibodies (shown in Table 6) for 30 24 
minutes at 4°C. Then 1 ml of PBS was added per tube and  centrifuged  at 25 
1000 rpm for 5 minutes, excess liquid  was removed and cells resuspended 26 
in 0.1% sodium azide in PBS and run through the flow cytometry machine. 27 
Cells were gated  by their forward - and  side-scatter characteristics and  to 28 
exclude dead  cells.  A minimum of ten thousand events was acquired  using 29 
a FACS Calibur Flow Cytometry System (Becton, Dickinson and  Company, 30 
Biosciences, San Diego, CA) and  analysed  using FlowJo (Treestar, Inc., San 31 
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2.4 Molecular techniques 1 
2.4.1 RNA extraction  2 
 3 
Cultured  cells were washed twice in PBS, 1 ml of Trizol (Invitrogen) was 4 
added and  the cell lysate passed  several times through a pipette. Then 0.2 5 
ml of chloroform was added and  tubes vortexed  for 15 seconds and  6 
centrifuged  at 13 000 rpm for 15 minutes at 4°C. The aqueous phase was 7 
transferred to a fresh tube and  an equal volume of phenol chloroform (1:1) 8 
was added, the tubes were vortexed  briefly and  centrifuged  at 13 000 rpm 9 
for 3 minutes at room temperature, the upper aqueous phase was 10 
transferred  to a new tube and  an equal volume of chloroform added, 11 
vortexed  and  centrifuged  as before. The upper aqueous phase was 12 
transferred  to a new tube and  mixed  with an equal volume of isopropyl 13 
alcohol and  centrifuged  at 13 000 rpm for 50 minutes at 4°C. The 14 
supernatant was removed and the pellet washed with 0.8 ml 70% ethanol, 15 
and  centrifuged  at 13 000 rpm for 2 minutes at 4°C. The ethanol was 16 
removed and the pellet air-dried  for 5 minutes before it was d issolved  in 17 
RNase free water. The RNA was stored  at -80°C or immediately used  for 18 
reverse transcription into cDNA. 19 
 20 
2.4.2 cDNA synthesis  21 
 22 
RNA was reverse transcribed  to cDNA using SuperScript III First -Strand 23 
Synthesis System (Sigma-Aldrich, UK). Up to 8 μl of total RNA, 1 μl of 50 μM 24 
Oligo (dT) Primer, and  1 μl of 10 mM dNTP mix was incubated  at 65°C for 5 25 
min, then placed  on ice for 1 min. The reaction mix for cDNA synthesis 26 
consisted  of 2 μl of 10X RT buffer (200 mM Tris-HCl, pH 8.4, 500 mM 27 
KCl), 4 μl of 25 mM MgCl2, 2 μl of 0.1 M DTT, 1 μl of RNaseOUT 28 
(ribonuclease inhibitor), and  1 μl of SuperScript III Reverse Transcriptase. 29 
The synthesis reaction was incubated  at 50°C for 50 min, and  then at 85°C 30 
for 5 minutes to terminate the reaction. The tubes were centrifuged  and  1 μl 31 
of RNase H (non-specific endonuclease) added and  incubated  at 37°C for 20 32 




The quality of the RNA and cDNA was assessed  my measuring the ratio of 1 
absorbance at 260 versus 280 nanometres using a NanoVue 2 
spectrophotometer (GE Lifesciences, UK) that measures 2 μl samples with 3 
high accuracy.  For RNA values greater than 2.0 indicated  adequate purity, 4 
and  for cDNA values greater than 1.8 were deemed acceptable. 5 
 6 
2.4.3 Polymerase chain reaction  7 
 8 
All quantitative polymerase chain reactions (PCR) was performed using a 9 
Rotor-Gene 6000 series (Corbett Life Sciences) and  analysed  using Rotor - 10 
Gene (version 1.7.34). For routine PCR, a PTC-225 Peltier Thermal cycler 11 
(MJ research, Watertown, MA, USA) was used . Specific oligonucleotides 12 
were designed  to amplify each DNA fragment of interest, and  are shown in 13 




Table 8. 18 
 19 
The following standard  reaction was used:  20 
 21 
 22 
Standard  PCR cycle parameters were as follows; initialisation (required  for 23 
hot start polymerases to be heat activated) at 95°C for 15 minutes, 24 
denaturation at 95°C for 15 seconds, annealing at (50- 65°C) for 1 minute, 25 
extension at (60-72°C) for 5 minutes final elongation  72°C and final hold  at 26 
4°C. Denaturation, annealing and  extension steps were repeated  between 27 
Component                                                      Volume 
DNA template (50 ng/  µl) 
Forward  primer (10 pmol/ µl) 
Reverse primer (10 pmol/ µl) 
2 X Thermoscript master mix or 
2 X GoTaq Promega qPCR master mix 
DNase free d istilled  water 





Up to a final volume of 20 µl 
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30-40 cycles. Annealing and  elongation temperatures and  times were 1 
altered  according to the primers used  and  product length respectively. 2 
The polymerase in both master mixes (Taq DNA polymerase) acts by 3 
extending the annealed  oligonucleotides to synthesise DNA from 3‘ end  of 4 
the oligonucleotide. This process of denaturation, annealing and  synthesis 5 
is repeated  numerous times, with each newly synthesised  DNA acting  as a 6 
template for the next reaction. Agarose gel electrophoresis (section 2.4.4) 7 
was used  to ensure that the PCR product was the correct size.  8 
2.4.4 Agarose gel electrophoresis 9 
 10 
Agarose gel electrophoresis was used  for analytical or preparative 11 
separation of DNA. A 1 % (w/ v) agarose gel solution in 1 x Tris /  Acetic 12 
acid  /  EDTA (TAE) buffer was prepared  by heating to d issolve the agarose.  13 
Once the solution had  cooled , ethid ium bromide (Invitrogen, Paisley, UK) 14 
was added (final concentration of 0.5 µg/ ml) and  the mixture poured  into 15 
the gel tray containing an appropriate gel comb. 10 X loading dye of the 16 
appropriate volume was added to the DNA sample and  the samples 17 
loaded, along with a 1 Kb GeneRuler marker (Fermentas, UK). DNA gels  18 
were run at 120 mA in 1 x TAE buffer, and  imaged using a UV light source. 19 
 20 
Table 7: Primers used to identify mesenchymal lineage specific genes.  21 






β ACTIN  CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 55 250 
B2M TGCTGTCTCCATGTTTGATG CAACCATGCCTTACTTTATC 55 332 
CD105 TGCCACTGGACACAGGATAA GATGAGGACGGCATCGAGAT 50 807 
RUNX2 CCGCACGACAACCGCACCAT CGCTCCGGCCTACAAATCTC 57.5 289 
COL1A1 ATCGAGCTGACCTTCCTGCG TCGAAGCCGAATTCCTGGTC 55 323 
BGLAP CGCAGCCACCGAGACACCAT GGGCAAGGGCAAGGGGAAGA 65 405 
PTH1R GCATCTCATAGTGCATCTGG CACAGCCTCATCTTCATGG 60 418 
ALP GGGGGTGGCCGGAAATACAT GGGGGCCAGACCAAAGATAG 60 543 
PPARG AAACTCTGGGAGATTCTCCT TCTTGTGAATGGAATGTCTT 50 248 
SOX9 CACACTACAGCCCCTCCTAC CCTCCTCAAGGTGGAGTGAG 55 259 








Table 8: Integrin primers 4 
All integrin primers anneal at 60°C. Primer sequences taken from (Wong et al. 2010) . 5 
6 
Integrin Forward primer 5'-3' Reverse primer 5'-3' 
Product 
size (bp) 
ITGA1/ α1 TCAGCCAAGTCAATGTTTCG CAAAAGCACTCAGCAGGATG 216 
ITGA2/ α2 CGGTTGATGGGACAGAAGTAA GGCTTGGAAACTGAGAGACG 167 
ITGA3/ α3 CCCAACTACAGGCGAAACA GCATCCGCAAAGGTAAAGAG 226 
ITGA4/ α4 GTTTTCCAGAGCCAAATCCA GCCAGCCTTCCACATAACAT 185 
ITGA5/ α5 CAGGGTGGTGCTGTCTACCT GCTCAGTGGCTCCTTCTCTG 237 
ITGA6/ α6 GATAAACTGCGTCCCATTCC TCGTCTCCACATCCCTCTTT 164 
ITGA7/ α7 CCTTTGATGGTGATGGGAAA CAGCAGGTCAGGGTATTGGT 164 
ITGA9/ α9 AAGCCGACCACATCCTACC TCCAGCCCAATAAAATGACC 203 
ITGA10/ α10 CCCAGAACAAGGAAACAGGA CACAGCCACATCAGCAAAAC 167 
ITGA11/ α11 GAAGGGTGGAAGGAAAGGAG GGGTCACTGGCGATGTATTT 207 
ITGAV/ αV ATGGCAAACTCCAAGAGGTG GAGATGGGACTGCGTTCAAG 249 
ITGB1/ β1 CTGCCTTGGTGTCTGTGCT CCTCGTTGTTCCCATTCACT 233 
ITGB2/ β2 TGGTGTTTGCCACTGATGAC GATGGGCTGGATGTTGTTTT 182 
ITGB3/ β3 GCGGCAAGTGTGAATGTG ACTGAGAGCAGGACCACCAG 367 
ITGB4/ β4 CACCAGCAGTCGCTCTACAC CTCGTCCACCATCTTGACCT 171 
ITGB5/ β5 TCTACAAAACCGCCAAGGAC AAGCCCAACAAGGAGGATG 161 
ITGB6β6 GTGAGACACAAAGGGCTGCT AACACACTTGCCACAAACACA 177 
ITGB7/ β7 ACCGTGACCCTTGAACACTC GCTTGGAGAGAAACCCAGAA 161 




2.5 Histology 2 
2.5.1 Cell fixation  3 
 4 
For immunofluorescence imaging, cells were either fixed  with 4 % (w/ v) 5 
paraformaldehyde (PFA) or 100 % m ethanol.  The 4 % PFA solution was 6 
prepared  by adding PFA powder (4 g) to PBS (100 ml), heated to 60C, and 7 
cleared  by the addition of 1 M NaOH.  8 
The culture medium was removed and the cells were gently washed twice 9 
with PBS and fixed  with either 4% (w/ v) PFA for 15 minutes at room 10 
temperature or with 100% methanol at -20°C for 10 min.  The fixative was 11 
removed by aspiration and  the cells were washed twice with PBS before 12 
immunofluorescence staining. 13 
 14 
Table 9: Antibodies used for direct immunofluorescence imaging. 15 
 16 
 17 
Antibody Host Clone Source 
Anti-human RUNX2/ CBFA1 
Anti-human Collagen type I 
Anti-human Osteocalcin 
Anti-human Vinculin 
Rhodamine conjugated  Phalloid in  
Anti-human endoglin/ CD105 
Anti-human Stro-1 
Anti-rat Alexa Fluor IgG 488 


































Primary antibody Secondary antibody 
100 % 
methanol 
5% goat serum 0.1 % BSA 
(30 minutes) 










1:200  in 1% goat serum 
Goat anti mouse Alexa 
Fluor 488 
1:200 1% goat serum 
100 % 
methanol 















Goat anti-mouse Alexa 
Fluor 488 
1:200 
4 % PFA 
10% goat serum, 1% BSA 
0.1% Triton X-100 (1 hour) 
Anti-human RUNX2 
1:200 in 1% blocking buffer 
Goat anti-rat Alexa Fluor 
488 
1:500 
4 % PFA 
Dako protein block (30 
minutes) 
Mouse monoclonal anti-
collagen type I 
1:200 in Dako antibody 
d iluent 
Goat anti-mouse Alexa 
Fluor 488 1:1000 antibody 
d iluent 
4 % PFA 
10% goat serum, 1% BSA, 
0.1% Triton X-100 (1 hour) 
Anti-human osteocalcin 
1:200 
Goat anti-mouse Alexa 
Fluor 488 
1:1000 
All solutions and antibodies were diluted in PBS unless otherwise stated. 
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2.5.2 Direct immunofluorescence 1 
 2 
After fixation cells were immunostained  using the appropriate antibodies 3 
(shown in Table 9). Following the protocols shown in Table 10. If required , 4 
cell membranes were permeabilised  by incubation with detergent d iluted  5 
in PBS. To prevent non-specific antibody binding cells were ‗blocked‘ with 6 
serum diluted  in PBS or Dako protein block (Dako, UK). Primary 7 
antibodies were incubated  at 4°C overnight with the exception of F-actin 8 
and  vinculin which were incubated  at 37°C for 1 hour. Cells were 9 
incubated  with secondary antibodies for 1 hour, at room temperature in the 10 
dark. Cells were washed three times with PBS in between each step, and 11 
counterstained  with DAPI as described  in section 2.5.3 and  mounted  using 12 
fluorescent mounting medium (Dako, UK) prior to imaging. 13 
 14 
2.5.3 DAPI counterstaining  15 
 16 
All cells stained  for immunofluorescence were counterstained  with 4‘,6- 17 
d iamino-2-phenylindole (DAPI) at a concentration of 2 µg/ ml in PBS, for 18 
20 minutes at room temperature, in the dark. DAPI binds to DNA, allowing 19 
visualisation of the cell nucleus. 20 
 21 
2.5.4 Alkaline Phosphatase staining  22 
 23 
Tissue non-specific alkaline phosphatase (ALP) activity was measured  by 24 
histochemical staining using an alkaline p hosphatase kit (Leukocyte 25 
Alkaline Phosphatase Kit, Sigma-Aldrich Ltd ., Poole, UK) following 26 
manufacturer‘s instructions. Briefly, cells were fixed  in 4% PFA as 27 
described  in (section 2.5.1), and  washed  several times with PBS. A 28 
diazonium salt solution was prepared  by adding 500 μl of sodium nitrate 29 
solution (0.1 M) to 500 μl of Fast Blue base-alkaline solution (5 mg/ ml). The 30 
solution was inverted and  allowed to stand  at room temperature for  2 31 
minutes. Distilled  water (22.5 ml) was added to 500 μl of naphthol AS-BI 32 
alkaline solution (4 mg/ ml), and  combined  with the d iazonium salt 33 
solution. After mixing, 250 μl of the solution was added to each well. The 34 
plates were then incubated  in the dark at room temperature for 15 minutes, 35 
CHAPTER TWO 
 52 
before each well was washed with PBS. The cells were counterstained  with 1 
DAPI as described  in section 2.5.3.  Rat femoral sections were used  as a 2 
positive control, an example of ALP staining (blue) seen in bone marrow 3 
and  bone matrix, shown in Figure 8 (A).  4 
 5 
Figure 8: Positive controls for lineage specific staining. 6 
Sections of rat tibia were fixed and stained for (A) alkaline phosphatase, (B) mineralisation 7 
(Von Kossa), (C) oil droplets (Oil red O), and for (D) glycosaminoglycans (Safranin O) 8 
scale bars represents 100μm. 9 
 10 
2.5.5 Von Kossa staining for phosphate 11 
 12 
Von Kossa staining was carried  out to assess mineralisation in the form of 13 
phosphate crystals.  The principle of this stain is the silver ions react with 14 
phosphate and  precipitate as metallic silver  under bright light, resulting in 15 
black staining (Kossa 1901). Briefly cells were fixed  in 4% PFA, washed 16 
three times with d istilled  water, then incubated  with 5% (w/ v) silver 17 
nitrate solution before being exposed  to a 60 watt light bulb for 10-15 18 
minutes. This allowed  staining of any mineralised  matrix produced, but 19 
not of the substrates that also contain calcium phosphate. Following 20 
exposure, cells were washed in d istilled  water and  incuba ted  in 5% (w/ v) 21 
sodium thiosulphate solution for 5 minutes to remove any unreacted  silver 22 
nitrate. Cells were washed three times in d istilled  water and  the cells 23 
counterstained  with DAPI (section 2.5.3). Rat femoral sections were used  as 24 
a positive control; mineralised  areas (black deposits) of trabecular bone are 25 






2.5.6 Oil Red O staining for lipid droplets 1 
 2 
Oil red  O can be used  to detect lipid  droplets produced by adipocytes, due 3 
to high solubility in lipids. Cells were fixed  with 4% PFA and washed three 4 
times with d istilled  water, then once with 60 % isopropyl alcohol. Stock 5 
solution (oil red  O 0.5% (w/ v) in isopropyl alcohol) was d iluted  3:2 in 6 
d istilled  water, allowed to stand  for 10 m inutes then filtered  through a 0.22 7 
μm filter. This ‗working‘ solution of oil red  O was added to cells and  8 
allowed to incubate for 15 minutes at room temperature. Then the cells 9 
were rinsed  briefly with 60% isopropyl alcohol, then washed three times 10 
with water and  counterstained  with DAPI, (section 2.5.3). Rat femoral 11 
sections were used  as a positive control; oil red  O stained  lipid  droplets 12 
red , within the bone marrow, and  is shown in Figure 8 (C). 13 
 14 
2.5.7 Safranin O staining for cartilage 15 
 16 
Safranin O is a dye that binds to glycosaminoglycans, which make up a 17 
large proportion of extracellular matrix found in cartilage (Camplejohn & 18 
Allard  1988). Cells were fixed  with 4% PFA and washed three times with 19 
d istilled  water and  once with 1% acetic acid  for 10 seconds. Safranin O 0.1% 20 
(w/ v) solution was added to cells and  allowed to incubate for 5 minutes at 21 
room temperature. Then the cells were washed three times with water and 22 
counterstained  with DAPI, (section 2.5.3). Rat femoral sections were used  23 
as a positive control; patellar articular cartilage was stain ed  orange with 24 












2.5.8 Imaging and image analysis 1 
 2 
2.5.8.1 Image acquisit ion  3 
 4 
All images were collected  using a Zeiss Axio Observer.Z1 microscope with 5 
LD Plan-Neofluar objective lenses (Carl Zeiss Ltd . Welwyn Garden City, 6 
UK). The microscope was coupled  to a Zeiss AxioCamMR3 camera. The 7 
image acquisition and  processing software used  was Zeiss Axiovison Rel 8 
4.8. and  Axiovison Version 4.7.1.0, respectively. When visualising 9 
immunofluorescence staining, Dako fluorescent imaging medium (Dako 10 
UK Ltd , Cambridgeshire, UK) was used . All images were collected  at room 11 
temperature.   12 
 13 
2.5.8.2 Semi-automated cell count ing 14 
 15 
To calculate the number of cells attached  to each substrate, cells were 16 
stained  with DAPI (section 2.5.3) the entire well was imaged and  cell 17 
number counted  using a self-created  macro (cell count macro) in ImageJ 18 
(National Institute of Health, USA) (see appendix). Figure 9 shows how the 19 
cell macro operates, and  full details of the macro are shown in the 20 




Figure 9: Diagram of how the cell counter macro operates.   2 
1. A mosaic image was taken of the entire well, where cell nuclei are stained with DA PI, 3 
shown here in blue. 2. The image was converted to an 8-bit image, in Image J.  3. The 4 
brightness and contrast were adjusted automatically.  4. An automatic theshold was set.  5 
5. The image was converted to mask.  6. The number of particles were counted, including 6 
all particles between 10 and 100 pixels in size, and the number of particles shown in a 7 







2.5.8.3 Area of staining quant ificat ion 1 
 2 
To quantify the area of alkaline phosphatase staining or area of 3 
mineralistion (Von Kossa) on each substrate, the cells were stained , imaged 4 
and  the area was quantified  using a self- created  macro (Area quant macro) 5 
using ImageJ (see appendix). An example of how images were processed  in 6 
the macro is shown in Figure 10 and  Figure 11. 7 
 8 
 9 
Figure 10: Von Kossa staining and quantification. 10 
Example of how Von Kossa staining is quantified by area, the image was converted to an 11 
8-bit image, an automatic threshold set and the area analysed using an automated area 12 
quantification macro. The upper image is 18.5% lower image is 60.5% 13 
 14 
 15 
Figure 11: Alkaline phosphatase staining and quantification. 16 
Example of how alkaline phosphatase is quantified by area of staining, the image was 17 
converted to an 8-bit image, an automatic threshold set and the area analysed using an 18 






2.6 Silicate substituted calcium phosphate and hydroxyapatite 1 
disc manufacture 2 
 3 
Hydroxyapatite was prepared  using the precipitation reaction between 4 
calcium hydroxide (Ca(OH)2) and  orthophosphoric acid  (H 3PO4) with 5 
molar ratios described  in Table 11 below. This precipitation method is 6 
based  on the method described  by (Akao et al. 1981). Silicate-substituted 7 
calcium phosphate (Si-CaP) was prepared  as described  by (Gibson et al. 8 
1999). Briefly, Si-CaP was prepared  by an acid -base neutralisation reaction, 9 
the precipitation reaction was carried  out at room temperature, and  the pH 10 
maintained  at 10.5 through the addition of ammonium hydroxide solution. 11 
The precipitation reaction was mixed  for several hours then left 12 
undisturbed  overnight. The solu tion was then filtered  though a filtration 13 
press at 600 bar for approximately 30 min, then dried  for 4 days at 40°C. 14 
The dried  precipitate was ground by hand into 10 mm 2 pieces, passed  15 
through a milling machine, which ground the precipitate into a powder 16 
w ith grains approximately 400 μm in d iameter, then calcined  at 700°C for 4 17 
hours.   18 
 19 



















0.5 0.297 0 1.68 1.68 
Silicate -substituted  
Calcium Phosphate 
(Si-CaP) 
0.5 0.289 0.008 1.73 1.68 
 22 
Calcined  powder was pressed  into d iscs 20 mm in d iameter, using a d ie 23 
and  pellet set and  a Manual Hydraulic Press (both Specac, UK). Samples 24 
were pressed  for 5 seconds at 2 MPa, removed from the pellet and  then 25 





2.6.1 Disc analysis 2 
 3 
Sintered  d isc height and  d iameter were measured  using d igital callipers 4 
(0.01mm) and weighed  using d igital scales (0.0001g).  5 
 6 
2.6.2 Mercury intrusion porosimetry 7 
 8 
The term ―porosimetry‖ is frequently used  to include the measurements of 9 
pore size, volume, d istribution and  density. Porosity is particularly  10 
important in understanding the formation, structure, and  potential use of 11 
many materials as porosity can affect a material‘s adsorption, permeability, 12 
strength, and  density (Abell et al. 1999). Mercury is a non-wetting liquid  13 
(one having a contact angle greater than 90°) and  therefore, will only 14 
intrude capillaries under pressure. The required  pressure is inversely 15 
proportional to the size of the pores, only slight pressure being required  to 16 
intrude mercury into large macropores, whereas much greater pressures 17 
are required  to force mercury in to smaller pores (micropores). Mercury 18 
intrusion porosimetry involves the progressive intrusion of mercury into a 19 
porous structure under strictly controlled  pressures. From the pressure 20 
versus intrusion data, the instrument generates volume and size 21 
d istributions using the Washburn equation (Washburn 1921), below.  22 
 23 
Equation 1 24 
 25 
 26 
Where r is the rad ius of the pore, p is pressure, γ is the contact angle 27 
between the mercury and  a surface of the solid  material tested  and  θ is the 28 
surface tension of mercury. 29 
The pore size d istribution is determined  from the volume intruded  at each 30 
pressure increment, and  total porosity was determined  from the total 31 
volume intruded . Porosity measurements were performed using a mercury 32 
intrusion porosimeter (Poremaster GT, Quantachrome UK Ltd . Hook, UK) 33 
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using pressures from 1 to 105 psi. Briefly, samples were weighed and  1 
loaded  into penetrometers (see Figure 12 the upper rim of the penetrometer 2 
was lubricated  using heat stable, silicone grease (Dow Corning, Belgium) 3 
and  contacts placed  on top, ensuring a tight seal, and  the caps were firmly 4 
screwed onto the contact. Two penetrometers were placed  into the low - 5 
pressure stations of the machine and  set to run. Once the low pressure run 6 
was complete the two penetrometers were removed, the capillary opening 7 
was filled  with up with hydraulic oil and  then placed  into metal casings, 8 
and  into the high-pressure chamber for the next run.  9 
 10 
 11 
Figure 12: Diagram of a mercury penetrometer containing sample and mercury.  12 
Mercury penetrometers were used with a intrusion porosimeter to determine porosity of 13 
discs. Under high pressures the mercury is forced into the pores of the disc and the volume 14 
of liquid displaced allows calculation of the volume of a range of pore sizes and total 15 
porosity of each disc. 16 
 17 
The data was integrated  from the low pressure and  high pressure runs and  18 
raw and volume vs. Pressure was graphed as shown in Figure 13. This was 19 
then converted  to –dV/ logD vs. Pore size, shown in Figure 14. This graph 20 
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shows the d istribution of pore size in relation to the intruded  volume of 1 
mercury. The pore size to be analysed  was chosen (0.1-5 µm), shown in  2 
Figure 15. A standard report summary was generated  and  the intruded  3 
volume (g/ cc) calculated  and  converted  to strut porosity, using the formula 4 
in Equation 2. 5 
 6 






Figure 13: Raw voiume (cc) Vs.pressure (psi).  13 
The change in volume is shown at different pressures, increasing until all the pores are 14 















Figure 14: dV/dlogD Vs. Pore size.   2 
The intruded volume is converted to pore size and the pore size, the peak indicates the 3 




Figure 15: dV/dlogD Vs. Pore size (5- 0.1 µm). 8 





2.6.3 Helium pycnometry 1 
 2 
Helium pycnometry is a method used  to determine the density of a 3 
material. A chamber is filled  with gas, generally helium; the object to be 4 
measured  is then placed  in the chamber and  filled  with gas again. The 5 
pycnometer then calculates density based  on gas d isplacement (Furuse 6 
1989).  7 
Pycnometric densities were measured  using a helium pyconometer 8 
(Ultrapycnometer 1200e, Quantachrome UK Ltd . Hook, UK). Prior to each 9 
analysis the pycnometer was calibrated  twice, once with an empty chamber 10 
and  secondly with a reference volume. Two discs were selected  and  11 
weighed, they were placed  inside the pycnometer and  run 18 times, with 10 12 
pulses at a pressure of 17 psi, a minimum of 6 runs were averaged  to 13 
achieve a standard  d eviation of ≤ 0.0005.  14 
 15 
Equation 3 16 
 17 
 18 
The volume of the samples was calculated  using the formula above. Where 19 
Vs.is the sample volume, V c is the volume of the empty sample chamber, V r 20 
is the volume of the reference volume, P1 is the first pressure (sample 21 
chamber) and  P2 is the second (lower) pressure after expansion of the gas 22 
into the combined  volumes of sample chamber and  reference chamber. 23 
The density was then calculated  using the following equation, where p is 24 
the density, m is the mass and  V  the volume of the sample (V=π r2 25 
h ) where (r = radius, h = height of d isc). 26 






2.6.4 Embedding and polishing  1 
 2 
Embedding and  polishing of specimens was performed prior to analysis of 3 
density using Scanning Electron Microscopy.  Discs were split in half using 4 
sharp-ended pliers and  dried  at 50-70°C for 12 hours; each sample was then 5 
cooled  at room temperature in a desiccator cabinet for 30 minutes. Samples 6 
were then placed  into numbered  moulds inside a vacuum impregnation 7 
cabinet (Struers Epovac, Struers, Rotherham, UK) and  held  under vacuum 8 
at approximately 200 Mbar for 15 minutes. Embedding resin was composed  9 
of 50 g epoxy resin (EpoFix, Struers), 8 g hardener (EpoFix hardener) and  < 10 
0.5 g Sudan blue dye (Sigma Aldrich). All components were mixed 11 
thoroughly for 5 minutes then applied  in stages, under vacuum, to each 12 
mould  until each sample was fully covered . After all the resin was added  13 
the samples remained  under vacuum for a further 10 minutes. To remove 14 
excess bubbles the pressure in the vacuum was increased  to 700 Mbar then 15 
decreased  back to 200 Mbar three times. The samples were then removed 16 
from the vacuum cabinet and  left to ‗cure‘ overnight in a fume hood. Once 17 
the resin had  fully hardened the sample were extruded  from the moulds 18 
using a toggle press, and  labelled  accordingly, an illustration of a emedded  19 
d isc is shown in  20 
 21 




Figure 16: Diagram of embedded and polished disc. 26 
 27 
All embedded d iscs were then polished  using a polishing machine (Struers 28 
TegraPol-21 and  a Struers Tegraforce-5 sample holder) using the regime 29 
shown in Table 12. The first step of grinding is used  to flatten the base of 30 
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the sample. The following steps are to smooth and  polish the upper face of 1 
the sample. In between each step, samples were washed in water to remove 2 
d irt or polishing lubricant. Once polishing was complete samples were 3 
dried  thoroughly using compressed  air. All samples were then stored  in a 4 
desiccator cabinet prior to scanning electron microscopy analysis. 5 
 6 
Table 12: Grinding and polishing parameters 7 
 8 
 9 
2.6.5 Scanning Electron Microscopy 10 
 11 
Scanning Electron microscopy was used  to analyse the internal structure 12 
and  surface of d iscs and  was performed using a Jeol, Neoscope JCM-500 13 
(Hertfordshire, England). 14 
Samples were plasma-sprayed  with gold , to prevent the accumulation of 15 
electrostatic charge, using a gold  coater (NeoCoater MP-19020NTCR) and a 16 
silver strip painted  to ground the charge. Five images were taken for each 17 
sample and  the number of artefacts were measured  and  quantified . 18 
Artefacts were classed  as pits or objects and  measured  using NIS Elements 19 
















Grinding 120 Water 15 150 1 N/ A 
120 Water 15 300 2 N/ A 
220 Water 15 300 3 N/ A 
600 Water 15 300 5 N/ A 














2.6.6 Data analysis 2 
 3 
Design expert software (Design Expert, version 7.1.6; Stat-Ease Inc. US) was 4 
used  to analyse all data. One-way Analysis of variance (ANOVA) was used  5 
to test d ifferences between test group sets. For all analyses a 95% 6 
confidence interval was used  and  significance level P<0.005. 7 




CHAPTER THREE: DISC MANUFACTURE AND 1 
OPTIMISATION 2 
 3 
3.2 Introduction 4 
 5 
Silicon substituted  calcium phosphate (Si-CaP) is commonly used  as a 6 
substrate to encourage and  support new bone formation in clinical 7 
situations such as spinal fusion, fractures and  small bon e defects as a 8 
structure to encourage and  support new bone formation. Si-CaP has been 9 
demonstrated  to possess superior bone regenerative capacity and 10 
resorbability when compared  to trad itional hydroxyapatite (HA). The 11 
bioactivity of Si-CaP has been established  by scientific research in vivo and 12 
in clinical studies (Patel et al. 2002; Reid  et al. 2006; Karin A Hing et al. 13 
2007; Patel et al. 2005). However, it remains unclear if the improved bone 14 
formation results from activation of stem/ progenitor cells (MSC) that 15 
d ifferentiate preferentially into osteoblasts. Thus in order to understand  16 
fully the influence of Si-CaP and HA on mesenchymal stem cells in vivo, 17 
extensive in vitro studies are needed. 18 
Si-CaP and HA can be produced in many forms for orthopaedic 19 
applications. Both materials are commonly used  as granules, which can be 20 
mixed  with blood or bone marrow aspirate, to form a cohesive graft. Bone 21 
marrow aspirate provides a source of osteoprogenitors and  mesenchymal 22 
stem cells, and  has been shown to enhance de novo bone formation when 23 
combined  with bone graft substitutes (Block 2005). New bone formation 24 
must always be preceded by the formation of a vascular network. This can 25 
be encouraged through the mixing of bone graft granules with au tologous 26 
blood. The extent of vascularisation and  has been shown to be strongly 27 
influenced by the degree of structural interconnectivity between pores (K A 28 
Hing et al. 2005). Si-CaP granules are specifically manufactured  to contain 29 
interconnected  pores of varying size, to enhance attachment, 30 
vascularisation, (Mastrogiacomo et al. 2006), osseointegration 31 
(Karageorgiou & Kaplan 2005) and  resorbability (K A Hing 2005). In 32 
particular strut porosity, defined  as ‗the fraction of porosity within the 33 
scaffold  struts, <10 μm in d iameter‘ has been shown to be d irectly linked 34 
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to vascularisation of bone grafts and  enhanced  osseointegration (K A Hing 1 
et al. 2005). 2 
In order to examine the response of MSC to the surface properties of Si-CaP 3 
and  HA without the influence of surface porosity or strut porosity the 4 
materials were pressed  into dense d iscs.  5 
Dense d iscs have previously been used  to analyse the response of 6 
osteoblasts to calcium phosphate based  substrates (Rosa et al. 2003; 7 
Courteney-Harris et al. 1995; Kumar et al. 2010). However, the response of 8 
mesenchymal stem cells to HA and Si-CaP in dense d isc form has not yet 9 
been examined. 10 
The preparation of calcium phosphates with d ifferent compositions an d  11 
morphology has been investigated  over recent years. Others have focused  12 
on the impact of d ifferent production methods, reporting wide variation in 13 
structural and  chemical properties (X. Liu & Ei-Ghannam 2010; G.-J. Oh et 14 
al. 2010; Wu et al. 2008; Rosa et al. 2003; Botelho et al. 2006; Pontier et al. 15 
2001; Juang 1996; Rodríguez-Lorenzo et al. 2001). When comparing these 16 
studies, confusion arises not only from the d ifferent compositions of 17 
powder but also from the d ifferent production methods. However, in each 18 
methodology dense d isc manufacture can be d ivided  into three d istinct 19 
stages: Powder processing, d isc pressing and  post pressing processing. 20 
 21 
Powder processing 22 
 23 
Calcium phosphate is commonly produced by precipitation, filtration, then 24 
dried  and  ground into a powder. This powder can be processed  to produce 25 
granules, mixed  with other components to make bone graft com posites or 26 
pressed  into dense d iscs. Prior to processing, powder is commonly calcined  27 
to remove unwanted  volatile fractions. Altering  the temperature of 28 
calcination has been shown to significantly affect the sintering properties of 29 
d iscs. Firstly, by decreasing grain size, making it finer than un -calcined  30 
powder, which can lead  to increased  powder packing. Secondly, calcining 31 
at high temperatures can delay the initiation of sintering, causing a 32 






Disc pressing 1 
 2 
Powder is commonly pressed  into d iscs using a hydraulic press, d ie and  3 
pellet set. Different compaction pressures have been studied , ranging from 4 
70 MPa (Rodríguez-Lorenzo et al. 2001) to 1100 MPa (Pattanayak et al. 5 
2005). Increasing applied  pressure has produced comparable results, and  as 6 
expected , as pressure increases, the density of d isc increases. Results from 7 
multiple groups confirm this effect, with increased  pressure resulting in 8 
d iscs with both lower porosity and  increased  density. However, above a 9 
compaction pressure greater than 1100 MPa density was shown to 10 
decrease, thought to be due to the formation of cracks in the d iscs 11 
(Pattanayak et al. 2005). 12 
Duration of pressure also d iffered  between studies, varying from 30 13 
seconds (Kumar et al. 2010; Rodríguez-Lorenzo et al. 2001) to 1 minute 14 
(Rodríguez-Lorenzo et al. 2001). Nonetheless, the impact of the duration of 15 
pressure d iscs on structure and  mechanical properties within one study has 16 
not yet been examined . 17 
 18 
Post pressing processing  19 
 20 
Sintering is one of the final stages of ceramic production, where granules or 21 
d iscs are heated  until particles adhere together.  This process is well 22 
documented  and  can have significant effects on material properties, 23 
depending upon the temperature and  duration of heating. Rodriguez - 24 
Lorenzo et al studied  the effect of d ifferent sintering temperatures (600- 25 
1300°C) on HA discs, and  found total pore area decreased  whereas density 26 
and  compressive strength increased  with increasing temperature up to 27 
1200°C (Rodríguez-Lorenzo et al. 2001). Calcined  human enamel 28 
hydroxyapatite studies revealed  similar results; that low densification  29 
(increase in density) is seen after sintering at low temperatures (1000°C, 30 
1100oC) and high densification is achieved  after sintering at higher 31 
temperatures (1200°C, 1300°C) (Oktar 2007).  32 
Conversely, a silica-calcium phosphate nanocomposite behaved very 33 
d ifferently; as sintering temperature increased  from 900°C to 1100°C, 34 
compressive strength and  modulus of elasticity decreased  (X. Liu  & Ei- 35 
Ghannam 2010). In the same study, sintering was shown to alter the phases 36 
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of material. Prior to sintering, silica-calcium phosphate was composed  of α- 1 
and β-cristobalite and  after sintering temperature increased , the intensity of 2 
characteristic peaks of α-cristobalite decreased  gradually (X. Liu & Ei- 3 
Ghannam 2010).  4 
 5 
The aim of this chapter was to optimise production yield  of dense d iscs 6 
whilst maintaining the desired  physical properties, described  below. 7 
 8 
Optimising production yield 9 
 10 
Dense d isc manufacture involves the use of a manual hydraulic press; this 11 
is a time-consuming and  labour intensive process. Therefore reducing the 12 
amount of effort (lowest pressure) and  decreasing production time 13 
(duration of pressure/ lubrication) could  lead  to improved production 14 
yield . 15 
 16 
Desired physical properties  17 
 18 
Dense d iscs must be strong enough to resist cracking upon handling; d iscs 19 
must also contain little or no surface or strut porosity and  should  be as 20 
smooth as possible without irregularities on the surface- all factors that 21 





3.3 Results 2 
3.3.1 Disc manufacture and optimisation 3 
 4 
Input parameters were identified  as factors, which could  affect the d iscs 5 
mechanical properties and  d isc production, these were d ivided  into the 6 
three stages of d isc production: Powder processing, d isc pressing and  post- 7 
pressing processing. At least one parameter was chosen per stage and 8 
several variables were selected  for d isc pressing. The input parameters 9 
identified  and  the parameters selected  for investigation are shown in Table 10 
13. These parameters were put into Design Expert software (Design Expert, 11 
version 7.1.6; Stat-Ease Inc. Minneapolis, US) and  a study comprising a five 12 
factor; two level design with midpoints for numerical factors was 13 
generated . Details of variables investigated  and  the values to be tested  are 14 
described  in Table 14.  15 
 16 
Table 13: Critical input parameters of disc production and parameters selected to 17 






























Yes   
  
Lubrication 
of d ie and  
pellets 
Yes   
  
Number of 
d iscs pressed  
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 19 
 20 
The standard  conditions previously used  to manaufacture dense d iscs of Si- 21 
CaP were: 1 g of calcined  powder, pressed  at 200 MPa, for a duration of 5 22 
seconds, without lubrication of the d ie and  pellet. Therefore, points above 23 
and  below were selected  to investgate the effects on dense d isc production, 24 














0.5 100 5 Calcined  Stearic acid  
 
1.25 200 17.5 Un-calcined  None 





Si-CaP powder was prepared  as described  in  materials and  methods 4 
section 2.6 and  was then heated  dry at 700°C for 4 hours (this process is 5 
called  calcination –and is used  to remove volatile fractions) or left un- 6 
calcined . Si-CaP powder (0.5 g, 1.25 g or 2 g) was pressed  into d iscs using a 7 
20 mm diameter d ie and  pellet set and a Specac Manual Hydraulic Press, 8 






Figure 17: Specac Manual Hydraulic Press and die and pellet set.  3 
 Hydraulic press (A), with pressure gauge, and coated pellet (B) and die set (C) used to 4 
manufacture all dense discs. 5 
 6 
Samples were pressed  at 100, 200 or 300 MPa for 5, 17.5 or 30 seconds either 7 
with or without lubrication in the form of 4 % w/ v stearic acid  (Sigma 8 
Aldrich, Poole, Dorset) in acetone.  Each sample was produced in triplicate  9 
and  all d iscs were sintered  at 1260°C for 1 hour and  33 minutes prior to 10 
analysis. Once sintered  the following properties of each d isc were 11 
examined: height, d iameter, calculated  density, measured  density, intruded  12 
volume, strut porosity and  the number of irregularities on the d isc surface. 13 
Microsoft Excel was used  to generate graphs showing relationships 14 
between investigated parameters. Design Expert software was used  to 15 
analyse all data. One-way Analysis of variance (ANOVA) was used  to test 16 
d ifferences between test group sets. For all analyses all five factors were 17 
included and  for all graphs standard  error (SEM*) of mean is shown A 18 
summary of results is shown in Table 15. It was found that d isc height and 19 
d iameters were influenced  by several factors, significant results were 20 




















Calcu lated  
density 
(kg/ m 3) 
Density 
(kg/ m 3) 
Intruded  
volume 








A 0.5 100 5 Calcined  Stearic acid  2.4451 3.1365 0.0285 8.07 16 
B 2 100 5 Calcined  None 2.7704 3.1008 0.0383 10.55 5 
C 0.5 300 5 Calcined  None 3.0466 3.1890 0.0000 0.00 2 
D 2 300 5 Calcined  Stearic acid  2.9954 3.0914 0.0000 0.00 19 
E 0.5 100 30 Calcined  None 2.8660 2.9489 0.0205 5.94 23 
F 2 100 30 Calcined  Stearic acid  2.9167 3.0789 0.0292 8.25 12 
G 0.5 300 30 Calcined  Stearic acid  3.1180 3.0737 0.0000 0.00 2 
H 2 300 30 Calcined  None 2.9921 3.1070 0.0003 0.09 3 
I 0.5 100 5 Un-calcined  None 2.9814 3.3148 0.0127 3.76 6 
J 2 100 5 Un-calcined  Stearic acid  2.9643 3.1066 0.0227 6.53 1 
K 0.5 300 5 Un-calcined  Stearic acid  2.7909 3.0060 0.0120 3.56 1 
L 2 300 5 Un-calcined  None 2.9611 3.0874 0.0084 2.52 3 
M 0.5 100 30 Un-calcined  Stearic acid  2.9439 3.0152 0.0157 4.61 0 
N 2 100 30 Un-calcined  None 2.8217 3.2662 0.0192 5.58 4 
O 0.5 300 30 Un-calcined  None 2.1781 3.0454 0.0007 0.22 3 
P 2 300 30 Un-calcined  Stearic acid  3.0735 3.1650 0.0002 0.06 5 
Q 1.25 200 17.5 Calcined  None 2.5823 3.0505 0.0005 0.15 4 
R 1.25 200 17.5 Un-calcined  None 2.8280 3.0678 0.0029 0.89 3 
S 1.25 200 17.5 Calcined  Stearic acid  3.2722 3.0067 0.0012 0.37 39 




3.3.1.1 Disc height  1 
 2 
Disc height was d irectly related  to powder weight and  pressure. The 3 
relationship between weight and  height of d iscs is shown in  4 
 5 
Figure 18. As expected the weight was d irectly proportional to d isc height 6 
in all batches, height in mm was approximately double the weight in 7 
grams, this relationship was highly significant (P<0.001).   8 
 9 
 10 
Figure 18: Relationship between powder weight and disc height.  11 
Effect of powder weight on disc height, the average height is shown and error bars 12 
represent standard error of mean SEM*.  Key: ns (P>0.05), * (P≤ 0.05), ** (P≤ 0.01), *** 13 
(P≤ 0.001), **** (P ≤ 0.0001). 14 
 15 
Similarly, as expected , when pressure was increased , d isc height decreased , 16 
this relationship was significant (P<0.001) and  is depicted  in Figure 19. The 17 
effect of pressure on height was notably d ifferent in d iscs pressed  using 18 
d ifferent powder weights. The effect of pressure on d isc height was most 19 
apparent in d iscs made varied  with 2 g of powder by 0.57 mm on average, 20 
compared  to a variation of 0.11 mm in d iscs made with 0.5 g of powder. 21 
Discs made of 1.25 g of powder were pressed  at 200 MPa, and  varied  by as 22 
much as 0.75 mm. Generally, increased  pressure results in increased  23 
density however, above a certain threshold density cannot increase, and  24 
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would  limit the height of d iscs. This was not observed  in the range of 1 
pressures examined here. 2 
 3 
 4 
Figure 19: Relationship between pressure and disc height. 5 
 Average height of all discs pressed at different pressures, error bars represent SEM*. Key: 6 
ns (P>0.05), * (P≤ 0.05), ** (P≤ 0.01), *** (P≤ 0.001), **** (P ≤ 0.0001). 7 
 8 
3.3.1.2 Disc diameter 9 
 10 
The d iameter of d iscs was limited  during pressing by the d ie and  pellet set, 11 
and  therefore d isc d iameter was never greater than 20 mm immediately 12 
after pressing. However, significant changes in d iameter were observed  13 
post processing/ after sintering. Several parameters significantly influenced  14 
d isc d iameter including; pressure, calcination and  lubrication. 15 
Powder weight affected  d isc d iameter ; increased  weight of powder 16 
resulted  in d iscs of a smaller d iameter, but this was not found to be 17 
statistically significant (P=0.0881). Pressure significantly influenced  d isc 18 
d iameter (P<0.0001) as shown in Figure 20. Increased  pressure lead  to d iscs 19 
with increased  d iameter. Discs pressed  at 300 MPa were on average 0.34 20 




Figure 20: Effect of pressure on diameter of discs.   2 
Average diameter of discs, error bars represent SEM*. Key: ns (P>0.05), * (P≤ 0.05), ** 3 
(P≤ 0.01), *** (P≤ 0.001), **** (P ≤ 0.0001). 4 
Prior to pressing d iscs, powder is commonly calcined  to remove unwanted  5 
volatile fractions. Figure 21 shows the effect of calcination on d isc d iameter. 6 
Calcination of powder produced d iscs of significantly greater d iameter 7 
than un-calcined  powder; although d iameter only varied  by 1.18 mm 8 
(P<0.001). 9 
 10 
Figure 21: Effect of calcination on diameter.   11 
Average diameter of discs, error bars represent SEM*.  Key: ns (P>0.05), * (P≤ 0.05), ** 12 




Lubrication in the form of stearic acid  also influenced  d isc d iameter, shown 1 
in Figure 22. Discs produced with lubrication were significantly larger in 2 
d iameter compared  to d iscs made without a lubricant (P= 0.0119). 3 
 4 
 5 
Figure 22: Effect of lubrication on diameter of discs.  6 
Average diameter of discs, error bars represent SEM*. Key: ns (P>0.05), * (P≤ 0.05), ** 7 
(P≤ 0.01), *** (P≤ 0.001), **** (P ≤ 0.0001). 8 
 9 
3.3.1.3 Int ruded strut  Porosity  10 
 11 
Strut porosity is also described  as microporosity and  strut pores are formed 12 
from the interconnected  spaces existing between the struts in the scaffold  of 13 
calcium phosphate biomaterials (Campion et al. 2011). Intruded  strut 14 
porosity was calculated  from intruded  volume measured  by mercury 15 
intrusion porosimetry, as described  in materials and  methods section 2.6.2.  16 
Figure 23: Effect of pressure on porosity. 17 
 (A) shows the relationship between intruded strut porosity and pressure in all 18 
discs. Porosity varied greatly, even when discs were formed at the same pressure. 19 
At several data points porosity was unexpectedly high, in partiular, there were 20 
two instances where the porosity of discs pressed at 300 MPa, was higher than in 21 
discs pressed at 100 MPa.  Prior to MIP discs were broken, these discs may have 22 
been broken into smaller pieces, providing a greater surface area for intrusion, 23 
thus explaining these unexpected results. However, when a subset of discs were 24 
examined (excluding discs made with 0.5 g of powder, calcined powder and 25 
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lubricated), the relationship between intruded strut porosity and pressure follows 1 
a more logical trend.Figure 23: Effect of pressure on porosity. 2 
 (B) shows in this section of d iscs where increased  pressure resulted  in 3 
decreased  porosity, a result that was statistically significant (P<0.001). 4 
 
 
Figure 23: Effect of pressure on porosity. 
(A) Effect of pressure on intruded strut porosity of all discs (B) Effect of Pressure on 
intruded strut porosity on selected discs. Average intruded strut porosity of discs (<0.5 g 
of powder, un-calcined and without lubrication) As measured by mercury intrusion 
porosimetry, error bars represent SEM*. Key: ns (P>0.05), * (P≤ 0.05), ** (P≤ 0.01), *** 
(P≤ 0.001), **** (P ≤ 0.0001). 






Results from pycnometry and  calculated  densities are shown in Table 15. 1 
All calculated  densities were lower than measured  pycnometric density 2 
values, and  neither set of values were significantly correlated  to the studied  3 
process parameters (see Table 16).  4 
 5 







Powder weight  0.3286 0.1916 
Pressure 0.4652 0.7028 
Duration of pressure 0.2400 0.9571 
Calcination 0.2104 0.6059 
Lubrication 0.3259 0.4549 
 8 
3.3.1.5 Surface analysis- Scanning Electron Microscopy   9 
 10 
Irregularities in the form of pits or objects, examples of which can be seen in 11 
Figure 24, were observed on the surface of most discs. The number, type, and size 12 
of irregularities were quantified, and the data depicted in Figure 25: Type and size 13 
of irregularities on discs. 14 
. More irregularities were seen on d iscs pressed  with stearic acid  as a 15 
lubricant, however this d id  not reach statistical significance (P=0.07) 16 
despite apparent d ifferences (see Figure 24 A and E). Discs pressed  with 17 
stearic acid  had  more pits and  objects than d iscs pressed  with no lubricant; 18 
again this was not statistically significant (P=0.06). There was also a larger 19 
number of large objects and  pits (500 µm and 100 µm in size) on d iscs 20 






Figure 24: Scanning elctron microscopy images of sintered disc surfaces.  3 
(A) Surface with no irregularities, (B) irregularity classified as an object, (C) irregularity 4 
classified as a pit, (D) example of how objects/pits were quantified (E) pitted surface and 5 
(F) multiple objects <100 µm in diameter. 6 
7 













Figure 25: Type and size of irregularities on discs. 
(A) Total number, (B) type and (C) size of irregularities on discs produced with stearic 
acid (light grey) or with no lubricant (dark grey) A total of ten discs were examined for 
each group and five images taken per disc. 
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3.3.1.6 Internal st ructure analysis -scanning elect ron microscopy  1 
 2 
The internal structures of each d isc was examined using SEM, the images 3 
below were taken near the edge of the d isc so the microstructure near the 4 
surface is visible. Figure 26 shows the effect of pressure on density; d iscs 5 
pressed  at lower pressures (100 MPa) had  loosely packed particles, with 6 
large spaces between the powder clearly seen (A). In d iscs pressed  at 300 7 
MPa, the d isc was much more dense and  no spaces were seen between 8 
powder particles (B). Less apparent was the effect of calcination, which also 9 
affected  d isc structure; d iscs are less dense when made with calcined  10 
powder (C), compared  to a d isc made of un-calcined  powder (D).   11 
 12 
 13 
Figure 26: Effect of pressure and calcination on internal structure of discs. 14 
Disc pressed at (A) 100 MPa and (B) 300 MPa (C) calcined powder (D) un-calcined 15 
powder. 16 
 17 
The surface of the d iscs was also affected  by calcination, as seen in Figure 18 
27, calcined  powder appeared  to be more dense, and  grains more rounded 19 
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compared  to the irregular grains seen in the un -calcined  sample. The 1 
surface of the calcined  d isc also appeared  to be smoother, with fewer 2 
irregularities such as p its and  objects, than the un -calcined  d isc. 3 
 4 
Figure 27: Effect of calcination on grain surface microstructure. 5 
Large image- scale bar represents 10 μm, inset- scale bar represents 5 μm. Discs made 6 
using calcined powder (left) and un-calcined powder (right) 7 
Figure 28: Effect of press duration and powder weight on internal structure of 8 
discs.  9 
 shows the internal structure of d iscs pressed  for d ifferent lengths of time 10 
(press duration) and  powder weight. Press duration and  powder weight 11 
d id  not appear to significantly affect the internal structure of d iscs. Discs 12 
pressed  for both 5 and  30 seconds appeared  similar in density, with little or 13 
no space between powder particles, and  the edge of the d isc appeared  to be 14 
smooth, seen in (A) and  (B) respectively. Discs made with more powder (D) 15 
appeared  to be slightly more dense than d iscs made with 0.5 g (C). In both 16 
d iscs spaces between particles can be seen, but also large areas of densely 17 
packed powder. 18 
SEM analysis determined  the internal structure of d iscs was influenced  by 19 
several factors, but most significantly by calcination of powder and  the 20 






Figure 28: Effect of press duration and powder weight on internal structure of 2 
discs.  3 
(A) Disc pressed for 5 seconds, (B) 30 seconds, (C) disc made with 0.5 g of powder, 4 
(D) 2 g powder, scale abr represents 50 μm. 5 
3.3.1.7 Sintering  6 
 7 
Sintering is one of the final stages of ceramic production, where powder or 8 
d iscs are heated  until the particles adhere together. The effect of sintering 9 
temperature on d isc surface, d iameter and  height was investigated on both 10 
HA and Si-CaP. Figure 29 shows the surfaces of d iscs sintered  at 1260°C, 11 
1000°C, 800°C, and  un-sintered  d iscs. The surface of both HA and Si-CaP 12 
were smooth when sintered  at 1260°C, and  appear rougher as sintering 13 
temperature decreases. At lower temperatures (1000-800°C and un- 14 
sintered) there are more small objects on the surface, and  larger areas of 15 
deeply pitted  surface. The surfaces of the d iscs sintered  at lower 16 






Figure 29: Surface of discs sintered at different temperatures,  3 
Left column- hydroxyapatite (HA), right column Silicate-substituted calcium 4 
phosphate(Si-CaP). Scale bar represents 20 μm. 5 
 6 
























Figure 30 shows how sintering temperature altered  height and  d iameter of 2 
d iscs made with HA or Si-CaP. Disc height decreased  as sintering 3 
temperature increased, and  varied  by only 1 mm. Both HA and  Si-CaP 4 
were similar in height at 1260°C, 800°C and when un -sintered . However, at 5 
1000°C the d ifference in height is significant (P=0.0016), with HA discs 6 
lower in height compared  to Si-CaP (2.02 and  2.295 mm respectively). A 7 
similar trend  is seen in d isc d iameter, with the only significant d ifference 8 
between HA and  Si-CaP occurring at 1000°C (P=0.0001). Overall, the height 9 
and  d iameter of d iscs decreased  as sintering temperature increased , this 10 
was more apparent with the d iameter varying by as much as 5 mm in both 11 






Figure 30: Effects of sintering on (A) disc height and (B) diameter.   4 
Temperature ranged from 0 (un-sintered) to 1260°C, Three discs were analysed at each 5 















Figure 31 shows the grain boundaries of Si-CaP after sintering for 1 hour 1 
and  33 minutes at 1260°C. Silicate grains appear much smaller, <1 μm in 2 
d iameter, and  are more rounded when compared  to the larger calcium 3 
phosphate grains which are up to 2 μm in d iameter and  are more hexagonal 4 
in shape.  5 
The grain boundaries shown here suggest the surface is not uniform; the 6 
d isc surface is composed  of multiple silica grains close together, 7 
interspersed  with large calcium phosphate grains. HA has an organised  8 
crystal lattice structure, whereas the surface of Si-CaP at this scale appears 9 
to be d isordered , and  composed  of areas of negative and  positive charge.  10 
 11 
Figure 31: Grain boundaries of sintered Si-CaP disc.  12 
Large grains (white arrow) calcium phosphate, smaller rounded grains are silicate (black 13 




3.4 Discussion 1 
3.4.1 Physical properties and production yield 2 
 3 
The aim of this chapter was to investigate critical process parameters in 4 
production of Si-CaP d iscs with desired  physical properties and  optimised  5 
production yield . 6 
 7 
Pressure greatly influenced  d isc height and  was particularly significant in 8 
d iscs made with 2 g of powder (P<0.001), or 0.5 g powder (p=0.02). High 9 
pressure (300 MPa) resulted  in lower d isc height. Conversely, lower  10 
compaction pressures (100 MPa) produced d iscs of greater height.  11 
Different compaction pressures have been studied  with similar results, 12 
ranging from 70 MPa (A. Sinha et al. 2001) to 1100 MPa (Pattanayak et al. 13 
2005), suggesting high compaction pressure increases density of d iscs, and  14 
in other studies, increases compressive strength and  modulus of elasticity 15 
(X. Liu & Ei-Ghannam 2010).  16 
 17 
Results in this study demonstrated  increased  pressure significantly 18 
reduced  porosity (P<0.001), but d id  not find  a significant relationship  19 
between density and  pressure. Calculated  densities ranged from 2.18 to 20 
3.11 kg/ m 3 slightly below the maximum theoretical density of 21 
hydroxyapatite (3.156 kg/ m 3). Pycnometric densities were much higher 22 
and  in certain cases (samples I, N and P in  Table 15) were in excess of this 23 
maximum theoretical density. This is likely due to the small sample size 24 
and  increasing error potential for this measurement technique, and  may be 25 
avoided  in future studies by increasing sample size to reduce error.  26 
Pressure also significantly affected  d isc d iameter (P<0.001). Disc d iameter 27 
increased  as pressure increased , which could  be due to the d iscs pressed  at 28 
high pressures being denser and  therefore more resistant to densification  29 
(increase in density) upon sintering.  30 
 31 
Differing pressure and  press duration have been studied , ranging from 30 32 
seconds to 1 minute (Rosa et al. 2003; Kumar et al. 2010; X. Liu & Ei- 33 
Ghannam 2010; Pattanayak et al. 2005). However, until now the effect of 34 
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altering duration of pressure on physical properties of dense d iscs had  not 1 
yet been examined. Press duration d id  affect strut porosity and  density, but 2 
neither reached statistical significance (P=0.187 and  P=0.2400 respectively).  3 
 4 
Discs were successfully manufactured  and  sintered  with as little as 0.5 g of 5 
powder. However, these d iscs cracked  easily, whereas d iscs produced with 6 
1.25 g and  2 g were more resistant to strain on handling. It may be useful in 7 
the future to investigate compressive strength and  modulus of elasticity to 8 
evaluate the strength of d iscs quantitatively. 9 
 10 
Powder weight d irectly affected  several parameters; including d isc height, 11 
d iameter and  strut porosity. As expected  height was increased  in d iscs 12 
made with greater powder weight and  this relationship was found to be 13 
significant (P=0.0156). Discs made with 2 g of powder resulted  in d iscs with 14 
smaller d iameters than d iscs made with 0.5 g of powder, but this was not 15 
significant (P= 0.0881). This may due to d iscs made of 2 g are less dense 16 
and  therefore more likely to shrink on sintering. Data from strut porosity 17 
and  SEM images, confirm this, and  show that d iscs made from 0.5 g of 18 
powder were denser after sintering.  19 
 20 
Prior to pressing d iscs, powder is commonly calcined  to remove unw anted  21 
volatile fractions. Altering the temperature of calcination has been shown 22 
to significantly affect the sintering properties of d iscs. Calcined  powder 23 
was found to produce d iscs with greater d iameters when compared  to un - 24 
calcined  powder (P= 0.016). Calcination makes the powder finer, and 25 
denser, therefore less susceptible to shrinking on sintering. The use of un - 26 
calcined  powder in d isc manufacture however, may not be desirable as 27 
some volatile fractions and  chemical impurities would  not be removed if 28 
the d iscs were left un-sintered .  29 
 30 
Several studies have utilised  lubricants in d isc manuafcture, commonly 31 
stearic acid  (Juang 1996; A. Sinha et al. 2001), to coat the d ie and  pellet. 32 
Stearic acid  greatly improved the ease with which the d iscs were removed 33 
from the pellet and d ie set; as such this was expected  to improve 34 
production rates. However, the time taken to clean the pellet and  d ie set 35 
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meant the rate of production was either unaffected  or prolonged . 1 
Furthermore, it d id not significantly affect any parameters, except 2 
d iameter. Which was likely caused  due to the stearic acid  contributing to 3 
internal density and  therefore preventing shrinkage. Notably, when 4 
compared  to d iscs manufactured  with no lubricant  there was a greater 5 
frequency of large irregularities in the form of both pits and objects 6 
(p=0.170). It has also been shown that stearic acid  can affect the surface 7 
chemistry of calcium based  materials (Rungruang et al. 2006). This is far 8 
from desirable as it may influence the cellular response. 9 
 10 
SEM analysis of gold  sputtered  d iscs demonstrated  that the sintered  d isc 11 
surface is not typically smooth at micrometer scale; many d iscs have a 12 
pitted  surface or may contain objects greater than 500 µm in length. 13 
Analysis of sectioned  d iscs revealed  internal structures and  variations in 14 
particle packing and  whilst this was not quantified , gave insight into the 15 
density and  structure of the d iscs. It is recommended that any future 16 
studies quantify the amount of strut-porosity using image analysis of 17 
embedded sections. 18 
 19 
Sintering is one of the final stages of ceramic production, where powders or 20 
d iscs are heated  until particles adhere together.  This process can have 21 
significant effects on material properties, depending upon the temperature 22 
and  duration of heating and  has been extensively studied  (Rosa et al. 2003; 23 
Kumar et al. 2010; Wu et al. 2008; Rodríguez-Lorenzo et al. 2001; 24 
Pattanayak et al. 2005; Gibson et al. 1999). 25 
 26 
Here it was demonstrated  that altering the sintering temperatures could  27 
significantly affect height, d iameter and  surface properties of dense d iscs. 28 
Sintering at low temperatures (800-1000°C) produced d iscs of a greater 29 
height and  d iameter, compared  to higher temperatures (1260°C) and 30 
resulted  in a rough surface with multiple objects and  pits. This is consistent 31 
with similar studies, which have shown low densification is seen after 32 
sintering at low temperatures (1000-1100°C) and  high densification is 33 
achieved  after sintering at higher temperatures (1200-1300°C) (Oktar 2007). 34 
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Sintering not only affects the structural and  mechanical properties of 1 
calcium phosphate but can alter the phases of material (X. Liu & Ei- 2 
Ghannam 2010) and  at very high temperature can result in melting of 3 
grains. This was not detected  in Si-CaP sintered  at 1260°C, suggesting this 4 
is the optimal sintering temperature. 5 
 6 
It was demonstrated  that d isc height and  d iameter were influenced  by the 7 
input parameters, but that intruded  strut porosity, calculated  and 8 
pycnometric densities were not affected  by input parameters. 9 
Discs could  be successfully produced with 0.5 to 2 g of powder, yet the 10 
minimum weight of powder required  to manufacture d iscs of sufficient 11 
handling strength was 1.25 g. 12 
The minimum pressure needed was found to be 100 MPa; however d iscs 13 
pressed  at 200 MPa or above contained  substantially less strut porosity. 14 
Press duration was not found to be critical to d isc manufacture, therefore 15 
the lowest press time investigated  (5 seconds) is suggested  to be optimal 16 
for greatest throughput. 17 
Un-calcined  powder was more readily compacted , however the use of un- 18 
calcined  powder in d isc manufacture may not be desirable, as volatile 19 
fractions and  chemical impurities would  not be removed if left un -sintered . 20 
Stearic acid  improved ease of extrusion of d isc from the d ie, however 21 
resulted  in a greater frequency of surface irregularities compared  to d iscs 22 
manufactured  without a lubricant. 23 
Sintering temperature affected  d isc height, d iameter and  surface 24 
characteristics of dense d iscs. 25 
The final recommendations for all parameters based  on data provided  in 26 





3.4.2 Influence of disc on cell response 2 
 3 
Disc manufacture was optimised  with regard  to physical properties and  4 
production yield . These dense d iscs were then used  to analyse cellar 5 
response to the surface chemistry of Si-CaP and HA, without the influence 6 
of porosity and  with minimal variation in surface topography.  7 
 8 
It has been demonstrated  that surface chemistry of biomaterials can greatly 9 
influence cell adhesion, proliferation and  d ifferentiation.  10 
 11 
Whether in vitro or in vivo, cells do not interact d irectly with the 12 
biomaterial, instead proteins in surrounding fluid  condition the 13 
biomaterial. This process of protein adsorption, where proteins adhere to 14 
the surface of a substrate, can be altered  by many variables including 15 
surface energy, topography, temperature and  pH. The orientation and 16 
conformation of protein absorption has a d irect influence on cell 17 
attachment, proliferation and  d ifferentiation (Boyan 1996). Surface charge 18 
has shown to be particularly influential in protein adsorption  (Combes & 19 
Rey 2002). 20 
The surface of Si-CaP was shown here to be heterogeneous, composed  of 21 
d ifferent grains with positive and  negative surface charge. This is 22 
consistent with previous studies (Botelho et al. 2002). 23 
The effect of the surface charge of Si-CaP and HA on protein adsorption 24 
has previously been investigated  (Botelho 2005). It was demonstrated  that 25 
Table 17: Recommended final parameters. 
Parameter Specification Tolerance 
Powder weight 1.25g +/ - 0.1g 
Pressure 200 MPa +/ - 10MPa 
Press duration 5 seconds +/ -1 second 
Lubrication None N/ A 
Calcination calcined N/ A 




Si-CaP had  a higher binding capacity for total human serum proteins, 1 
particularly collagen type I due to its overall positive charge, when 2 
compared  to HA (Botelho et al. 2004). This preferential binding of 3 
positively charged  proteins was due to the of overall electronegative cha rge 4 
of Si-CaP (Botelho et al. 2002). The more electronegative Si-CaP surface was 5 
shown to enhance the nucleation of an amorphous calcium phosphate 6 
apatite layer than the HA surface, known as an apatite layer –considered  to 7 
be an important factor for osseointegration (Botelho 2005).  8 
Many studies have closely examined the surface charge of Si-CaP and its 9 
subsequent effect on protein adsorption and  nucleation. As such this thesis 10 
will focus on the attachment, proliferation and  d ifferentiation of 11 






CHAPTER FOUR: CHARACTERISATION OF 1 
MESENCHYMAL STEM CELLS 2 
 3 
4.1 Introduction 4 
 5 
Multipotent mesenchymal stem cells (MSC) are well established  as a source 6 
of cells for tissue engineering and  cellular therapy. In vivo, a population of 7 
MSC are known to reside within bone marrow (Kolf, Cho & Tuan 2007a; 8 
Nombela-Arrieta et al. 2011; Chamberlain et al. 2007; Crisan et al. 2008; 9 
Barry & J. M. Murphy 2004; Boyd et al. 2009; Haasters et al. 2009; 10 
Yoshimura et al. 2006; Pittenger 1999; Jack et al. 2002).  11 
MSC are thought to migrate to sites of damage, (Chamberlain et al. 2007; 12 
Haasters et al. 2009; Yoshimura et al. 2006; Pittenger 1999), where they are 13 
capable of d ifferentiating into, and  repairing mesenchymal tissues 14 
including bone, cartilage and  adipose tissue (Augello et al. 2010). MSC 15 
represent a very small fraction of the total population of cells in bone 16 
marrow, 0.001-0.01% (Pittenger 1999). Despite this, they can be isolated  and  17 
readily expanded in culture (Dominici et al. 2006).  18 
Under defined  conditions in vitro, MSC have been shown to d ifferentiate 19 
into osteoblasts (in the presence of serum, ascorbic acid , beta 20 
glycerophosphate and  dexamethasone), chondrocytes (in serum free 21 
medium containing TGF-β1, TGF-β2 or TGF-β3), and  adipocytes (in the 22 
presence of isobutylmethylxanthine) (Barry & J. M. Murphy 2004). This 23 
multipotent d ifferentiation potential, plastic adherence, and  specific surface 24 
antigen expression, are considered  to be the minimal criteria for MSC in 25 
vitro (Dominici et al. 2006). Despite many attempts to develop a robust cell- 26 
surface antigen profile for the identification and  purification of MSC (Kolf, 27 
Cho & Tuan 2007a), the defining characteristics of MSC are still debated  28 
amongst investigators and  therefore definitive MSC surface antigen 29 
expression remains a contentious issue (Dominici et al. 2006). As such, a 30 
combination of multiple surface markers should  be used  to positively 31 




It is generally accepted  that MSC express (amongst others) the cell sur face 1 
markers CD90, CD73, CD105, Stro-1, and  are negative for haematopoietic 2 
progenitor markers CD34, CD45 and CD14. The reported  expression of 3 
these markers by a number of studies is reviewed in Table 18.  4 
 5 
Table 18: Reported cell surface marker expression in mesenchymal stem cells. 6 




(Kolf, Cho & Tuan 2007b; Chamberlain  et al. 2007; Crisan 
et al. 2008; Vodyanik et al. 2010; Haasters et al. 2009; 
Sanchez-Guijo et al. 2009; Yoshimura et al. 2006; 
Kozhevnikova et al. 2008; Jack et al. 2002; Dominici et al. 
2006; Ohgushi et al. 2005; Orciani et al. 2010) 
CD73 
(Kolf, Cho & Tuan 2007b; Chamberlain et al. 2007; Crisan 
et al. 2008; Barry & J. M. Murphy 2004; Boyd  et al. 2009; 
Haasters et al. 2009; Kozhevnikova et al. 2008; Pittenger 
1999; Jack et al. 2002; Dominici et al. 2006; Orciani et al. 
2010) 
CD105 
(Chamberlain et al. 2007; Kolf, Cho & Tuan 2007b; Crisan 
et al. 2008; Barry & J. M. Murphy 2004; Boyd  et al. 2009; 
Haasters et al. 2009; Kozhevnikova et al. 2008; Pittenger 
1999; Yoshimura et al. 2006; Blitterswijk et al. 2007; Foster 
et al. 2005; Jack et al. 2002; Dominici et al. 2006; Orciani et 
al. 2010) 
Stro-1 
(Kolf, Cho & Tuan 2007b; Vodyanik et al. 2010; Jack et al. 
2002; Tare et al. 2012) 
CD146 (Crisan et al. 2008; Boyd  et al. 2009; Jack et al. 2002) 
Negative 
CD34 
(Chamberlain et al. 2007; Kolf, Cho & Tuan 2007b; Barry 
& J. M. Murphy 2004; Boyd  et al. 2009; Haasters et al. 
2009; Yoshimura et al. 2006; Pittenger 1999; Crisan et al. 
2008) 
CD45 
(Nombela-Arrieta et al. 2011; Kolf, Cho & Tuan 2007b; 
Chamberlain et al. 2007; Crisan et al. 2008; Barry & J. M. 
Murphy 2004; Boyd  et al. 2009; Haasters et al. 2009; 
Yoshimura et al. 2006; Pittenger 1999; Jack et al. 2002) 
CD14 
(Chamberlain et al. 2007; Haasters et al. 2009; Yoshimura 







Each of these surface markers is thought to play a role in maintaining 1 
multipotency of mesenchymal stem cells or in identifying haematopetic 2 
progenitor cells. 3 
 CD90 (Thy-1) is a glycosylphosphatidylinositol (GPI)-anchored , 4 
extracellular surface, protein found on mesenchymal stem cells, and  5 
is thought to be related to mutipotency (Oishi & Ito-Dufros 2006). 6 
 CD73 or lymphocyte-vascular adhesion protein 2 is a nucleotidase 7 
expressed  on many cell types, including lymphocytes, and  is not 8 
specific to mesenchymal stem cells. Nonetheless, it does not react 9 
with osteoblasts or osteocytes, which may contaminate MSC 10 
cultures and  its persistence throughout culture supports its utility as 11 
an MSC marker (Kolf, Cho & Tuan 2007b).  12 
 CD105 is a transmembrane, transforming growth factor (TGF)-beta 13 
receptor associated  with mesenchymal stem cells (Barry et al. 1999): 14 
it has been shown to play a role in proliferation, d ifferentiation and 15 
migration (Banas et al. 2007; Mitchell et al. 2005).   16 
 The best-known MSC marker by far is Stro-1, cells negative for Stro- 17 
1 are not capable of forming colonies (Simmons & Torok-Storb 18 
1991b). However, Stro-1 is a contentious MSC marker for several 19 
reasons: first, no mouse counterpart of Stro-1 has been found; 20 
second, Stro-1 expression is not exclusive to MSC; third , its 21 
expression in MSC is gradually lost during culture expansion 22 
(Gronthos et al. 2003), and  fourth, the exact function of the Stro-1 23 
antigen is unknown. 24 
 CD34 is a primitive haematopoietic stem cell marker, rarely 25 
expressed  in human MSC, although it is positive in mice MSC 26 
(Peister 2004). CD45 and CD14 are found in cells of the 27 
haematopoietic lineage (Chamberlain et al. 2007). 28 
Despite this confusion around antigen expression, the most defining 29 
property of MSC is their capacity for multi-lineage d ifferentiation. 30 
 31 
Bone marrow derived  MSC can be used  to study osteogenic d ifferentiation 32 
in vitro; induced  through the addition of soluble factors known to stimulate 33 
d ifferentiation, and  also cultured  on substrates engineered  to d irect cell 34 




availability, donor genetic variability, variability in age and  condition of 1 
the tissue at the time of donation, and  heterogeneity in culture. To date, 2 
multipotent stem cells have been extracted  from a variety of organs, such as 3 
skeletal muscle (Péault et al. 2007), bone marrow (Pittenger 1999), skin 4 
(Toma et al. 2001), pancreas, fat (Zuk et al. 2001), dental pulp (Gronthos 5 
2000), placenta (Scherjon et al. 2004), and  umbilical cord  (Erices et al. 2000).  6 
One of the most promising sources of multipotent adult stem cells is from 7 
adipose tissue, largely due to the ease by which adipose tissue can be 8 
accessed .  Initial enzymatic d igestion of extracted  ad ipose tissue yields a 9 
combination of stromal and  vascular cells often referred  to as the stromal- 10 
vascular fraction. These ad ipose derived  multipotent stromal cells 11 
(ADMSC) appear to be very similar to bone marrow derived  MSC with 12 
similar cell surface marker expression (Gronthos, D. M. Franklin, et al. 13 
2001a), hold  comparable d ifferentiation potential (Guilak et al. 2005; Zhang 14 
et al. 2011), and  possess a similar proliferative capacity (Crisan et al. 2008). 15 
Ideally a population of healthy, homogenous cells with unlimited  16 
expansion potential would  be optimal to study osteogenic d ifferentiation in 17 
vitro and  the route to obtaining these may be through the growth an d  18 
d ifferentiation into MSC of human embryonic stem cells (hES). 19 
hES have an infinite proliferative capacity  in vitro (Wang et al. 2008) and  20 
have the potential to d ifferentiate into derivatives of all three germ layers; 21 
however, a major drawback of these cells is the risk of tumour formation in 22 
vivo (Pera et al. 2000). An alternative is to use hES to derive lineage 23 
restricted  progenitor cells, which do not form teratomas. Human 24 
Embryonic stem cell derived  mesenchymal progenitors (hES-MP) are a 25 
commercially available (Cellartis, Dundee, UK) source of homogenous cells 26 
with extensive proliferative capacity. These cells do not express markers 27 
associated  with hES, and  have a similar gene expression pattern to MSC 28 
data (de Peppo, Sjovall, et al. 2010a). It has been demonstrated  that hES-MP 29 
express MSC associated  surface markers, can d ifferentiate along osteo -, 30 
chondro- and  adipogenic lineages and  have an MSC-like morphology in 31 
culture (Karlsson et al. 2009). 32 
Despite the potential therapeutic benefits of pluripotent hES cells, legal and  33 
ethical controversies concerning their use still remain. As a result, sources 34 




In this thesis, three d ifferent sources of cell types; MSC, hES-MP and 1 
ADMSC, were utilised  to analyse the osteogenic influence of Si-CaP and 2 
HA.  3 
 4 
The aim of this chapter was to determine similarities and  d ifferences of 5 
cells from different sources. 6 
Each cell type was examined with  regard to: morphology in culture, 7 
expression of cell surface markers, expression of transcription factors and 8 





4.2 Results 1 
 2 
MSC supply was limited  due to a variety of logistical reasons; the priority 3 
for tissue samples was for clinical bone banking, and  only tissues not 4 
suitable for this purpose were made available for research use.  In addition, 5 
a number of groups were in competition for these samples, further 6 
restricting access to clinical samples.  Consequently, when samples were 7 
obtained , cells were expanded for several passages to ensure sufficient cell 8 
number for experimental purposes. 9 
In order to ensure the MSC used  at later passages were equivalent to cells 10 
used  at earlier passages characterisation was carried  out at both early (P2) 11 
and  later passages (P6). The effect of passage number on cell characteristics 12 
was also examined in hES-MP and in ADMSC. 13 
 14 
4.2.1 Morphology 15 
 16 
Cells d isp layed  similar morphology despite originating from different 17 
sources. All three cell types adhered  strongly to tissue culture plastic and  18 
d isplayed  a fibroblast-like morphology as shown in Figure 32, where all 19 
three cell types are compared .  20 
MSC (A) had  a relatively small cell body with long thin processes; the 21 
population appeared  to be relatively homogenous with all cells similar in 22 
length and  shape. hES-MP (B) were more heterogeneous, in length, wid th 23 
and  size. They tended to grow in clusters, which was most apparent when 24 
cells became confluent. ADMSC (C) morphology was very similar to MSC, 25 








Figure 32: Typical morphology of cells in culture  4 
Representative images of cell morphology cultured on tissue culture plastic (A) MSC, (B) 5 
hES-MP, (C) ADMSC.  Scale bars represent 400 μm. 6 
 7 
4.2.2 Proliferation 8 
 9 
Cells of each of the three MSC types were allowed to proliferate over 21 10 
days, and  at regular intervals were fixed , counted  and  the average number 11 
of attached  cells per mm 2 calculated ; these counts were used  to produce 12 
growth curves for each cell type, and  these are shown in Figure 33. These 13 
data were used  to calculate cell-doubling rates, using the formula below 14 
where N 1 is the number of cells on Day 1 and  N 21 is the number of cells on 15 
Day 21. 16 
 17 
Doubling rate (Days)  = [log10(N 21) − log10(N 1)]/ log10(2), 18 
 19 
ADMSC proliferated  the fastest and  most consistently, with a doubling rate 20 
of 1.7 ± 0.09 days (mean±SD). MSC doubling rate was less than half that of 21 
ADMSC (4.1 ± 1.6 days). Doubling rates of d ifferent MSC isolates were 22 
relatively consistent between donors (4.3, 3.89, and  4.1 days) and  similar 23 
variation was observed  (SD of 2.0, 1.2, and  1.6 days respectively). In hES- 24 
MP, the average doubling rate was 4.9 ± 3.5 days, and  was also relatively 25 
consistent between passages (4.8, 4.8, and  4.9 days) but at the latest passage 26 
(P11) greater variation was observed  (SD of 4.9, compared  to 2.5 and  2.8 27 
days for P9 and  P10 respectively).  28 
 29 






Figure 33: Proliferation of different mesenchymal cell types.  3 
Cells on tissue culture plastic over 21 days, for MSC three donors were used, for ADMSC 4 
two donors were used and each sample was run in triplicate. 5 
 6 
4.2.3 Flow cytometric analysis  7 
 8 
Flow cytometry was used  to determine expression of surface markers 9 
associated  with mesenchymal stem cells: CD90, CD73, CD105 and Stro-1. 10 
Cells were gated  according to their side scatter vs. forward  scatter 11 
properties, in order to eliminate dead , d ifferentiated  or cell aggregates, as 12 
shown in Figure 34. 13 
Each cell type d isplayed  d ifferent forward  scatter (FSC) and  side scatter 14 
(SSC) profiles. MSC had a high FSC, suggesting these cells are larger than 15 
both hES-MP and  ADMSC. hES-MP had  low SSC suggesting these cells 16 
were less granular compared  to MSC. They also appeared  to be the most 17 
homogenous, which would  be expected  from a cell line. ADMSC had a 18 
lower FSC compared  to MSC, suggesting they are smaller; SSC was higher 19 
and  more d iverse, suggesting these cells were more heterogeneous and  20 
complex in granularity, which could  be due to either intracellular or 21 





Figure 34: Flow cytometry gated populations 2 
Cell gates defined based on forward scatter (FSC) and side scatter (SSC). 3 
 4 
The expression of a number of cell surface markers of MSC (outlined  in 5 
Table 18) was analysed  on each of the gated  populations and  the 6 
histograms obtained  are shown in Figure 35. 7 
 8 
MSC MSC highly expressed  CD90 (99.6%), CD73 (100%), CD105 9 
(96.1%), and  had  moderate expression of Stro-1 (20.8%). All 10 
cells appeared  to be homogenous as evidenced  by a clear shift 11 
of the whole population to the right. 12 
hES-MP  hES-MP highly expressed  CD90, CD73, CD105; (83.9, 98.5, 13 
99.9%, respectively) and  had  slightly more Stro-1 positive 14 
cells (65.2%) compared  to MSC. Similarly, most markers were 15 
homogenous within the population of cells, with the 16 
exception of CD90, which appeared  to contain two d istinct 17 
subpopulations, both of which were positive, termed CD90 18 
high and  CD90 low.  Subsequently these d istinct populations 19 
were sorted  by fluorescence-activated  cell sorting (FACS), 20 
and  examined for d ifferences in transcription factor 21 
expression prior to and  after culture for 1 week. These results 22 
will be d iscussed  in a later section (see section 4.2.6). 23 
ADMSC A high percentage of ADMSC were positive for CD90 (99.3%) 24 
CD73 (94.2%) and  CD105 (92.2%).  The Stro-1 positive 25 




be an artifact of a higher level of nonspecific background 1 
staining seen with this cell type. 2 
 3 
Despite the homogeneity of hES-MP apparent in the forward  and  side 4 
scatter profiles shown in Figure 34, MSC appear to be the most 5 
homogenous in marker expression, as evidenced  by the narrow window of 6 






Figure 35: Flow cytomtery immunotyping.  
Representative histograms show expression of surface markers associated with mesenchymal stem cells, expressed as a percentage of 






The MSC population is derived  from bone marrow, which is a site of 1 
haematopoiesis and  therefore contains haematopoietic stem cells. ADMSC, 2 
derived  from adipose tissue is also a highly vascular tissue. 3 
To examine the possibility of contamination with haematopoietic 4 
progenitors, each population was analysed  for expression of markers 5 
associated  with the haematopoietic lineage: CD34, CD14 and CD45. The 6 
percentage of positive cells expressing these surface markers, versus the 7 
mesenchymal associated  markers: CD90, CD73, CD105 and Stro-1 are 8 
shown in Table 19 for each cell type. 9 
 10 
Table 19: Percentage of cells expressing MSC or haematopoietic cell surface 11 
markers. 12 
Cell type Passage CD90 CD73 CD105 Stro-1 CD34 CD14 CD45 
MSC 
P2 99.9 32 2.6 3.44 0.9 1.08 1.0 
P6 99.6 100 96.1 20.8 1.8 6.12 1.65 
hES-MP 
P8 83.9 98.5 99.9 65.2 40.9 78.5 N/ A 
P8 (Gelatin) 95.3 99.5 99.8 19.4 0.8 11.7 0.7 




P11 (Gelatin) 85.3 37.1 99.2 17 2.7 8.53 1.9 
ADMSC P1 98.3 98.2 92.2 46.9 9.5 15.8 5.5 
N/A indicates this maker was not analysed. 13 
 14 
hES-MP were originally established  as a cell line grown on a gelatin 15 
substrate, although it was suggested  that they could  also be grown on 16 
uncoated  tissue culture plastic (Karlsson et al. 2009).  The cell line was 17 
therefore analysed  after several passages on either 0.1% gelatin, or 18 
uncoated  tissue culture plastic, to examine how the substrate influenced  19 
cell surface marker expression. Initially cells were then cultured  on gelatin, 20 
as recommended by the supplier. A portion of these cells were transferred  21 
at P6 to culture on tissue culture plastic alone, to allow comparable results 22 
with MSC and ADMSC, which were routinely cultured  on uncoated  23 
plastic. This change in culture conditions d id  not sign ificantly affect the 24 
expression of CD90, CD73 and CD105 on hES-MP cells. However, hES-MP 25 
cultured  on plastic d id  have higher Stro-1, CD34 and CD45 expression. The 26 




expression to determine whether gelatin or plastic was influencing CD90 1 
expression. However, there was no significant d ifference in expression, 2 
between the subsets of CD90 between gelatin and  plastic, as seen in Table 3 
20. 4 
 5 











CD90 low 46.4 30.2 
CD90 high 53.6 278.5 
P11 
CD90 low 25.5 21.2 
CD90 high 54.5 155.8 
P8 (gelatin) 
CD90 low 20.9 36 
CD90 high 79.1 209.2 
P11 
(gelatin) 
CD90 low 32.8 30.0 
CD90 high 67.2 168.7 
 7 
 8 
MSC did  not express CD34, CD14 or CD45 in a significant proportion of 9 
cells at either P2 (<1.1%) or P6 (<6.13%). A high percentage of hES-MP 10 
expressed  CD34 (40.9%) and  CD14 (78.5%) at P8, when cultured  on plastic; 11 
at P11, this was greatly reduced  (0.803% and 7.96% respectively).  12 
hES-MP had a higher percentage of cells expressing CD14 than MSC. Yet, 13 
there was no significant d ifference between cells cultured  on plastic vs. 14 
gelatin with regard  to CD34, CD14 and CD45 expression overall. ADMSC 15 
had  a greater number of cells expressing CD34 (9.47%), CD14 (15.8%) and  16 
CD45 (5.48%) when compared  to MSC.  17 
The mean fluorescence intensity (MFI) was also examined, and  was 18 
calculated  by subtracting the median fluorescence intensity of the positive 19 
sample from the control sample (no antibody), and  results are shown in 20 
Table 21. Under saturated  conditions, MFI is d irectly related  to the amount 21 
of bound antibody, and  therefore the number of receptors per cell 22 





Table 21: Mean fluorescence intensity of surface markers on cells 2 
Cell type Passage CD90 CD73 CD105 Stro-1 CD34 CD14 CD45 
MSC 
P2 1204.7 50.5 20.6 16.1 2.7 4 2.8 
P6 917.6 180.1 69.2 20.3 1.2 15.7 8.3 
hES-MP 
P8 137.5 47.3 128.5 16.5 22.5 14.6 N/ A 
P8 (Gelatin) 119.2 42.3 114.2 7.7 0 2.9 -0.4 
P11 86.9 29.7 65.9 6.25 0.18 4.6 0.5 
P11 (Gelatin) 105.7 29.8 81.7 10.9 1.1 3.4 -1.7 
ADMSC P1 1514.3 506.3 168.3 154.3 22.1 55.1 27.2 
N/A indicates this maker was not analysed. 3 
 4 
Significant d ifferences in expression were observed , when compared  to 5 
percentage expression. MSC had high mean fluorescence intensity (MFI) 6 
values for CD90, in both P2 and  P6 (1204.7 and  917.6 respectively), P2 MSC 7 
d isplayed  a MFI of 50.5 for CD73, and  this was greater in in P6 (180.12). 8 
However, CD105 and Stro-1 were much lower (20.2 and  16.1 respectively). 9 
Haematopoietic markers CD34, CD45 and CD14 were low, with MFI values 10 
similar to hES-MP cultured  on gelatin. hES-MP cultured  on plastic (P8) had  11 
high MFI values for all haematopoietic markers, but this was not seen at 12 
the later passage (P11). A high percentage of hES-MP cells expressed  CD90, 13 
CD73 and CD105. Yet, their MFI was considerably lower than MSC and 14 
ADMSC.  15 
 16 
ADMSC displayed  the highest MFI for all surface markers, with the 17 
exception of CD90, the MFI was greater than 2-fold  higher than any other 18 
cell type. This could  be due to larger cells binding more antibody, however 19 
when the population was d ivided  according to size (FSC) and  analysed , 20 
this was not proven. 21 
To confirm that hES-MP had a mesenchymal stem cell phenotype they 22 
were also examined using markers associated  with embryonic stem cells, 23 




percentage of cells, of TRA1-60, TRA1-80, SSE1 and SSEA3. However 1 
SSEA4 expression was high, expressed  by 83.5% of cells and  had  a MFI 2 
value at least 13.7–fold  greater than any other hES associated  marker. 3 
 4 
Table 22: Embryonic stem cell associated marker expression in hES-MP. 5 
Marker 
Percentage of cells 
(%) 
Mean fluorescence intensity 
(MFI) 
TRA1-60 6.1 3.1 
TRA1-81 2.6 0.41 
SSEA1 1.23 0.1 
SSEA3 3.51 3.1 
SSEA4 83.5 101.19 
 6 
 7 
To determine localisation of staining, and  confirm flow cytometry results, 8 
cells were stained  for CD105 and Stro-1 at several passages.  9 
All cell types expressed  CD105 and  Stro-1 throughout culture on tissue 10 
culture plastic, in standard  growth medium, MSC (P1-P4) hES-MP (P7-P15) 11 
and  ADMSC (P2-P12).   12 
Figure 36 shows the d istribution of CD105 and Stro-1 staining for each cell 13 
type, representative of the level of staining seen at each passage.  14 
MSC showed CD105 positive staining throughout the cell surface, but the 15 
strongest staining was detected  near the nucleus. Stro-1 expression in MSC 16 
was similar to CD105, but was not detected  in all cells. The majority of hES- 17 
MP cells expressed  CD105 and the staining was similar in intensity 18 
compared  with MSC. Stro-1 staining however, was much weaker in 19 
intensity and  yet most cells showed positive expression. CD105 expression 20 
in ADMSC was noticeably d ifferent to hES-MP and MSC (distribution of 21 
staining was consistent across the cell surface) and  there was also a clear 22 
d ifference in levels of expression between cells, with some cells much 23 
brighter than others. A large proportion ADMSCs expressed  Stro-1, and  the 24 










  4 
Figure 36: CD105 and Stro-1 immunostaining of MSC, hES-MP and ADMSC.  5 













4.2.4 Transcription factor expression 2 
 3 
Each cell type was analysed  using semi quantitative PCR to measure 4 
transcription factor expression in undifferentiated  cells; cells were cultured 5 
in standard  growth media, with no additional supplementation. For each 6 
gene analysed , expression was normalised  to β-2 microglobulin (B2M ) 7 
expression in the same cell type, and  these normalised  levels are shown in  8 
 Figure 37. MSC expressed  all genes analysed  at lower levels than B2M , 9 
except from CD105 (1.12-fold). The osteogenic associated  transcription 10 
factors RUNX2 and  OSX  were the highest out of the lineage specific genes 11 
(0.58 and  0.53 respectively). SOX9, ACAN  (Aggrecan) and  PPARG were 12 
expressed  at levels lower than 0.36-fold , significantly lower than B2M 13 
(p<2x10-6). 14 
hES-MP expressed  the highest levels of lineage specific markers out of all 15 
cell types analysed , with the exception of  PPARG, which was 0.87-fold  less 16 
than ADMSC. hES-MP also expressed  significantly lower levels of CD105 17 
(0.59-fold) compared  with MSC (p=0.0001) and  ADMSC (p=0.00001). 18 
Expression of both RUNX2 and  SOX9 in hES-MP was high; significantly 19 
greater than in MSC and ADMSC (p<0.00004). OSX  levels in hES-MP were 20 
also higher than in MSC (1.27-fold), and  (2.18-fold) in ADMSC (p=0.00004). 21 
ACAN  and  PPARG expression were not significantly d ifferent in any cell 22 
type. 23 
ADMSC expressed  high levels of CD105 (1.18-fold), and  low levels of 24 
lineage specific makers. RUNX2, OSX  and  ACAN  expression levels were all 25 
lower than in any of the other cell types. SOX9 was significantly lower than 26 
in hES-MP (p=0.0004) but not significantly d ifferent to MSC (p=0.31). 27 
ADMSC expressed  the highest levels of PPARG but this was not 28 






 Figure 37: Transcription factor and gene expression in undifferentiated cells.  2 
Relative expression of lineage associated genes, representative of cells at different passages, 3 
each sample was run in duplicate. 4 
 5 
4.2.5 Multipotency 6 
 7 
By definition a stem cell must possess two qualities, self renewal and  8 
potency or ‗the ability to give rise to d ifferentiated  cell types‘ (Kolf, Cho & 9 
Tuan 2007a; Pittenger 1999; Nombela-Arrieta et al. 2011; Chamberlain et al. 10 
2007; Crisan et al. 2008; Barry & J. M. Murphy 2004; Boyd et al. 2009; 11 
Haasters et al. 2009; Yoshimura et al. 2006; Jack et al. 2002). To confirm the 12 
cells used  in this thesis were multipotent, each cell type was cultured  for up 13 
to 21 days in standard growth medium or in lineage specific d ifferentiation 14 
medium, and  d ifferentiation along adipogenic, osteogenic and  15 
chondrogenic lineages investigated .  16 
 17 
Adipogenic d ifferentiation was induced  in all cells types through the 18 
addition of 1-methyl-3-isobutylxanthine, dexamethasone, insulin and  19 
indomethacin to standard  growth medium. In MSC, ad ipogenic induction  20 
was apparent by Day 14, when lipid –rich vacuoles within the cells 21 
appeared , see Figure 38 (A). hES-MP differentiated  into ad ipocytes and  22 
after only 7 days lipid  vacuoles were detected , then by Day 14 strong 23 




form adipocytes; lipids were detected  as early as Day 7, and  continued  to 1 
accumulate in culture over two weeks (I). 2 
 3 
In the presence of β-glycerophosphate, ascorbic acid  and  dexamethasone, 4 
cells underwent osteogenic d ifferentiation. All cells acquired  an 5 
osteoblastic morphology and  up -regulated  alkaline phosphatase activity, as 6 
seen in Figure 38. Alkaline phosphatase staining was detected  in MSC after 7 
7 days in osteogenic medium and continued  to increase in intensity and  8 
area over 21 days (B). hES-MP rapid ly produced alkaline phosphatase, 9 
observed  as early as 24 hours in culture with osteogenic mediu m; which 10 
continued  to increase over time, Figure 38shows staining at 21 days (F). The 11 
strongest alkaline phosphatase staining was seen on Days 14 and  21, in 12 
ADMSC confirming these cells were also d ifferentiating into osteoblasts  (J).  13 
 14 
Under osteogenic culture conditions cells also produced a mineralised  15 
matrix as detected  by the Von Kossa stain  (Chamberlain et al. 2007; Kossa 16 
1901; Haasters et al. 2009; Yoshimura et al. 2006; Pittenger 1999). This was 17 
detected  in MSC, as early as Day 14, and  on Day 21 mineralisation was 18 
widespread  and  darker staining was observed  in areas, suggesting bone 19 
nodule formation see Figure 38 (C). hES-MP rapid ly formed a mineralised  20 
matrix, which was detected  as early as Day 7. Staining increased  in 21 
intensity and  area up to 21 days (G), where its was more d isperse, when 22 
compared  to the staining seen with MSC. No staining was observed  in 23 
ADMSC until Day 14, where it covered  roughly 50 % of the culture d ish. 24 
On Day 21, a greater area of mineralisation was detected  (K) and  was 25 
darker and  more widespread  than staining seen with MSC, and  hES-MP. 26 
 27 
Chondrogenic d ifferentiation was initiated  when cells were cu ltured  in the 28 
absence of fetal bovine serum with the addition of transforming growth 29 
factor–β3, dexamethasone, insulin, L-ascorbic acid , sodium pyruvate, 30 
transferrin, and  proline, Differentiation along the chondrogenic lineage was 31 
detected  by Safranin-O staining which detects glycosaminoglycans, shown 32 
in Figure 38. Cells cultured  in chondrogenic medium condensed  to form 33 
spheres and  occasionally detached  from the tissue cu lture plastic after two 34 




occurred . MSC differentiated  in culture and  stained  positively with 1 
Safranin-O by Day 14 (D). Differentiation in hES-MP occurred  much more 2 
rapid ly, and  strong positive staining was seen on  Day 7 (H). ADMSC 3 
d ifferentiated  and  stained  positively after Day 14 (L).  4 
 5 
As d ifferentiation along the three lineages proceeded, cells appeared  6 
healthy and  no signs of apoptosis or necrosis were observed . In each 7 
culture, cells appeared  to progress along the desired  lineage and  multiple 8 
lineages were not present, based  on phenotypic characterisation and  9 
histological analysis. Cells cultured  in standard  growth medium did  not 10 

























Figure 38: Adipogenic, osteogenic and chondrogenic differentiation of cells. 
Oil Red O staining - adipogenic differentiation, alkaline phosphatase staining - osteogenic differentiation, Safranin O staining - chondrogenic 
differentiation and von kossa staining- bone nodule formation, in MSC, hES-MP and ADMSC, Scale bars represents 200 μm. 
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To confirm lineage restriction, RNA was collected , prior to d ifferentiation 1 
and  at 7, 14 and  21 days during d ifferentiation; and  u sed  to amplify 2 
expressed  transcripts involved  in ad ipogenic (PPARG), osteogenic 3 
(RUNX2, COL1A1, ALPL, BGLAP) and  chondrogenic d ifferentiation (SOX9, 4 
ACAN, COL2A1), these transcripts were analysed  by semi quantitative PCR 5 
and  are shown in Figure 39. 6 
 7 
PPARG is a regulator of ad ipogenic d ifferentiation, promoting 8 
ad ipogenesis, and  preventing osteogenesis (Augello et al. 2010; Kolf, Cho & 9 
Tuan 2007b). PPARG was expressed  by MSC, hES-MP and ADMSC as they 10 
d ifferentiated  along the ad ipogenic lineage. Expression levels of PPARG 11 
transcription levels were highest in hES-MP and in ADMSC at Day 7, 12 
whereas in MSC expression was highest on Day 14 (8.9-, 15-, and  7.2-fold  13 
greater than on Day 0 respectively).   14 
 15 
RUNX2 expression is be both necessary and  sufficient to d irect MSC 16 
towards the osteoblast lineage (Pittenger 1999; Ziros et al. 2008; Shui et al. 17 
2003). RUNX2 expression was highest in all cell types after 7 d ays of 18 
osteogenic d ifferentiation; when it was expressed  at significantly higher 19 
levels in both MSC (p=0.02) and  ADMSC (p=0.0004) when compared  with 20 
hES-MP. (RUNX2 was significantly higher in ADMSC than MSC (p=0.005)). 21 
RUNX2 levels reached a 16.5-fold  increase in MSC, 27.2-fold  in ADMSC 22 
and 1.7-fold  in hES-MP (relative to Day 0). After Day 7 levels decreased , 23 
and  were not significantly d ifferent between each cell type. 24 
Collagen type I, constitutes 90% of the total organic extracellular matrix in 25 
mature bone, and  is synthesised  by pre-osteoblasts and  mature osteoblasts 26 
(Dominici et al. 2006; Reffitt et al. 2003). In MSC, COL1A1 was increased  27 
1.6- fold  on Day 7 and  up to 4.2-fold  (greater than Day 0) on Day 14. 28 
Expression in hES-MP peaked later, at Day 14 (2.4-fold , relative to Day 0) 29 
then decreased  1.8-fold  on Day 21.  30 
ADMSC expressed  the highest levels of COL1A1, and  expression was 31 
significantly greater than MSC and hES-MP at each time point (p≤ 0.017). 32 
On Day 7, COL1A1 reached  8.2-fold  (greater than Day 0) then continued  to 33 
increase to 12.5-fold  (greater than Day 0) on Day 14 and  remained  high at 34 
Day 21.  35 
CHAPTER FOUR 
 117 
Alkaline phosphatase (ALPL) is expressed  by mature osteoblasts, and  is 1 
thought to play a vital role in mineralisation (Barry & J. M. Murphy 2004; E. 2 
Golub 2007). ALPL levels steadily increased  over time in each cell type. 3 
Initially ADMSC expressed  the highest levels of ALPL, significantly higher 4 
than MSC (p=0.02). Levels of ALPL increased  in ADMSC and remained  5 
significantly higher than MSC at all time points (p≤0.03). hES-MP also 6 
expressed  greater ALPL than MSC (relative to B2M), but d id  not reach 7 
significance until Day 21 (p=0.01). 8 
Osteocalcin is the most bone specific protein produced by mature 9 
osteoblasts (Dominici et al. 2006; Malaval et al. 2005), and  is encoded by the 10 
BGLAP gene. In all cell types BGLAP expression was low on Day 7, and 11 
increased , on days 14 and  21.  In MSC, BGLAP increased  rapid ly (0.3-fold) 12 
on Day 14 and  (8.8-fold) on Day 21. hES-MP followed a similar trend , levels 13 
were low on Day 14 then increased  to the highest level on Day 21. This 14 
expression was significantly lower than ADMSC at the same time point 15 
(p=0.002). ADMSC expression of BGLAP was significantly higher than 16 
MSC at all time points (p≤0.01); and  also had the greatest expression of 17 
BGLAP overall, on days 14 (15.8) and  21 (25.3). 18 
 19 
All genes associated  with chondrocytes were elevated  as each cell type 20 
underwent chondrogenic d ifferentiation. 21 
The only transcription factor, shown to be required  for the initiation of 22 
cartilage d ifferentiation during embryogenesis is SOX9 (Kolf, Cho & Tuan 23 
2007a; Kulyk & J. Franklin 2000). SOX9 expression was elevated in MSC 24 
and  ADMSC on Day 7, when levels were 3-fold  (MSC) and  5.8-fold  25 
(ADMSC) greater than Day 0. On Day 7, SOX9 expression in ADMSC was 26 
significantly higher than in MSC (p=0.04), and  hES-MP (p=0.01). 27 
Expression of SOX9 in hES-MP increased  later, on Day 14 where it reached 28 
3.2. Unlike MSC, both ADMSC and hES-MP continued  to express SOX9 on 29 
Day 21 (2.1- and  2.3-fold , greater than Day 0).  30 
Aggrecan is a major component of cartilage and  encoded by the gene 31 
ACAN  (Dominici et al. 2006; Barry et al. 2001). Expression levels of ACAN  32 
were high on Day 7 in all cell types; MSC, ADMSC and hES-MP (3-, 8.6-, 33 
and  15.7-fold , greater than Day 0). ACAN  was expressed  in hES-MP, at 34 
levels significantly greater than ADMSC (p=0.01) and  MSC (p=0.003). On 35 
Day 14 ACAN  levels in MSC and ADMSC greatly decreased . In hES-MP 36 
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however, it remained  significantly greater than MSC (p=0.0005) and  1 
ADMSC (p=0.0006) at 5.8. By Day 21 ACAN  levels decreased  (ADMSC 1.3- 2 
fold) or were undetectable (MSC and hES-MP). 3 
Collagen type II (encoded by the gene COL2A1) is the major component of 4 
hyaline and  articular cartilage (Kolf, Cho & Tuan 2007b; Barry et al. 2001; 5 
Chamberlain et al. 2007; Crisan et al. 2008; Vodyanik et al. 2010; Haasters et 6 
al. 2009; Sanchez-Guijo et al. 2009; Yoshimura et al. 2006; Kozhevnikova et 7 
al. 2008; Jack et al. 2002; Dominici et al. 2006; Ohgushi et al. 2005; Orciani et 8 
al. 2010). COL2A1 expression in MSC increased  on Day 7 and  14 were it 9 
reached 6-fold  greater than Day 0, then decreased  on Day 21 3.3-fold . hES- 10 
MP expression of COL2A1 followed a similar trend , and  was not 11 
significantly d ifferent to either MSC or ADMSC on Day 14 (p ≥0.93). On 12 
Day 21 however, COL2A1 expression was 6.3-fold , significantly greater 13 
than MSC (p=0.015), and  ADMSC expressed  the highest levels of COL2A1 14 
on days 7 and  21, where they were significantly greater than MSC 15 
(P≤0.0007) and  hES-MP (p≤0.0016). On Day 21 COL2A1 expression reached 16 











Figure 39: Lineage specific semi quantitative PCR.  
mRNA levels of genes of interest and are represented as level of expression normalised to 
beta-2 microglobulin and to Day 0. For MSC three donors were used, for ADMSC two 




4.2.6 CD90 analysis 1 
 2 
The bimodal population of CD90 positive hES-MP detected  by flow 3 
cytometry was sorted  by FACS, and  examined for d ifferences in 4 
transcription factor expression  prior to and  after 1 week of culture.  5 
Morphologically cells appeared  very d ifferent in culture, shown in  6 
Figure 40. The CD90 high cells were small, with a pronounced nucleus and  7 
appeared  proliferate at a greater rate, whereas CD90 low cells were longer, 8 




Figure 40: Morphology of sorted CD90 high and CD90 low hES-MP. 13 
Representative morphology of hES-MP after sorting and 1 week of culture, scale bar 14 
represents 400 μm. 15 
 16 
To examine possible d ifferences in multipotency, RNA from cells was 17 
collected , reverse transcribed  and  analysed  by semi quantitative PCR for 18 
transcription factors associated  with each lineage and  the results are shown 19 
in  20 
Figure 41. Immediately after sorting, CD90 high cells expressed  21 
significantly more PPARG (p=0.00008), RUNX2 (p=0.000001) and  SOX9 (p= 22 
0.0002) than CD90 low cells. After 1 week in culture, levels of PPARG, 23 
RUNX2, and  SOX9, in CD90 high remained  significantly greater than in 24 
CD90 low cells, (p=0.002, 0.0006, and  0.0000003 respectively). At both time 25 
points RUNX2 was expressed  at higher levels than B2M, but this was not 26 





Figure 41: Transcription factor analysis of CD90 high and CD90 low hES-MP.  3 
(A) Cells immediately after sorting, (B) cells after 1 week in culture. Two  samples of each 4 
cell population were analysed and run in duplicate Gene expression was normalised to 5 
Beta-2-microglobulin in each sample, and transcription factors involved in adipogenic 6 
(PPARG), osteogenic (RUNX2) and chondrogenic differentiation (SOX) were analysed. 7 








4.3 Discussion 1 
 2 
The aims of this chapter were to characterise the undifferentiated  cells and  3 
to determine their d ifferentiation capacity. This is the first time MSC, hES- 4 
MP and ADMSC have been characterised  and  analysed  together. The 5 
results ind icate similarities and  d ifferences in the morphology, 6 
proliferation, surface marker expression and  multipotency of these cell 7 
populations. 8 
Despite isolation from different sources, MSC and ADMSC appeared  9 
homogenous in size, shape and  had  very similar morphology, an 10 
observation that has been described  previously (Kolf, Cho & Tuan 2007b; 11 
Kern et al. 2006; Chamberlain et al. 2007; Crisan et al. 2008; Barry & J. M. 12 
Murphy 2004; Boyd et al. 2009; Haasters et al. 2009; Kozhevnikova et al. 13 
2008; Pittenger 1999; Jack et al. 2002; Dominici et al. 2006; Orciani et al. 14 
2010). A common origin of multipotent adult stem cells was proposed  by 15 
one group (Chamberlain et al. 2007; Crisan et al. 2008; Kolf, Cho & Tuan 16 
2007b; Barry & J. M. Murphy 2004; Boyd et al. 2009; Haasters et al. 2009; 17 
Kozhevnikova et al. 2008; Pittenger 1999; Yoshimura et al. 2006; Blitterswijk 18 
et al. 2007; Foster et al. 2005; Jack et al. 2002; Dominici et al. 2006; Orciani et 19 
al. 2010), which could  explain these similarities. hES-MP however, 20 
appeared  to be more a more heterogeneous population of cells, which is 21 
likely due to the bimodal population of CD90 positive cells.  22 
 23 
Proliferation analysis revealed  significant d ifferences in doubling rates; 24 
ADMSC proliferated  at a rate two-fold  greater than MSC, and  significantly 25 
greater than hES-MP. The lower rate of proliferation seen in MSC may be 26 
due to donor age, a relationship which has been described  by several 27 
groups (Kolf, Cho & Tuan 2007b; Stenderup et al. 2003; Vodyanik et al. 28 
2010; Phinney et al. 1999; Jack et al. 2002; Mendes et al. 2002; Tare et al. 29 
2012; Muschler et al. 2006).  This has been further confirmed by studies that 30 
have examined proliferation of bone marrow derived  MSC and adipose 31 
derived  MSC (ADMSC) isolated  from the same patient, and  found no 32 
significant d ifferences in growth kinetics (Crisan et al. 2008; Schäffler & 33 
Büchler 2007; Boyd et al. 2009; De Ugarte et al. 2003; Jack et al. 2002). The 34 
high variance in doubling times of hES-MP may also be a resu lt of the 35 
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bimodal CD90 population, as CD90 low cells were observed  to have a much 1 
slower rate of proliferation. 2 
 3 
Flow cytometry results demonstrated  MSC expressed  surface makers 4 
commonly associated  with mesenchymal stem cells (CD90, CD73, CD105). 5 
However, expression of the colony forming associated  marker, Stro -1 was 6 
expressed  by less than 25% of MSC, detected by flow cytometry. Stro-1 is a 7 
contentious MSC marker for several reasons, described  previously.  8 
Haematopoietic progenitor markers CD34, CD14 and CD45, were 9 
expressed  in a small percentage of MSC, and  overall expression of these 10 
markers in MSC was lower than in hES-MP and ADMSC. MFI values for 11 
mesenchymal associated  markers were high in MSC; in particular CD90, 12 
and  CD73 were greater than in hES-MP; indicating a greater number of 13 
receptors per cell. 14 
 15 
hES-MP were more heterogeneous for expression of mesenchymal markers, 16 
CD90, CD73, CD105 and Stro-1, with expression varying significantly 17 
between passages.  18 
MIP results also demonstrated  hES-MP did  not express the same levels of 19 
surface antigens as MSC, and  MIP values were significantly lower for all 20 
mesenchymal markers. One passage of hES-MP (P8, cultured  on plastic) 21 
also expressed  significant levels of the CD34, and  CD14. These commonly 22 
used  markers of the haematopoietic lineage (Chamberlain et al. 2007; Kolf, 23 
Cho & Tuan 2007b; Haasters et al. 2009; Barry & J. M. Murphy 2004; 24 
Pittenger 1999; Boyd et al. 2009; Yoshimura et al. 2006; Crisan et al. 2008), 25 
which were not evaluated  in the original paper (Nombela-Arrieta et al. 26 
2011; Karlsson et al. 2009; Kolf, Cho & Tuan 2007b; Chamberlain et al. 2007; 27 
Crisan et al. 2008; Barry & J. M. Murphy 2004; Boyd et al. 2009; Haasters et 28 
al. 2009; Yoshimura et al. 2006; Pittenger 1999; Jack et al. 2002). Embryonic 29 
markers TRA1-60, TRA1-80, SSE1 and SSEA3, were not detected  at 30 
significant levels, consistent with results from Karlsson et al. Inconsistent 31 
with this study was SSEA4 expression, previously thought to be an 32 
embryonic stem cell marker (Chamberlain et al. 2007; Barraud  et al. 2006; 33 
Haasters et al. 2009; Yoshimura et al. 2006; Pittenger 1999). However, more 34 
recent studies have shown that SSEA4 also identifies bone marrow derived 35 
MSC (Oishi & Ito-Dufros 2006; Gang et al. 2007), which may explain this 36 
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ambiguity. Although not analysed  here, it would  be interesting to 1 
investigate the expression of SSEA4 on MSC and ADMSC.   2 
 3 
Results here have shown ADMSC to have a similar immune phenotype to 4 
MSC, an observation reflected  in data from a number of papers (Kolf, Cho 5 
& Tuan 2007b; Kuznetsov et al. 1997; Filshie et al. 1998; Nuttall et al. 1998; 6 
Gronthos 1999; Park & Oreffo 1999; Pittenger 1999; Erices et al. 2000; 7 
Simmons & Torok-Storb 1991a; Simmons & Torok-Storb 1991b; 8 
Haynesworth et al. 1992; Galmiche et al. 1993; Simmons et al. 1994; Rickard 9 
et al. 1996; Gronthos et al. 1997; Bruder et al. 1997).  10 
 11 
ADMSC were highly homogenous, as evidenced  by a clear, compact shift 12 
in relative fluorescence of surface markers associated  with mesenchymal 13 
stem cells (CD90, CD73, CD105), and  the MFI for each of these markers was 14 
highest out of all cell types, suggesting they have greater expression of the 15 
cell surface markers, per cell. However, MFI was not calculated  under 16 
saturated  conditions, as would  be required  to verify these results. A higher 17 
proportion of ADMSC expressed  haematopoietic markers CD34, CD14 and  18 
CD45, compared  to MSC, but given the vascularity of ad ipose tissue, this 19 
was not surprising, and  was only detected  at early passages. 20 
 21 
Transcription factor expression was analysed  to determine levels of gene 22 
expression in undifferentiated  cells, and  to indicate whether cells may be 23 
pre-committed  to a certain lineage. In MSC and ADMSC lineage associated  24 
transcription factors and  gene expression were lower than the 25 
housekeeping gene, B2M, suggesting lineage associated  genes are 26 
transcribed  at very low levels.  27 
In hES-MP however, expression of osteoblast-associated  transcription 28 
factor RUNX2 and  chondrogenic related  transcription factor SOX9 was 29 
higher than both B2M  and  CD105 expression. This elevated  RUNX2 30 
expression was noted  by the group who derived  hES-MP however, was not 31 
identified  as a pontetial issue (Barry et al. 1999; de Peppo, Svensson, et al. 32 
2010b). The increased  levels of lineage related  genes suggest that ind ividual 33 
cells are expressing multiple transcription factors, at higher levels 34 
compared  to MSC and ADMSC, or indicative of a subpopulation of pre- 35 
committed  cells. CD90 analysis suggests that in fact this may be due to the 36 
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population of CD90 high cells that are expressing high levels of lineage 1 
specific transcription factors.   2 
 3 
In addition to the identification of MSC based  on plastic adherence, 4 
morphology or molecular characteristics, is to identify MSC populations is 5 
by their multilineage capacity in vitro. Results from histochemical staining 6 
and  gene expression demonstrate each cell type was capable of 7 
d ifferentiating along three d istinct lineages, ind icating each cell population 8 
was multipotent. Cells were supplemented  with soluble factors known to 9 
d irect cell fate and  analysed  over 21 days, which is a commonly used  and  10 
widely recognised  time frame for ad ipogenic, chondrogenic and  osteogenic 11 
d ifferentiation. 12 
 13 
MSC differentiated  along each lineage, as evidenced  by histological 14 
analysis. Multiple lineages d id  not appear to be present, and  was 15 
conformed by real time PCR. Differentiation occurred  at a slightly slower 16 
rate in MSC, when compared  to ADMSC and hES-MP, as evidenced  by 17 
later gene expression and  histological staining. The lower rate of 18 
proliferation associated  with MSC in this study may have impacted  upon 19 
the rate at which cells d ifferentiate. Yet, during chondrocyte d ifferentiation 20 
MSC had the greater levels of SOX9 on Day 7 compared  to hES-MP and 21 
had  the highest relative levels of COL10A1 over 21 days. 22 
hES-MP were shown to d ifferentiate along adipo- osteo- and chondrogenic 23 
lineages in the original research paper. However, Karlsson et al. reported 24 
results after longer culture in supplemented  medium, ad ipogenic 25 
d ifferentiation (25 days), Chondrogenic d ifferentiation (6 weeks) and  26 
osteogenic d ifferentiation (5 weeks). Furthermore, analysis of 27 
d ifferentiation consisted  solely of histochemical staining and  d id  not 28 
include gene expression analysis (Banas et al. 2007; Karlsson et al. 2009; 29 
Mitchell et al. 2005). These are the first results to combine both 30 
histochemistry and  gene expression of hES-MP in one study. 31 
Previous studies have demonstrated  that ADMSC are capable of 32 
d ifferentiation along the three lineages examined here (Simmons & Torok- 33 
Storb 1991b; Hui et al. 2005; Im et al. 2005), and  some cases w ere shown to 34 
be inferior to MSC, which was not observed  here. Results from PCR and  35 
histology demonstrated  ADMSC differentiated  rapid ly along the three 36 
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lineages and  had  the highest expression of ad ipogenic transcription factor 1 
PPARG, and  osteoblast related  genes RUNX2, COL1A1, and  BGLAP.  2 
 3 
MSC 4 
Whilst MSC may represent the most clinically relevant source of stem cells 5 
to study osteogenic differentiation they have several drawbacks: (1) the 6 
cells used  in this thesis were obtained  from patients who had  damaged 7 
bone or cartilage as a result of d isease; (2) there was a limited  supply of 8 
samples and  often small volumes of tissue; (3) unsorted  MSC derived  from 9 
bone marrow may contain a heterogeneous population of cells; (4) 10 
variability between patient tissue samples, was noted , with regard  to MSC 11 
number and  expansion potential. Despite these drawbacks, MSC were 12 
readily expanded, and  morphologically appeared  to be healthy.  13 
The only criterion for selection was plastic adherence, and  MSC were not 14 
enriched  or sorted  according to surface markers. Nevertheless, MSC were 15 
relatively homogenous, as evidenced  by morphology, flow cytometry and  16 
only slight heterogeneity was detected  in immunostaining.  17 
Transcription factor and  gene expression results suggest MSC were not 18 
pre-committed  to a specific lineage, and  were cap able of d ifferentiating into 19 
multiple cell types, ind icating a truly multipotent population. 20 
A common and major drawback of studies u tilising primary cells is donor 21 
variability. MSC displayed  high donor variability with regard  to CD73, 22 
CD105 and Stro-1 staining as detected  by flow cytometry. However, 23 
significant variance between donors was not found in immunostaining, 24 
transcription factor expression or d ifferentiation potential.  25 
Despite several d isadvantages, MSC remain the most extensively studied , 26 
characterised , and  most clinically relevant source of cells to examine 27 
osteogenic d ifferentiation in vitro. Recently, Prochymal® (remestemcel-L), 28 
was approved for the treatment of acute graft-vs-host d isease (GvHD) in 29 




hES-MP were derived , and  first characterised  in 2009 to overcome the 34 
drawbacks associated  with primary MSC. hES-MP claim to have no donor 35 
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variability, exhibit a more extensive proliferative capacity, and  represent a 1 
more homogenous source of multipotent stem cells (Peister 2004; Karlsson 2 
et al. 2009). Results shown here are in agreement with these previous 3 
reports, which suggest hES-MP resemble MSC, with regard  to surface 4 
marker expression, and  multipotency. However, several notable d ifferences 5 
were observed .  6 
CD90 was consistently expressed  by a high percentage of hES-MP 7 
throughout culture, however, a dual population was observed  at several 8 
passages.  Analysis of the CD90 positive population revealed  two d istinct 9 
sub-populations, which once sorted  and  analysed  were very d ifferent. 10 
CD90 high cells appeared  to be more d ifferentiated - expressing significantly 11 
higher lineage specific markers than CD90 low cells, in particular RUNX2. 12 
This elevated  expression of RUNX2 was also noted  in transcription factor 13 
analysis of the unsorted  population. 14 
Until now, a bimodal d istribution of CD90 in mesenchymal stem cells has 15 
not been described  or investigated . CD90 is widely regarded  to be a marker 16 
expressed  by undifferentiated  cells (Chamberlain et al. 2007; Kolf, Cho & 17 
Tuan 2007a; Dominici et al. 2006) and  even in cancer stem cells (Péault et al. 18 
2007; Parry & Engh 2012). However, one study has described  expression of 19 
CD90 in cells of the osteoblast lineage. Furthermore, has demonstrated  th at 20 
CD90 expression is altered  during d ifferentiation: CD90 expression was 21 
maximal at the earliest stage of osteoblast maturation, during the 22 
proliferative phase, and  then declined  as the cells matured  (Pittenger 1999; 23 
X. D. Chen et al. 1999). This observation is in agreement with results shown 24 
here, with CD90 high cells expressing the early osteoblast marker RUNX2.  25 
Although hES-MP were shown to contain this subpopulation of pre- 26 
committed  cells, the total population still possessed  the ability to 27 
d ifferentiate into multiple lineages; suggesting that CD90 low cells are 28 
multipotent. 29 
hES-MP were recommended to be cultured  on 0.1% gelatin, which is 30 
thought to enhance attachment and  proliferation of cells (Toma et al. 2001; 31 
Chai & Leong 2007). However, once transitioned  from gelatin to plastic, 32 
hES-MP attached  strongly to PL and proliferation rates, although not 33 




hES-MP were shown to d ifferentiate rapid ly into ad ipocytes, osteoblasts 1 
and  chondrocytes, notably faster than MSC. This may be due to the origin 2 
of the MSC in this study (from mature, d iseased  patients) or due to hES-MP 3 
possessing a greater proliferative capacity. 4 
 5 
Despite several drawbacks, hES-MP were readily expandable, and  d id  not 6 
rely on surgical operations, or involve lengthy extraction procedures. 7 
Although these cells are unlikely to be used  in the clinical setting, due to 8 
their derivation from embryonic tissue, they represent a valuable tool to 9 




Bone marrow derived  mesenchymal stem cells hold  great potential for use 14 
in tissue regeneration and  repair. However, there are practical issues, 15 
which have limited  clinical use; including low yield , the need  for 16 
expansion, and  significant morbid ity imposed  on the donor. As such 17 
interest has rapid ly increased  identifying MSC from alternate sources, such 18 
as ad ipose tissue. The ADMSC used  here were isolated  from the stromal 19 
vascular fraction of lipoaspirate or from whole fat, using an established  20 
extraction procedure (Zuk et al. 2001; Crisan et al. 2008). Representing a 21 
less painful, alternative source of highly proliferative cells. 22 
Transcription factor analysis revealed  undifferentiated  ADMSC and MSC 23 
had  similar gene expression profiles. This is in agreement with multiple 24 
studies, which suggest ADMSC and MSC display similar expression 25 
profiles based  on mRNA analyses (Gronthos 2000; Gimble et al. 2007). 26 
Overall, undifferentiated  ADMSC expressed  lower levels of lineage specific 27 
markers than MSC and hES-MP, suggesting ADMSC may represent a 28 
population of less committed  cells. 29 
 30 
ADMSC were first shown to be multipotent in 2001 (Scherjon et al. 2004; 31 
Zuk et al. 2001), and  since then have been d ifferentiated  into multiple cell 32 
types, including card iac, neuronal, and  pancreatic lineages (Erices et al. 33 
2000; Locke et al. 2011; Strem et al. 2005).  Here we demonstrated  ADMSC 34 
could  be successfully d ifferentiated  along adipo- osteo- and  chondrogenic 35 
lineage, as evidenced  from histology and  real time PCR. ADMSC expressed 36 
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high levels of lineage specific markers once committed  to each cell type, 1 
and  genes specific to the osteoblast lineage were expressed  at significantly 2 
greater levels in ADMSC, compared  to both MSC and hES-MP.  3 
ADMSC were notably more proliferative than MSC, this may be due to the 4 
lower donor age and health status. Due to relative ease of extraction, 5 
expansion potential, and  similar characteristic to MSC, ADMSC represent 6 
an attractive, alternative source of cells to study osteogenic d ifferentiation. 7 
The MFI for each of these markers was highest out of all cell types, 8 
suggesting they have greater expression of cell surface markers, per cell. 9 
Immunostaining confirmed this, where uniform, intense, CD105 staining 10 
was observed . Although a higher proportion of ADMSC expressed  11 
haematopoietic markers CD34, CD14 and CD45 compared  to MSC, but 12 
given the vascularity of ad ipose tissue, this is not surprising, and  was only 13 
detected  at early passages.  14 
In conclusion, each cell type has its own advantages and  d isadvantages to 15 
study osteogenic d ifferentiation in vitro, and  is summarised  in Table 23. 16 
 17 
Table 23: Advantages and disadvantages of each cell type. 18 
 MSC hES-MP ADMSC 
Availability + +++ ++ 
Clinical relevance +++ + +++ 
Proliferation capacity + ++ +++ 
Differentiation potential ++ ++ +++ 
Donor varaibility ++ N/ A ++ 
Ethical issues N/ A ++ N/ A 
Heterogeneity + ++ + 







CHAPTER FIVE: OSTEOGENIC EFFECT OF 1 
SUBSTRATES ON MESENCHYMAL STEM CELLS 2 
5.1 Introduction 3 
 4 
Bone tissue engineering, which utilises the endogenous bone remodeling 5 
capacity within the patient, offers a proof of principle that holds out the 6 
promise that more active regenerative strategies can result in complete 7 
regeneration of bone and  restoration of its function . 8 
Currently, bone tissue engineering involves the transplantation of graft 9 
materials combined  with cells. Calcium phosphate based  bone grafts are 10 
used  to fill small bone defects and  in spinal fixation. In the form of porous 11 
granules, these materials are commonly mixed  with autologous bone 12 
marrow to form a cohesive graft (Gronthos, D. M. Franklin, et al. 2001a; K 13 
A Hing 2005). 14 
Bone marrow contains a source of multipotent stem cells (MSC) that can be 15 
expanded and  d ifferentiated  along a restricted  set of lineages in vitro 16 
(Guilak et al. 2005; Muschler et al. 1997; Zhang et al. 2011); for example, the 17 
addition of β–glycerophosphate, ascorbic acid  and  dexamethasone results in 18 
commitment to the osteoblast lineage. This is a complex, highly regulated  19 
process involving the parallel and  sequential expression of lineage specific 20 
genes. An essential transcription factor controlling this process is RUNX2, 21 
which is believed  to be both necessary and  sufficient to d irect MSC toward 22 
the osteoblast lineage (Crisan et al. 2008; Ziros et al. 2008; Shui et al. 2003). 23 
RUNX2 acts by binding to a regulatory element found in the promoter of 24 
all major osteoblast genes, including COL1A1 (collagen type I) (Wang et al. 25 
2008; Komori 2010) and  BGLAP (osteocalcin) (Pera et al. 2000; Makita et al. 26 
2008). The proteins associated  with these genes, amongst others, are 27 
secreted  by osteoblasts and  are incorporated  into osteoid , the organic phase 28 
of bone (de Peppo, Sjovall, et al. 2010a; Glimcher 1984). Alkaline 29 
phosphatase is produced, initially in parallel with osteoid  production, then 30 
declining as matrix mineralisation occurs (Karlsson et al. 2009; Stein et al. 31 
1990), in which calcium phosphate crystals are deposited  to form the 32 
mineral phase of bone (Karlsson et al. 2009; Zhao et al. 2007).  Osteoblasts 33 
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that are left behind  during osteoid  production are then encased  in the 1 
mineralised  osteoid , cease proliferation and  become terminally 2 
d ifferentiated  osteocytes, which express DMP1 (dentin matrix acid ic 3 
phosphoprotein 1)(Riquelme et al. 2006; Dallas & Bonewald  2010). 4 
Soluble osteogenic factors are an excellent tool to study osteogenesis in 5 
vitro, however they are unlikely to be practical in the clinical setting. An 6 
alternative approach is to use a scaffold  or matrix engineered  to provide 7 
cues for d ifferentiation to eliminate the need  for soluble factors.  8 
Hydroxyapatite (HA) is currently used  in fracture repair, spinal fixation 9 
and  treatment of bone defects (Karin A Hing et al. 2007). HA is 10 
osteoconductive, and  has been shown both to support bone formation in 11 
vivo (Bansal et al. 2009). Yet, it has poor degradation rates and  in some 12 
cases is not completely remodeled  (Habraken et al. 2007). 13 
Clinical and  in vivo studies have demonstrated  that the incorporation of 14 
silicon, in the form of silicate, into the calcium phosphate lattice improves 15 
degradation rates, the quality of new bone formed, and  rate of bone growth 16 
when compared  to hydroxyapatite (Wheeler et al. 2007; Jenis & Banco n.d .; 17 
KA Hing et al. 2004b). However, is not clear whether the increased  bone 18 
formation associated  with these materials is the result of increased  19 
osteoblast activity or increased  numbers of osteoblasts resulting from 20 
increased  activation and  d ifferentiation of stem/ progenitor cells.  21 
Most studies examining the osteogenic potential of bone grafts in vitro have 22 
used  cells that are either immature osteoblasts or osteoblast-like cell lines 23 
(Dalby et al. 2006; Botelho et al. 2006; Rosa et al. 2003; Keeting et al. 1992). 24 
In vivo it is thought that MSC or progenitor cells are the first cell types to 25 
colonise a bone graft after implantation (Olivares-Navarrete et al. 2010).  26 
Understanding the biological and  physiological interaction between  bone 27 
grafts and  stem/ progenitor cells is critical to improving bone grafts and  28 
their successful incorporation (Kalfas 2001). Bone marrow derived 29 
mesenchymal stem cells (MSC) are though to be the most physiologically  30 
relevant cell type to investigate this interaction. However, extraction of 31 
these cells can be painful and  often the population of cells has a limited 32 
expansion potential in vitro.  33 
The unlimited  proliferative and  d ifferentiation capacity of human 34 
embryonic stem cells has generated  significant interest in bone tissue 35 
engineering (Bielby et al. 2004; Nieden et al. 2003; Sottile et al. 2003; Sinae 36 
CHAPTER FIVE 
 132 
Kim et al. 2008). Yet, tumor formation and  ethical debate over the origin of 1 
these cells has prevented  their use in the clinical setting. One way of 2 
overcoming the associated  risks of using pluripotent stem  cells is to restrict 3 
their lineage capacity prior to implantation. hES-MP are a commercially 4 
available mesenchymal progenitor cell line, derived from human 5 
embryonic stem cells (hES); these cells possess the extensive capacity of 6 
hES but do not  share the risk of teratoma formation (Karlsson et al. 2009). 7 
Consequently, human embryonic stem cell derived  mesenchymal 8 
progenitors (hES-MP) are appealing alternatives to MSC in bone tissue 9 
engineering applications (de Peppo, Svensson, et al. 2010b). Furthermore, 10 
the use of a cell line removes potential issues associated  with  primary cells 11 
such as availability, donor variability and  may also provide more 12 
reproducible results. 13 
Adipose tissue has been the focus of much stem cell research, as it is an 14 
abundant and  more accessible source of multipotent stem cells than bone 15 
marrow (Gimble & Guilak 2003). Recent studies have demonstrated  that 16 
ad ipose derived  mesenchymal stem cells (ADMSC) show similar 17 
characteristics and  d ifferentiation capacity, to those of bone marrow 18 
derived  mesenchymal stem cells (Guilak et al. 2004; Gimble et al. 2007). 19 
This more accessible and  abundant supply of primary multipotent  cells, 20 
provides an excellent source of cells to study biomaterial-stem cell 21 
interactions. 22 
Bone marrow derived  MSC, hES-MP and ADMSC were selected  to 23 
investigate whether the enhanced  bone formation observed  on silicate 24 
substituted  calcium phosphate (Si-CaP) is the result of increased  osteoblast 25 
d ifferentiation or increased  activation and  d ifferentiation of 26 
stem/ progenitor cells.  27 
 28 
This chapter aims to firstly determine whether Si-CaP and HA can support 29 
d ifferentiation of MSC in the presence of soluble osteogenic factors (+OS): 30 
and  secondly, determine whether either substrate can initiate the 31 
d ifferentiation of MSC, hES-MP and ADMSC in the absence of soluble 32 
osteogenic factors. In order to determine and  quantify the degree of 33 
osteogenic d ifferentiation upon both substrates, attachment, proliferation, 34 
gene expression, protein production, and  mineralisation of extracellular 35 
matrix will be analysed . 36 
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5.2 Results 1 
5.2.1 MSC 2 
5.2.1.1 Osteogenic different iat ion w ith soluble factors. 3 
 4 
MSC were cultured  on Si-CaP and HA in the presence of osteogenic media 5 
(OS), cells cultured  on tissue culture plastic (PL) alone served  as negative 6 
controls and  cells on plastic in the presence of osteogenic media (PL+OS) 7 
were positive controls. Cells were cultured  for up to 21 days and  analysed 8 
for alkaline phosphatase expression, mineralisation and  gene expression. 9 
5.2.1.1.1  Alkaline phosphatase   10 
 11 
Tissue non-specific alkaline phosphatase (ALP) is an enzyme produced by 12 
cells during osteogenesis (Malaval et al. 1994). To assess the degree of 13 
d ifferentiation along the osteogenic pathway, ALP activity was calculated  14 
by measurement of the area of ALP positive staining cells after 15 
histochemical staining at d ifferent time points in culture, as described  in 16 
materials and  methods section 2.5.8.3. The percentage area of ALP staining 17 
on each substrate is shown in  18 
 Figure 42. 19 
 20 
 21 
 Figure 42: Area of alkaline phosphatase staining.  22 
ALP activity of cells on substrates quantified by analysing the area of ALP positive cells 23 
using image analysis software and the mean area calculated per disc / well. The results 24 




ALP staining was limited  in cells cultured  on PL, and  remained  low at all 2 
time points. Cells cultured  in the presence of osteogenic media (Si-CaP+OS, 3 
HA+OS and PL+OS) produced significant levels of ALP, and the ALP 4 
positive area increased  over time. On Day 1 cells on Si-CaP+OS, HA+OS 5 
and  PL+OS expressed  detectable levels of ALP, and  from Day 1 to 21 cells 6 
on Si-CaP+OS and HA+OS displayed  significantly greater ALP activity 7 
than cells on PL+OS (p<0.01). ALP activity increased  significantly on Si- 8 
CaP+OS, HA+OS and PL+OS on Day 14, while ALP activity on PL 9 
remained  low. At this time point Si-CaP+OS and HA+OS were 1.39–fold 10 
and  1.28–fold  higher than PL+OS respectively, and  by Day 21 ALP activity 11 
on Si-CaP+OS and HA+OS were 1.37–fold  and  1.30–fold  greater than 12 
PL+OS. On days 7 to 21 ALP staining was significantly greater on both Si- 13 
CaP+OS and HA+OS when compared  to PL+OS (P<0.05). 14 
 15 
5.2.1.1.2  Mineralisation  16 
 17 
To determine whether cells cultured  on substrates in the presence of 18 
osteogenic supplementation were capable of producing a mineralised  19 
matrix, cultures were stained  using the Von Kossa reagent. Areas of 20 
mineralisation were quantified  as described  in section 2.5.8.3 and  the extent 21 
of mineralisation on the d ifferent substrates is shown in  22 
 Figure 43.  23 
On Day 1 there was no detectable staining was observed  on any substrate. 24 
On Day 7 there was no staining was seen on PL and PL+OS. However, a 25 
significant increase in staining on Si-CaP+OS and HA+OS was detected 26 
(p<0.0307).  On Day 14 a rapid  increase in area of mineralisation was 27 
detected  on Si-CaP+OS, HA+OS and PL+OS, (increasing 9.9–fold , 6.5-fold  28 
and  49.9-fold  respectively). This rate of mineralisation continued , and  by 29 
Day 21 the greatest area of mineralisation was detected  on Si-CaP+OS 30 
(77.6%). On HA+OS the area of mineralisation was also highest on Day 21, 31 
but peaked at 71.3% and on PL+OS reached 63.6%. At this final time point 32 
the area of mineralisation on both Si-CaP+OS and on HA+OS was 33 






 Figure 43: Area of mineralisation. 3 
Mineralisation on substrates was measured by analysing the area of black deposits using 4 
image analysis software and the mean area covered was calculated per disc / well. The 5 
results represent the mean ± SD of three donors with samples run in triplicate. 6 
 7 
5.2.1.1.3  Gene expression 8 
 9 
To confirm that Si-CaP and HA were capable of supporting ostegenic 10 
d ifferentiation, cells were cultured  on substrates for up to 21 days in the 11 
presence of osteogenic supplementation and  the transcription of selected  12 
osteoblast related  genes was analysed . To account for d ifferences in cell 13 
numbers on the various substrates, the expression levels were normalised  14 
to that of the house keeping gene β2 microglobulin; the normalised  values 15 
for the expression of the selected  osteoblast specific genes are shown in   16 
 Figure 44. 17 
 18 
RUNX2 expression increased  in Si-CaP+OS, HA+OS and PL+OS on Day 1. 19 
Yet, expression on Si-CaP+OS, HA+OS increased  to levels 2.14-fold  and  20 
2.13–fold  greater than PL+OS respectively. On Day 7, RUNX2 expression 21 
increased  slightly on HA+OS (1.05-fold) and  decreased  on Si-CaP+OS 22 
(0.74-fold) and  PL+OS (0.55-fold). On Day 14, RUNX2 expression decreased  23 
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on Si-CaP+OS and HA+OS, but increased  significantly on PL+OS to 2.32– 1 
fold  greater than PL (p=0.0059). By 21 days in culture, levels of RUNX2 2 
expression decreased  on Si-CaP+OS, HA+OS and PL+OS. Cells cultured  on 3 
PL in the absence of soluble factors showed a slight increased  in RUNX2 4 
expression over time, but remained  lower than Si-CaP+OS, HA+OS up to 5 
14 days. 6 
 7 
COL1A1 expression increased  rapid ly on Si-CaP+OS on Day 1 and  8 
continued  to increase over time, with highest levels on Day 21 where it was 9 
2.69-fold  greater than PL+OS. On HA+OS, COL1A1 expression also 10 
increased  over time but remained  lower than Si-CaP+OS at all time points. 11 
COL1A1 levels on HA+OS were higher than on PL+OS at all time points, 12 
and  significantly so on days 7 (p=0.002) and  14 (p=0.008). On PL+OS 13 
COL1A1 expression increased  slightly on Day 1 then decreased  1.01–fold  14 
on Day 7, after which levels continued  to increase peaking on Day 21. On 15 
PL COL1A1 increased  slightly (1.58-fold) on Day 7, but decreased  on days 16 
14 and  21 to levels significantly lower than on all other substrates (p<0.01). 17 
 18 
Late stage marker BGLAP, expression began to increase on all substrates as 19 
early as Day 1 and  continued  to increase on both Si-CaP+OS and HA+OS 20 
until Day 14 where levels peaked at 1.31–fold  and  1.14–fold  greater then 21 
PL+OS. BGLAP expression on PL+OS decreased  0.83–fold  on Day 7, then 22 
rapid ly increased  on Day 14 peaking at 1.58–fold  greater than PL. On Day 23 
21 levels decreased  but remained  higher than on Si-CaP+OS and HA+OS. 24 
On PL, BGLAP expression increased  up to Day 14, but decreased  on Day 21 25 









 Figure 44: Real time gene expression profile of MSC on substrates. 5 
mRNA levels of genes of interest and are represented as level of expression normalised to 6 




5.2.1.2 Osteogenic different iat ion in the absence of soluble factors  1 
 2 
Initial results from ALP staining, mineralisation and  gene expression 3 
suggest MSC were able to d ifferentiate into osteoblasts on Si-CaP, HA and  4 
PL in the presence of osteogenic supplementation (+OS). MSC cultured  on 5 
Si-CaP and HA rapid ly d ifferentiated  into osteoblasts as evidenced  by 6 
increased  osteoblast related  gene expression; enhanced  production of ALP, 7 
and  produced a greater area of mineralisation when compared  to PL+OS.  8 
This augmented  d ifferentiation may be due to osteoinductive properties of 9 
theses calcium phosphate based  substrates. To investigate this possibility 10 
the response of MSC in the absence of osteogenic supplementation was 11 
investigated . 12 
 13 
5.2.1.2.1    Attachment 14 
 15 
MSC were allowed to attach to each substrate over 8 hours. Every 2 hours, 16 
unbound  cells were washed off and  cells attached  to the substrates were 17 
fixed , stained  and  counted . The average number of cells attached  per mm 2 18 
is shown in Figure 45.  19 
The number of cells attached  to all substrates increased  with time and the 20 
number of cells attached  to PL was greater than that obtained  for HA at all 21 
time-points. The number of cells attached  to Si-CaP were significantly 22 
lower than that on PL for time-points up to and  including 6 hours. 23 
However, in the 6–8 hours time period  there was a marked  increase in the 24 
mean (±SD) number of cells attached  to Si-CaP and by 8 hours the number 25 
of cells attached  to this substrate was com parable to that for PL (129 ± 10.3 26 
vs. 119 ± 8.6 cells/ mm 2; p=0.222). On HA, the rate of attachment showed 27 
the same time dependence as for Si-CaP, with a rapid  increase in the 28 
number of cells attached  at 6 and  8 hours. Significantly more cells attached  29 
to Si-CaP than to HA at 2 hours (32 ± 1.3 vs. 18 ± 0.8 cells/ mm 2; p<0.05) and  30 




Figure 45: Attachment of MSC to substrates. 2 
Number of cells attached to substrates over time normalised to surface area. The results 3 
represent the mean ± SD of three donors with samples run in triplicate 4 
 5 
5.2.1.2.2    Proliferation 6 
 7 
Bone marrow derived MSC were seeded  onto scaffolds and  allowed to 8 
proliferate over 21 days. At regular intervals, cells on scaffolds were fixed , 9 
stained  and  counted . The average number of cells attached  per mm 2 was 10 
calculated  and  is shown in Figure 46. A time dependent increase in cell 11 
number for cultu res on Si-CaP, HA, PL and PL+OS was observed  up to 12 
21 days. On Day 1, cell number was similar for all substrates, after which 13 
cells proliferated  at d ifferent rates on each substrate. The greatest increase 14 
in cell number over time was observed  for cells cu ltured  on PL without 15 
osteogenic media. The addition of osteogenic factors led  to a decrease in the 16 
growth rate, with cell density being significantly lower for PL+OS than for 17 
PL at all time-points after Day 1. However, this d ifference only achieved 18 
statistical significance on days 7 and  14 (p=0.02 and  p=0.03, respectively). 19 
Cells cu ltured  on Si-CaP and HA showed  a similar growth curve to cells on 20 
PL+OS; cell numbers on both Si-CaP and HA were lower than PL at all 21 
time-points but the d ifference between Si-CaP and HA did  not achieve 22 





Figure 46: Proliferation of MSC on substrates. 2 
Cell proliferation over time on substrates, normalised to surface area. The results represent 3 
the mean ± SD of three donors, with five samples run per donor. 4 
 5 
5.2.1.2.3    Gene expression 6 
 7 
Culturing MSC on d ifferent substrates for up to 21 days resulted  in 8 
d ifferential expression of osteoblast specific genes. To account for 9 
d ifferences in cell numbers on the various substrates, the expression levels 10 
were normalised  to the house keeping gene β2 microglobulin and  the 11 
normalised  values for the expression of a range of MSC and osteoblast 12 
specific genes are shown in  Figure 47.  13 
 14 
Endoglin (CD105) is a cell surface receptor commonly associated  with 15 
MSC, and  it decreases in expression as these cells d ifferentiate. CD105 16 
expression decreased  on Si-CaP and PL+OS, but d id  not change 17 
significantly on HA and PL. Expression of CD105 was significantly reduced 18 
on Si-CaP and PL+OS on Day 7 and  remained  lower than PL at all time 19 
points thereafter. Cells cultured  on HA expressed  lower levels on  Day 1 20 
than compared  to all other substrates; but d id  not decrease over time, and  21 
remained  at similar levels to PL on  Day 21.  22 
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RUNX2 has a key role in osteoblast d ifferentiation. It binds to the 1 
promoters of a number of osteoblast specific genes including collagen type 2 
1 and  osteocalcin, inducing their expression. RUNX2 expression was 3 
upreguated  in cells cu ltured  on Si-CaP, HA and PL+OS. High expression 4 
was observed  earlier in cells cultured  on Si-CaP and HA, compared  to 5 
PL+OS. RUNX2 levels were highest on Day 1 for both Si-CaP and HA, 6 
where they were 1.6- and  1.4-fold  greater than PL respectively. Cells on 7 
PL+OS demonstrated  a high level of RUNX2 expression much later, on Day 8 
14, where they reached 1.8-fold  greater than PL.  9 
 10 
Parathyroid  hormone receptor 1 (PTH1R) expression is associated  with 11 
endochondral ossification and  plays a vital role in calcium homeostasis in 12 
bone (Alonso et al. 2011; McCauley et al. 1996). PTH1R expression is 13 
associated  with a mature, cuboidal cell, and  is expressed  as osteoblastic 14 
cells d ifferentiate (McCauley et al. 1996). PTH1R was upregulated  on Si- 15 
CaP, HA and PL+OS however, the timing of expression was d ifferent on 16 
each substrate. Initially cells on Si-CaP expressed  high levels of PTH1R, 17 
followed by PL+OS, then HA .  Cells on Si-CaP significantly upregulated  18 
PTH1R expression on Days 1 and  7: 1.8- and  3.6-fold  greater than PL. 19 
However, cultures on HA and PL+OS demonstrated  the greatest levels of 20 
expression on Day 21, 2.4– and  5.6- fold  greater than PL respectively. Cells 21 
on PL did  not show any increase in PTH1R expression over 21 days.  22 
 23 
An early marker of osteoblast d ifferentiation and  a reporter of osteoblast 24 
activity, Collagen type I (COL1A1) was increased  in cells on Si-CaP, HA 25 
and  PL+OS. COL1A1 expression peaked at d ifferent time points on each 26 
substrate, first on Si-CaP, then HA and much later PL+OS. In cells on Si- 27 
CaP, COL1A1 was highly upregulated  on Day 7, 3.9-fold  greater than PL. 28 
On HA COL1A1 expression was highest at Day 14, 2.5-fold  greater than PL. 29 
Levels of COL1A1 in cultures on PL+OS increased  from  Day 14 and  but 30 
peaked later on Day 21, to 2.6-fold  greater than PL. Expression of COL1A1 31 
was maintained  at a low level in cells cultured  on PL.  32 
 33 
Osteocalcin (BGLAP) is a late marker of osteoblast d ifferentiation, 34 
expressed  at the onset of mineralisation. There were no significant 35 
d ifferences in BGLAP expression on any of the substrates. Cells cultured  on 36 
CHAPTER FIVE 
 142 
Si-CaP, showed the greatest expression of BGLAP on Day 14, however this 1 
increase d id  not reach statistical significance (P=0.988). 2 
Dentin matrix acid ic phosphoprotein 1 is encoded by the DMP1 gene and  3 
thought to be restricted  to mineralised  tissue (Kalajzic et al. 2004), where it 4 
is produced by terminally d ifferentiated  osteoblasts (Toyosawa et al. 2001). 5 
DMP1 expression was low in cells on all substrates on Days 1 to 14 6 
however, on Day 21 expression greatly increased  in cells on Si-CaP (5.5- 7 
fold), HA (5.1-fold) and  PL+OS (7.8-fold). Cells on PL expressed  low levels 8 
of DMP1, less than 1-fold  increase, on Day 21, and  was significantly lower 9 










Figure 47: Real time gene expression profile of MSC on substrates.  3 
Data are mRNA levels of genes of interest and are represented as level of expression 4 
normalised to beta-2 microglobulin and to Day 0. Three donors were used, and each 5 






5.2.1.2.4    Protein prod uction  1 
 2 
To confirm gene expression correlated  with protein production, cells were 3 
immunostained  for three key osteoblast proteins, RUNX2, collagen type I, 4 
and  osteocalcin. 5 
RUNX2 was detected  via immunohistochemistry in cells cultured  on 6 
PL+OS, Si-CaP and HA and is shown in Figure 48. Cells cultured  on 7 
PL+OS expressed  nuclear RUNX2 on days 7 and  14. Cells grown on Si-CaP 8 
and  on HA showed the same nuclear  pattern of RUNX2 expression on Day 9 
7. However, on Days 14 and  21 RUNX2 appeared  to be present also in the 10 
cytoplasm, although RUNX2 protein expression was predominantly 11 
nuclear (in approximately 91% and 87% of cells cultured  on Si-CaP and on 12 
HA, respectively). RUNX2 was not detected  in cells from any of the PL 13 
samples.  14 
 15 
Figure 48: RUNX2 immunostaining of MSC on substrates. 16 






Collagen type I protein expression in cells cultured  on the various 1 
substrates on days 1, 7, 14 and  21 is shown in  2 
Figure 49. Collagen type I protein was detected  as early as Day 1 in cells 3 
cultured  on Si-CaP and HA, with expression increasing in intensity until 4 
Day 21. Collagen type 1 was detected  in cells cultured  on PL and PL+OS at 5 
all time-points; however, its expression was less intense and  less 6 
widespread  compared  with that of cells grown in Si-CaP and HA.  7 
 8 
Figure 49: Collagen type I immunostaining of MSC on substrates.  9 
Collagen type I (yellow) and DAPI (blue) Scale bar represents 100μm. 10 
 11 
Osteocalcin staining, shown in  12 
 Figure 50, was not detected  in cells on any substrate on Day 1. On Day 7 13 
faint staining was seen in cells cu ltured  on PL+OS, but not on Si-CaP, HA 14 
or PL. By Day 14 however, there was strong staining in cells on Si-CaP, HA 15 
and  PL+OS, the majority of staining was cytoplasmic, yet in some cells 16 
nuclear staining was also detected . On d ays 14 and  21 no osteocalcin 17 
staining was observed  in cells on PL. On PL+OS on Day 21 osteocalcin 18 
intense staining was detected  in approximately 90% of the cells and  in 19 
some areas small, punctate, extracelluar staining was seen. On HA and Si- 20 





 Figure 50: Osteocalcin immunostaiing of MSC on substrates.  3 
Osteocalcin (red) and DAPI (blue) Scale bar represents 100μm 4 
 5 
5.2.1.2.5    Alkaline phosphatase  6 
 7 
The ALP positive area was low on cells cultured  on plastic alone (PL), but 8 
was strongly ‗induced‘ in PL+OS cultures, In contrast to cells maintained  9 
on PL alone, cells cultured  on Si-CaP and HA in the absence of osteogenic 10 
supplements showed  intense widespread  positive staining for ALP, as 11 
shown in Figure 51. The area of staining was quantified  and  the average 12 
area of staining on each substrate is shown in Figure 52.   13 
Cell numbers and  ALP staining were comparable for cells cultu red  on Si- 14 
CaP, HA and PL+OS. The ALP activity on PL was lower , even though cell 15 
numbers were similar. The ALP positive fraction was significantly 16 
increased  on Si-CaP and HA compared  with PL (42.9 ± 9.3 and  32.9 ± 6.7 vs. 17 
6.3 ± 8.5 % total substrate area, respectively; P<0.01). There was no 18 
statistically significant d ifference between the ALP activity of cells cultured  19 
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on Si-CaP versus HA; there was also no significant d ifference between 1 
either of these versus the positive control, cells cultured  on PL+OS. 2 
 3 
Figure 51: Alkaline phosphatase staining on substrates.   4 
Staining of differentiating cells on substrates at Day 21 (upper panels), lower panel shows 5 
nuclear stain (DAPI) of same area to show cell density.  (Scale bar represents 200μm). 6 
 7 
 8 
Figure 52: Area of alkaline phosphatase staining on substrates.  9 
ALP activity of cells on substrates quantified by analysing the area of ALP positive cells 10 
using image analysis software and the mean area calculated per disk / well. The results 11 







3.4.2.1.1    Mineralisation  1 
 2 
Areas of mineralisation were detected  by staining using the von Kossa 3 
method, with black staining, ind icating calcium deposits (shown in  4 
 Figure 53). The staining was quantifed  and  the area of mineralisation on 5 
substrates is shown in Figure 54. The extent of mineralisation increased  6 
with time for all substrates except for PL, where no changes from baseline 7 
levels were observed . No significant increase in mineralised  deposits on 8 
HA was detected  until Day 14, at this time-point, the area covered  with 9 
mineralised  matrix was lower for HA when compared  with Si-CaP (20.8 ± 10 
8.2 % vs. 36.5 ± 12.3% total substrate area). In all substrates the area covered 11 
with mineralised  matrix continued  to increase up to the furthest time point 12 
at Day 21. At this time-point, the area of mineralisation on Si-CaP and HA 13 
was significantly greater than on PL (48.9 ± 14.5 and  42.5 ± 11.0 vs. 1.2 ± 0.2 14 
% total substrate area, respectively; p<0.05 in both comparisons). 15 
 16 
 17 
 Figure 53: Von Kossa staining on substrates.  18 
Staining of calcium deposits in mineralisation on substrates at Day 21(top panel), lower 19 
panel shows same fields with nuclear stain (DAPI) to show cell density (Scale bar 20 








Figure 54: Area of mineralisation on substrates. 2 
Mineralisation on substrates was measured by analysing the area of black deposits using 3 
image analysis software and the mean area covered was calculated per disk / well. The 4 
results represent the mean ± SD of three donors with samples run in triplicate. 5 
 6 
5.2.2 hES-MP 7 
 8 
5.2.2.1.1    Attachment 9 
 10 
Cells attached  to all substrates, increasing in a time dependent manner  as 11 
shown in  12 
 Figure 55. Initially, at 2 hours, very few cells attached  to all substrates: only 13 
9.44 ± 4.03 cells per mm 2 attached  to PL, more cells attached  to Si-CaP and 14 
HA, 17.5 ± 3.2, and  12.7 ± 4.1 per mm 2 respectively. At this time, the 15 
number of cells attached  to Si-CaP was significantly higher than on PL 16 
(P=0.006). At 4 hours post-seeding the number of cells attached  to each 17 
substrate increased  rapid ly. On PL cell number increased  4.5-fold , to 43.2 18 
cells per mm 2 and  cell number on Si-CaP increased  2.9-fold  and  cell 19 
number on HA increased  2.8- fold , and  cell number d id  not vary 20 
significantly between substrates. At 6 hours cell numbers on PL continued  21 
to increase,  (71.5 ±12.9) significantly higher than cell number on both Si- 22 
CaP and HA (p=0.0001 and p=0.03 respectively). Average cell number on 23 
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Si-CaP d id  not increase at this point; instead  it decreased  from 50.6 to 50.1 1 
per mm 2. On HA, cell number was lower than both Si-CaP and PL and 2 
increased  on average by 0.4 cells per mm 2. At 8 hours post seeding average 3 
cell number again increased  greatly on PL (73.7 ± 18.4). Cell number on Si- 4 
CaP and HA remained  low on (55.5 ± 11.19, and  45.8 ± 9.9 respectively). At 5 
this final time point significantly more cells were attached  to PL, compared 6 
with HA (p=0.01) yet cell number on PL d id  not vary significantly 7 
compared  to Si-CaP.  8 
 9 
 10 
 Figure 55: Attachment of hES-MP to substrates. 11 
Number of cells attached to substrates over time normalised to surface area. The results 12 
represent the mean ± SD of cells at three different passages with samples run in triplicate. 13 
 14 
5.2.2.1.2    Proliferation 15 
 16 
On Day 1, cell numbers were similar on all substrates with no significant 17 
d ifferences between PL, PL+OS, Si-CaP and HA (P> 0.78), as shown in  18 
Figure 56. On Day 3 cell number increased  on all substrates, but d id  not 19 
d iffer significantly (P≥1). On PL, in the absence of osteogenic factors, cells 20 
proliferated rapid ly, with cell number increasing over time, and  by Day 5 21 
cell number on PL was significantly higher than PL+OS (P=0.02). Average 22 
cell number was also high on Si-CaP, but d id  not reach statistical 23 
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significance. At Day 7 average cell number varied  greatly between 1 
substrates: the greatest number of cells was seen on PL, and  PL+OS had  the 2 
least. Cells on PL continued  to proliferate up to Day 21, where cell number 3 
reached its maximum, and  w as significantly greater than any other group 4 
(P<10-7). PL+OS had  the least number of cells from days 7 to 21. On Day the 5 
average cell number on HA and Si-CaP was similar, cell number on Si-CaP 6 
was higher than on HA on days 14 and  21, but d id  not vary sign ificantly 7 
(P> 0.2). On Day 21, cell number on Si-CaP and HA was significantly 8 




Figure 56: Proliferation of hES-MP on substrates. 13 
Cell proliferation over time on substrates and on PL in OS media, normalised to surface 14 
area. The results represent the mean ± SD of cells at three different passages with five 15 










5.2.2.1.3 Gene expression  1 
 2 
CD105 expression in cells on PL was maintained  at a relatively constant 3 
level in cells cultured  on PL, and  varied  by only 1.27-fold  over 21 days, 4 
(shown in Figure 57). 5 
On Si-CaP, CD105 expression was highest on Day 1, then decreased  over 6 
time. Cells on PL+OS showed similar trend  in expression, initially highest 7 
on Day 1, and  then decreasing over time. On HA, CD105 expression 8 
fluctuated , levels increased  on Day 7, and  then decreased  on days 14 and 9 
21.  10 
 11 
hES-MP cultured  on Si-CaP  showed the highest RUNX2 expression on Day 12 
1, 16.1-fold  greater than PL. After Day 1, RUNX2 expression decreased 13 
gradually but on Day 21 remained  higher than on PL. On HA RUNX2 14 
expression increased  on Day 1 and  was highest on Day 7, 19.2–fold  greater 15 
than PL. On Day 14 expression decreased  slightly, but remained  at similar 16 
levels on Day 21. RUNX2 expression on PL+OS initially decreased  on Day 17 
1, but increased  significantly on Day 7, to 38.2-fold  greater than PL; on days 18 
14 and  21 RUNX2 expression decreased , but remained  higher than PL. hES- 19 
MP on PL, showed very little RUNX2 expression and  d id  not vary by more 20 
than 0.5–fold . 21 
 22 
OSX  expression on Day 1 was highest on Si-CaP (2.4-fold  greater than PL). 23 
After Day 1, OSX  levels decreased  until Day 21, when OSX  expression 24 
increased  slightly. On HA, OSX  expression was also greatest on Day 1 2.0– 25 
fold  greater than PL, then decreased  over time until Day 21 when levels 26 
increased  slightly. On PL+OS, OSX  expression decreased  on Day 1 to 0.5– 27 
fold  less than PL. Then on Day 7, levels increased  to 10.2–fold  greater than 28 
PL, decreased  on Day 14, and  remained  at similar levels on Day 21. On PL 29 
OSX  expression decreased  0.3–fold  on Day 7, then gradually increased  to 30 
1.1–fold  on Day 21. 31 
 32 
COL1A1 expression increased  on Si-CaP on Day 1, 4.3–fold  greater than PL 33 
and  continued  to increase on Day 7, where it was highest and  significantly 34 
greater than PL (p=0.002). On Day 14 COL1A1 levels decreased , then 35 
increased  slightly on Day 21 to levels significantly greater than PL (p=0.04). 36 
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On HA, Col1A1 expression peaked later, on Day 14 6.2–fold  greater than 1 
PL. Expression then decreased  on Day 21, to 3.0–fold  greater than PL, when 2 
it was significantly greater than PL (p=0.02). Col1A1 expression on PL+OS 3 
increased  gradually on days 1 and  7, then decreased  slightly on day 14 yet 4 
was still 5.1–fold  greater than PL. On Day 21 expression increased  to levels 5 
significantly greater than on any other substrate. On PL COL1A1 6 
expression d id  not vary significantly, and  was consistently lower than on 7 
all other substrates. 8 
 9 
Expression of BGLAP was detected  as early as Day 1 on  PL+OS where 10 
expression reached 3.8–fold  greater than PL. Levels of BGLAP continued  to 11 
increase on PL+OS, Si-CaP and HA until Day 21, when the greatest 12 
expression was seen. Compared  to PL at this time point BGLAP levels were 13 
4.1-fold  greater on Si-CaP, 4.6–fold  on HA and on 6.2–fold  PL+OS 14 
compared  to PL. BGLAP expression increased  on PL over time and reached  15 
2.0-fold  on Day 21, but was significantly lower than on any other substrate 16 
(p<0.004). 17 
 18 
DMP1 was not expressed  at significant levels on any substrate u ntil Day 21. 19 
At this time point cells cultured  on Si-CaP, HA and PL+OS expressed 20 
significant levels of DMP1: 26.7-fold , 38.7-fold  and  43.4–fold  greater than 21 
PL respectively, (p<0.002). On PL cells d id  not express high levels of DMP1. 22 
A slight increase was seen on Day 7 however this was not significantly 23 











Figure 57: Real time gene expression profile of hES-MP on substrates. 
 Data are mRNA levels of genes of interest and are represented as level of expression 
normalised to beta-2 microglobulin and to Day 0. Cells at three different passages were 






5.2.2.1.4  Protein production  1 
 2 
RUNX2 was detected  by immunostaining in cells cultured  on substrates, 3 
over 21 days, and  is shown in 4 
Figure 58. On Si-CaP cells expressed  RUNX2, as early as Day 1 where 5 
staining was bright and  seen in the majority of cells. RUNX2 was observed  6 
throughout the cell, but the strongest staining was seen in the nucleus.  7 
Similar levels of RUNX2, were observed  at days 7 and  14, however, by Day 8 
21 expression was largely cytoplasmic, with few cells having nuclear 9 
staining. Cells cultured  on HA, also d isplayed  RUNX2 positive staining on 10 
Day 1, but again this was largely cytoplasmic. By Day 7, strong nuclear 11 
staining was detected  in roughly half of the cells, then after 14 days 12 
localisation was similar to cells on Si-CaP, with the majority of cells 13 
d isplaying cytoplasmic staining. RUNX2 was detected  at low levels in hES- 14 
MP cultured  on PL, and  appeared  to increase in intensity over time up  to 15 
21 days. Very few cells had  nuclear staining and  in most cases cells 16 
expressed  low levels in the cytoplasm. Cells cultured  on PL+OS had  strong 17 
nuclear and  cytoplasmic staining on Day 1. Over time, less nuclear staining 18 
was detected , and  cytoplasmic RUNX2 was observed .   19 
 20 
Figure 58: RUNX2 immunostaining of hES-MP on substrates. 21 
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RUNX2 (green) and DAPI (blue) Scale bar represents 100μm. 1 
 2 
 Figure 59 shows Collagen type I immunostaining of cells cultured  on each 3 
substrate over 21 days. On Day 1 collagen type I staining was not detected 4 
on any substrates. Yet by Day 7, extracellular collagen stainin g was seen on 5 
Si-CaP, HA and PL+OS. On Si-CaP and HA collagen staining was widely 6 
d ispersed , but intense in certain areas. ON PL+OS staining was also 7 
widespread , but appeared  to be more filamentous. Intense, similar staining 8 
was observed  on Si-CaP, and  PL+OS on days 14 and  21 and  became more 9 
widespread  and  significantly brighter at each time point. Staining on HA 10 
appeared  to localised  to certain areas, in the form of nodules, or aggregates. 11 
No mature collagen type I staining was observed  on PL at any time p oint. 12 
 13 
 14 
 Figure 59: Collagen type I immunostaining of hES-MP on substrates.   15 







On Day 1, very little osteocalcin staining was detected  on HA, PL and  1 
PL+OS as shown in  2 
Figure 60. However, strong staining was seen in several cells on Si-CaP, 3 
this staining increased  in intensity over time and by Day 21 staining  was 4 
widespread  and  notably brighter is certain cells. Cells on HA also showed 5 
intense osteocalcin staining, which increased  over time however, staining 6 
was more punctate and  less evenly d istributed  throughout the cells, this 7 
was most apparent on days 7 and  14. On Day 21 staining appeared  to be 8 
extracellular, filamentous, and  d isorganised . Cells on PL, d id  not express 9 
osteocalcin to the same extent as cells on Si-CaP, HA and PL+OS, however 10 
some weak staining was detected  on Day 14, this was relatively weak, but 11 
was similar in localisation to staining seen on HA. Cells cultured  on PL+OS 12 
showed weak staining up to Day 21, when staining was intense. Both 13 




Figure 60: Osteocalcin immunostaining of hES-MP on substrates.  18 




5.2.2.1.5  hES-MP alkaline phosphatase activity  1 
 2 
ALP activity in cells cultured  on all substrates was measured  over 21 days 3 
as before and  is shown in  4 
 Figure 61. Detectable levels of ALP were observed  as early as Day 1 in 5 
hES-MP cultured  on all substrates, and  at  this time there was no significant 6 
d ifference between ALP activity on any substrate (p>0.85). On Day 7, ALP 7 
activity increased  rapid ly on Si-CaP (7.3-fold), HA (6.8-fold) and  on PL+OS 8 
(5.8-fold). At this time, there was significant variance between ALP activity 9 
at d ifferent passages, as evidenced  by large error bars. On Day 7, ALP 10 
activity was significantly higher on Si-CaP than any other substrate 11 
(p<0.04). ALP levels on Day 7 were also high on HA, significantly greater 12 
than on PL+OS (p=0.023). On Day 14, ALP activity on PL+OS increased  to 13 
44.1%, higher but not significantly d ifferent to Si-CaP (p=0.25) and  HA 14 
(p=0.30). ALP activity on Si-CaP and  PL+OS increased  on Day 21 and  15 
peaked at 51.2% and 53.1% respectively. ALP activity on HA only increased  16 
slightly to 41.6%, significantly lower than both Si-CaP (p<0.0001) and  17 
PL+OS (p<0.0001). Cells on PL showed continued  low -level ALP activity, 18 
and  peaked on Day 21 at 8.64%. ALP produced on PL, d id  not vary 19 
considerably between passages, and  the error bars show the wide standard 20 





 Figure 61: Area of alkaline phosphatase on substrates. 2 
ALP activity of cells on substrates quantified by analysing the area of ALP positive cells 3 
using image analysis software and the mean area calculated per disk / well. The results 4 
represent the mean ± SD of cells at three different passages with samples run in triplicate. 5 
 6 
5.2.2.1.6    Mineralisation  7 
 8 
Cells cultured  on PL, d id  not produce a mineralised  matrix (shown in  9 
 Figure 62), and  no significant staining was observed  over 21 days.  10 
However, a mineralised  matrix w as formed on Si-CaP, HA and  PL+OS, 11 
and  the area of mineralisation increased  over time. On Day 7, a significant 12 
d ifference between cells on PL and cells on PL+OS, SiCaP and  HA was 13 
detected  (p<0.00001) and  by Day 14 Si-CaP and HA, had  very similar areas 14 
of mineralisation 39.2% and 39.3% respectively. Mineralisation on PL+OS 15 
was slightlylower, 35.5%, but not significantly so (p> 0.34).  On Day 21 area 16 
of mineralisation increased  on PL+OS, to 74.4%, significantly higher than 17 
all other substrates (p>0.0004). Mineralisation on Si-CaP covered  a greater 18 




 Figure 62: Area of mineralisation on substrates. 2 
Mineralisation on substrates was measured by analysing the area of black deposits using 3 
image analysis software and the mean area covered was calculated per disk / well. The 4 
results represent the mean ± SD of cells at three different passages with samples run in 5 
triplicate. 6 
 7 
5.2.3 ADMSC 8 
5.2.3.1.1    Attachment 9 
 10 
ADMSC attached  to all substrates and  average cell number increased  over 11 
time, as shown in  12 
 Figure 63. At 2 hours post seeding there were significantly more cells 13 
attached  to PL, compared  to Si-CaP (P= 0.007) and  HA (P=0.003). At this 14 
time point the average number of cells attached  to HA was greater than on 15 
Si-CaP but the d ifference was not statistically significant (34.74 ± 9.3 Vs.32 16 
± 7.4 respectively, p=0.73).  At 4 hours, the number of cells attached  to HA 17 
increased  1.6-fold , and  was (1.17-fold) higher than on Si-CaP. Yet, this d id  18 
not reach statistical significant – in fact the average number of cells 19 
attached  to Si-CaP d id  not vary significantly to HA at any time point 20 
(p>0.7). On PL the number of cells attached  continued  to increase, and  at 6 21 
hours remained  significantly higher than both HA and  Si-CaP (P < 0.02). By 22 
8 hours post seeding similar number of cells were seen attached  and  there 23 
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was no significant d ifference between attachment each of the substrates (P 1 
> 0.054). 2 
 3 
 Figure 63: Attachment of ADMSC on substrates. 4 
Number of cells attached to substrates over time normalised to surface area. The 5 
results represent the mean ± SD of two donors with samples run in triplicate. 6 
 7 
5.2.3.1.2    Proliferation 8 
 9 
Cell number on all materials was similar on Day 1 then increased  over 10 
time, as shown in Figure 64. Cell number on PL, increased  at near 11 
exponential rate up to Day 14 then slowed on Day 21. On Day 3, cell 12 
number was comparable on all substrates with the exception on PL+OS, 13 
HA and Si-CaP where cell number was significantly lower then PL 14 
(P=0.04). On Day 5 cell number increased  on all substrates and  d id  not vary 15 
significantly between substrates. However, on Day 7 cell number on PL 16 
was significantly higher than HA (P=0.02), Si-CaP (P=0.0006) and  PL+OS 17 
(P= 0.02). This trend  continued  to Day 21, where cell number on PL was 18 




Figure 64: Proliferation of ADMSC on substrates. 2 
Cell proliferation over time on substrates and on PL in OS media, normalised to surface 3 
area. The results represent the mean ± SD of two donors, with five samples run per donor. 4 
 5 
5.2.3.1.3  Gene expression 6 
 7 
ADMSC gene expression was analysed  and  is shown in Error! Reference 8 
source not found.. Mesenchymal associated  CD105 expression detected  on 9 
all substrates and  decreased  over time and expression levels varied by less 10 
than 1-fold  over 28 days in culture. CD105 expression was highest in cells 11 
cultured  on PL at all time points, but decreased  slightly over 28 Day in 12 
culture. Expression of CD105 in cells cultured  on PL+OS, Si-CaP and HA 13 
decreased  more significantly over time. On Si-CaP and HA, expression of 14 
CD105 decreased  more rapid ly compared  to PL+OS. On Day 7 levels of 15 
CD105 were 2- and  3-fold  lower on HA and Si-CaP respectively compared  16 
to PL+OS.  At 14 days CD105 expression increased  slightly on Si-CaP and 17 
HA, at Day 21 a similar increase was seen on PL+OS, after which 18 
expression continued  to decrease over time. This small increase was the 19 
only time point where expression on PL was not significantly higher than 20 
PL+OS (p=0.22). CD105 expression on Si-CaP and HA was significantly 21 
lower than PL at all time points (p<0.00001). At 28 days transcript levels in 22 
cells on Si-CaP were similar to PL+OS and levels of expression on HA were 23 
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significantly lower than on PL+OS (p<0.0001). Expression of RUNX2 on 1 
substrates varied  greatly over time. On PL+OS RUNX2 expression was 2 
highest at Day 7, where it was 22-fold  higher than on PL. After Day 7 3 
RUNX2 expression on PL+OS decreased  to levels not significantly d ifferent 4 
to PL (p>0.2). RUNX2 expression on Si-CaP and HA followed a similar 5 
trend , peaking on Day 1, and  then decreasing over time. On Day 1 6 
expression on Si-CaP was 10.7 –fold  and  HA 8.1–fold  higher than PL. After 7 
Day 1, RUNX2 expression on HA decreased  but remained  higher than PL 8 
until Day 21. On Si-CaP RUNX2 levels decreased  after Day 1, but again 9 
were higher than on PL up to Day 28. 10 
OSX  expression was highest on PL+OS at Day 1, where it was 22.6 –fold 11 
higher than on any other substrate. After Day 1 OSX  expression on PL+OS 12 
decreased  over time, but remained  higher than on any substrate. On Si-CaP 13 
and  HA, OSX  expression was highest on Day 7 (10.9 –fold  and  8.3 –fold  14 
higher than PL respectively). On Si-CaP, OSX  decreased  on Day 21 and  on 15 
Day 28 remained  low. Levels of OSX  decreased  on Day 14 on HA, and  also 16 
remained  low thereafter. Cells cultured  on PL d id  not express significant 17 
levels of OSX and d id  not increase by more than 1.8-fold  over culture. 18 
COL1A1 expression was consistently low on PL, but increased  over time on 19 
Si-CaP, HA and PL+OS. On Days 1 and  7 expression levels were similar on 20 
all substrates, and  d id  not vary significantly (p>0.9). On Day 14, COL1A1 21 
expression increased  gsignificantly on Si-CaP, HA and PL+OS (15.8-fold  22 
14.4–fold  and  23.0–fold  greater than PL respectively). On Day 21 COL1A1 23 
levels decreased  slightly in Si-CaP, and  PL+OS. On Day 28 COL1A1 24 
expression increased  on Si-CaP and was 1.2–fold  higher than PL+OS, 25 
expression levels on HA also continued  to increase over time and on Day 26 
28 there was no significant d ifference between Si-CaP, HA and PL+OS 27 
(p>0.8).  28 
Expression of BGLAP on PL+OS was low until Day 21, when it increased  29 
rapid ly (23.7-fold  greater than on PL). Cells on Si-CaP showed  similar 30 
expression of BGLAP, and  levels increased  alongside PL+OS on Day 21, 31 
and  d id  not vary significantly (p>0.9). On HA BGLAP expression was 32 
much lower on Day 21, but 8.6–fold  greater than PL. By Day 28, BGLAP 33 
expression on HA increased  to similar levels to Si-CaP and PL+OS. On PL 34 
BGLAP expression increased , but significantly lower than on any other 35 
substrate (p<0.01).  36 
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In cells cultured  on PL+OS, DMP1 expression was detected  as early as Day 1 
14, and  continued  to increase up to Day 28, when it reached 24.5–fold  2 
greater than PL. DMP1 expression on Si-CaP and HA was similar and  not 3 
detected  until Day 21, where levels were 8.9-fold  and  8.4–fold  greater than 4 
PL respectively. Expression of DMP1 continued  to increase on Si-CaP and 5 
HA, and  on Day 28 was not significantly d ifferent to PL+OS. Cells on PL 6 
d id  not produce significant levels of DMP1 and  expression varied by less 7 





Figure 65: Real time gene expression profile of ADMSC on substrates.  
Data are mRNA levels of genes of interest and are represented as level of expression 
normalised to beta-2 microglobulin and to Day 0. Two donors were used, and each sample 
was run in duplicate. 
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5.2.3.1.4  Protein production  1 
 2 
RUNX2 was detected by immunohistochemistry over 21 days in culture and is 3 
and is shown in  4 
Figure 66. RUNX2 staining was observed  in cells cultured  on HA and was 5 
strongest on days 1 and  7, where its localisation was similar to Si-CaP. 6 
However, on Day 14 staining was much weaker on HA, compared  to Si- 7 
CaP. No staining was seen at any time points in cells cultured  on PL, 8 
although similar numbers of cells were observed . On Day 1 no RUNX2 9 
staining was detected  on PL+OS. On Day 7 however, strong nuclear 10 
RUNX2 staining was observed  throughout the major ity of cells. By Day 14 11 
staining was weak and  localised  to the cytoplasm of few cells, and  by Day 12 




Figure 66: RUNX2 immunostaining of ADMSC on substrates.  17 




Collagen type I was detected  by immunostaining in cells cultured  on 1 
substrates over 21 days, as shown in Figure 67. Cells cultured  on Si-CaP 2 
and  HA showed undetectable staining on Day 1. But by Day 7 stain ing was 3 
detected  in the cytoplasm of the majority of cells. The intensity of staining 4 
varied  on Si-CaP and was notably brighter in a small proportion of cells. 5 
On HA on Day 14 more intense staining was detected  and  cells appeared  to 6 
have aligned  in one d irection. On Si-CaP mature filamentous Collagen type 7 
I was detected  in several areas, whilst the majority of cells still showed 8 
weaker cytoplasmic staining. Cells also appeared  to be aligned in one 9 
d irection and  this was observed  on several samples. Staining  on Day 21, on 10 
Si-CaP was mostly extracellular; it was filamentous and  appeared  to be laid  11 
down in a woven fashion. On HA, similar staining was seen and  was more 12 
intense in certain areas, and  d ispersed  less evenly compared  to Si-CaP. 13 
Cells on PL+OS also d isplayed  weak cytoplasmic staining on Day 1 14 
however; this was not seen at any time point thereafter. On days 7, 14 and  15 
21 very intense staining was detected ; this was exclusively filamentous and  16 
far brighter than the staining seen on Si-CaP and HA. No mature collagen 17 
staining was observed  on PL at any time point. 18 
 19 
Figure 67: Collagen type I immunostaining of ADMSC on substrates.  20 
Collagen type I (yellow) and DAPI (blue) Scale bar represents 100μm.  21 
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Osteocalcin staining was detected  on Si-CaP, HA and PL+OS and is shown 1 
in Figure 68. On Day 1 very little staining was detected  on Si-CaP, HA and 2 
PL+OS. Yet, by Day 7 staining was observed  in the majority of cells on Si- 3 
CaP and was d istributed  throughout the cytoplasm. On HA, staining was 4 
more d iffuse and  expressed  in roughly 50 % of cells. Cells on PL+OS 5 
d isplayed  very d ifferent staining, which appeared  to be localised  in the 6 
cytoplasm, but was brightest at the cell periphery. Staining on Si-CaP, HA 7 
and  PL+OS was more intense on days 14 and  21 again was very d ifferent 8 
on each substrate. On Si-CaP osteocalcin was detected  throughout the 9 
cytoplasm, but also in large bundles or nodules, where staining was 10 
globular and  intense. On HA staining was still cytoplasmic but much  11 
brighter and  in some areas small punctate areas of intense staining was 12 
seen. Osteocalcin in cells on PL+OS, at Day 14, was similar to staining on 13 
Si-CaP at Day 7, and  was detected  in most cells. At Day 21 cells on PL+OS 14 
stained  brightly for osteocalcin and  again this was notably more intense 15 
around the cell periphery. On Si-CaP and HA staining was similar in 16 
d istribution, and  intensity. Intense, globular staining was seen in areas and  17 
was also still visible in the cytoplasm. Cells cultured  on PL d id  not p roduce 18 
detectable levels of osteocalcin at any time point. 19 
 20 
Figure 68: Osteocalcin immunostaining of ADMSC on substrates.  21 
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Osteocalcin (red) and DAPI (blue) Scale bar represents 100μm. 1 
 2 
5.2.3.1.5 Alkaline phosphatase  3 
 4 
The area of ALP staining was quantified  as before (Figure 42) and  is shown 5 
in  6 
Figure 69. Initially, ADMSC on all substrates had  similarly low levels of 7 
ALP activity. On Day 7, ALP activity increased  greatly in cells cultured  on 8 
Si-CaP, HA and  PL+OS (5.1-fold , 4.5-fold  and  8.2-fold  respectively). ALP 9 
activity on PL remained  low and was significantly lower than all other 10 
substrates (p<0.00001). ALP levels continued  to increase on Si-CaP, HA and 11 
PL+OS on Day 14; where a particularly rapid  increase in activity was 12 
detected  in cells cultured  on HA. However, levels d id  not vary significantly 13 
to Si-CaP (p=0.21) and  PL+OS (p=0.37). On Day 21, ALP activity increased  14 
on all substrates and  reached 47.6% on Si-CaP and 43.9% on HA; levels that 15 
d id  not vary significantly (p=0.36). PL+OS increased  rapid ly (2.6-fold) to 16 
66.3%, significantly greater than HA, but not Si-CaP (p= 0.02 and  p>0.0001 17 
respectively). On PL ALP activity increased  slightly on Day 21, but 18 
remained  low (4.69 %). 19 
 20 
Figure 69: Area of alkaline phosphatase on substrates. 21 
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ALP activity of cells on substrates quantified by analysing the area of ALP positive cells 1 
using image analysis software and the mean area calculated per disk / well. The results 2 
represent the mean ± SD of two donors with samples run in triplicate. 3 
 4 
5.2.3.1.6    Mineralisation  5 
 6 
Production of a mineralised  matrix was detected , quantified  and  is shown 7 
in Figure 43. Initally, no detectable mineralised  matrix was seen, and  on 8 
Day 7 less than 3 % of mineralisation was observed  on any substrate. By 9 
Day 14 however, a rapid  increase in area of mineralisation was detected  on 10 
Si-CaP, HA and PL+OS (increasing 28–fold , 15-fold  and  34-fold  11 
respectively). This rate of mineralisation then slowed, by Day 21, and  at 12 
this time the greatest area of mineralisation was detected  on PL+OS (67.21 13 
%). On Si-CaP and HA the area of mineralisation was also highest on Day 14 
21, but peaked at 56.28 % and 54.07 % respectively. At this point the area of 15 
mineralisation on Si-CaP and HA was not significantly d ifferent to PL+OS 16 
(p>0.99). Cells on PL d id  not produce appear to produce a mineralised  17 
matrix at any time point. 18 
 19 
  20 




Mineralisation on substrates was measured by analysing the area of black deposits using 1 
image analysis software and the mean area covered was calculated per disk / well. The 2 




5.3 Discussion  7 
 8 
The results presented  above show that d ifferent substrates can both 9 
support and  induce mesenchymal stem cell d ifferentiation into osteoblasts 10 
and  can actively promote bone formation. 11 
Previous studies have used  either osteogenic supplementation alone or in 12 
combination with specific substrates, however here it was shown that the 13 
substrates alone were capable of d ifferentiating mesenchymal stem cells 14 
into osteoblasts. 15 
 16 
Osteogenic media commonly contains dexamethasone, ascorbic acid  and  β- 17 
glycerophosphate. Although these constituents are not specific to 18 
osteogenic d ifferentiation (Pittenger 1999; Johnstone et al. 1998), each 19 
component has been shown to support osteogenic d ifferentiation of 20 
mesenchymal stem cells in vitro (Nuttelman 2005). 21 
Dexamethasone is a synthetic corticosteroid known to influence osteoblast 22 
gene expression (Viereck et al. 2002). In vitro, dexamethasone functions at 23 
several stages of osteogenic d ifferentiation, upregulating the expression of 24 
RUNX2, and  subsequently, osterix, osteocalcin, bone sialoprotein and  25 
alkaline phosphatase. Duration of supplementation is controversial, with 26 
various recommendations from different studies: som e suggest it should  be 27 
continuously present to prevent d ifferentiation along alternative pathways 28 
and  to ensure maximal osteoblastic d ifferentiation, whereas others indicate 29 
continual supplementation to culture could  have toxic effects and  cause cell 30 
lysis (R. M. Porter et al. 2003b; Nuttelman 2005). This contradictory effect is 31 
thought to be due to the anti-proliferative effects of this corticoid  (Jaiswal et 32 
al. 1998). The results shown here (Figure 46,  33 
Figure 56 and  Figure 64) reflect this anti-proliferative effect, and  were 34 




Ascorbic acid  is required  to stabilise the collagen triple helix and  to form 2 
intermolecular crosslinks within collagen (Murad  et al. 1981). Although 3 
several studies suggest ascorbic acid  can enhance collagen production 4 
(Aronow et al. 1990; Franceschi & Iyer 1992) and  ALP activity (Franceschi 5 
et al. 2009) it does not actively drive osteogenic d ifferentiation. 6 
Immunohistochemistry results clearly demonstrated  collagen production is 7 
independent of ascorbic acid . However, clear d ifferences in the structure of 8 
extracellular collagen type I were observed , in ADMSC in particular, 9 
suggesting ascorbic acid  supplementation is required  for optimal post 10 
translational modification.  11 
 12 
β-glycerophosphate is thought to promote osteogenic d ifferentiation by 13 
provid ing a source of organic phosphate ions that act as a bone-like mineral 14 
phase in vitro (Chung et al. 1992). Both Si-CaP and HA will release ions in 15 
vivo and in culture, thus provid ing a source of phosphate, eliminating the 16 
need  for β-glycerophosphate. Calcium is also released  from both substrates 17 
through d issolution, and  regulates important cellular and  molecular 18 
functions. Ca2+ has been demonstrated  to positively influence osteoblast 19 
d ifferentiation (Khoshniat et al. 2011) yet its exact role is not fully 20 
understood. 21 
 22 
In combination, dexamethasone, ascorbic acid  and  β-glycerophosphate are 23 
able to promote osteogenic d ifferentiation of MSC, although each 24 
component cannot actively induce d ifferentiation .  It is therefore unclear 25 
exactly why these components drive osteogenic d ifferentiation , and  it is 26 
more likely these factors act synergistically to support the preferential 27 
d ifferentiation along the osteogenic lineage.  28 
 29 
Si-CaP and HA have been shown to d irect osteogenic d ifferentiation at a 30 
similar rate, through activation of the same genes as these osteogenic 31 
supplements. However, it is not clear whether these substrates are 32 
mimicking these supplements or are utilising alternative pathways. Many 33 
studies have examined how substrates can influence cell fate, yet the 34 
majority of these do so in the presence of soluble factors known to induce 35 
osteogenic d ifferentiation (Müller et al. 2007), as a result it is unclear which 36 
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pathways are actually involved . A number of signaling pathways may be 1 
involved  in substrate driven d ifferentiation and  these will be d iscussed  in 2 
more detail in the next chapter. 3 
Results shown here demonstrate both Si-CaP and HA support and  actively 4 
d irect d ifferentiation of each type of multipotent cells in vitro.  Previous 5 
results from multip le clinical (Jenis & Banco n.d .; Jenis & Banco 2008; Jenis 6 
2010) and  in vivo studies (A. E. Porter et al. 2003a; Patel et al. 2005; Wheeler 7 
et al. 2007) have demonstrated  Si-CaP supports greater bone formation and  8 
enhanced  bioactivity when compared  to HA. Studies by d ifferent groups 9 
have examined silicon substitution with similar results; demonstrating 10 
silicon substituted  calcium phosphates promote accelerated  osteoblast 11 
d ifferentiation (Ponader et al. 2008) and  more rapid  mineralisation than 12 
non-substituted  controls (Thian et al. 2007). 13 
The enhanced  bioactivity of Si-CaP is thought to be due to the inclusion of 14 
silicate imparting improved physical properties to HA, which are described  15 
below. 16 
 Silicate increases the rate of d issolution of calcium  phosphate, 17 
provid ing an apatite layer in vivo or in vitro, which is known to 18 
increase the rate of mineralisation (A. E. Porter et al. 2003a; Patel et 19 
al. 2005).   20 
 During d issolution silicate ions are released  (Guth et al. 2006) which 21 
enhance osteoblast gene expression; protein production and  can 22 
increase ALP levels (Reffitt et al. 2003).  23 
 The addition of silicon into the calcium phosphate lattice alters grain 24 
size, causing chemical changes at the surface, which may lead  to a 25 
change of the biological response (Botelho et al. 2005; A. E. Porter, 26 
Patel, et al. 2004b; A. E. Porter, Botelho, et al. 2004a; A. E. Porter et al. 27 
2006).  28 
 Due to altered  surface chemistry Si-CaP is capable of adsorbing a 29 
greater quantity of protein when compared  to both HA, which has 30 
been shown to increase cell attachment (Anselme 2000; Guth & 31 




These properties appear to significantly impact cell respon se in vitro, and  1 
results shown in this chapter demonstrate that Si-CaP showed  greater 2 
attachment than HA, for each cell type analysed . This preferential 3 
attachment, was has been previously linked  to the micro- and  macro- 4 
porosity of Si-CaP (K A Hing 2005), but more recently thought to be 5 
influenced  by silicate d issolution from the graft (Guth, Campion, Buckland 6 
& Hing 2010a). Preferential silicate d issolution has been shown to enhance 7 
protein adsorption, and  increase osteoblast attachment (Guth et al. 2006). 8 
As both substrates were in the form of dense d iscs, thus eliminating 9 
porosity, it is proposed  that the d issolution of ions, and  protein adsorp tion 10 
is also encouraging undifferentiated  cells to attach to Si-CaP. On average, 11 
more cells attached  to PL compared  to Si-CaP and HA, this was observed 12 
for each cell type. However, after 8 hours the average cell numbers on Si- 13 
CaP and PL did  not vary significantly.  14 
Attachment or adhesion of cells to bone grafts is critical to their long -term 15 
integration, as contact with the graft will influence the cell‘s capacity to 16 
proliferate and  d ifferentiate. Cells attach to substrates via specific 17 
structures, known as focal adhesions, which are composed  of receptors 18 
such as integrins and  adapter proteins. The morphology and  focal 19 
adhesions of cells attached  to Si-CaP and  HA are examined in the next 20 
chapter. 21 
Once cells have attached  to the surface of the substrate, the degree of cell 22 
colonisation is dependent on proliferation. The balance between 23 
proliferation and  d ifferentiation must be precisely regulated  in order for a 24 
bone graft to successfully integrate with the surrounding tissue. If cells 25 
were to d ifferentiate into committed cells upon attachment without any 26 
proliferation there may not be enough cells to form sufficient new bone 27 
without further recruitment from external sources. This may be relevant in 28 
therapeutic applications involving pre-seeded material grafts (Owen 1988). 29 
Conversely, if cells continually proliferate and  do not d ifferentiate there 30 
also will be a failure of new bone formation.  In both cases this will lead  to 31 




Similar trends in proliferation were seen for all cell types, on PL all cell 1 
types showed a simple exponential grow th rate, increasing over time, 2 
whereas on Si-CaP and HA the rate of proliferation of all cell types 3 
decreased  similarly, compared  to cells on PL+OS, appearing to give a more 4 
linear growth rate compared  to the exponential growth seen on PL. One 5 
interpretation of such a linear growth rate is that it reflects asymmetric 6 
d ivision of stem cells, in which one committed  cell and  one daughter stem 7 
cell are produced at each d ivision.  Within the stem cell niche, cells 8 
undergo asymmetric cell d ivisions to balance proliferation and  9 
d ifferentiation (D'Angelo et al. 2011). This form of d ifferentiation on Si-CaP 10 
and  HA is advantageous as it allows d ifferentiation of committed  cells in 11 
addition to provid ing a source of progenitors for further d ifferentiation 12 
when required . One study has observed  a similar decrease in proliferation 13 
rates of cells as they d ifferentiate, and  have proposed  a similar mechanism 14 
(de Peppo et al. 2012). Cells cultured  in d ifferentiation media (PL+OS) 15 
doubled  at an even slower rate, likely due to the anti-proliferative effects of 16 
dexamethasone, which is also consistent with a model in which 17 
d ifferentiation of MSC starts as proliferation ceases.  18 
 19 
The d ifferentiation of stem cells along the osteogenic lineage proceeds 20 
through a series of defined  stages and  is marked  by the changing 21 
expression of key genes and  proteins as the cell moves down the 22 
d ifferentiation pathway from a multipotent MSC to a terminally 23 
d ifferentiated  osteocyte, this process is shown in Chapter one, Figure 4. 24 
In order to determine further d ifferences between Si-CaP and HA, 25 
osteoblast related  genes and  key transcription factors were analysed .  26 
Cells on Si-CaP showed a more rapid  decrease in expression of CD105 27 
compared  to HA, suggesting m ultipotency is lost as cells commit to the 28 
osteoblast lineage. 29 
The most specific osteoblast associated  transcription factor, controlling 30 
osteoblast commitment, d ifferentiation and  matrix mineralisation is 31 
RUNX2. In each cell type RUNX2 gene expression was greater on Si-CaP 32 
compared  to HA; ADMSC cultured  on Si-CaP showed the greatest increase 33 
in RUNX2 expression, which was significantly greater than on HA. These 34 
results were also reflected  in protein levels detected  by immunochemistry, 35 
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although RUNX2 protein was detected  later than gene expression but was 1 
maintained  until Day 21. This prolonged expression of RUNX2, has been 2 
shown to enhance osteogenic differentiation (Zhang et al. 2006). In MSC in 3 
particular, RUNX2 expression appeared  to be both cytoplasmic and  nuclear 4 
on Si-CaP and HA. Some transcription factors including RUNX2 can 5 
translocate from the nucleus to the cytoplasm. The cytoplasmic staining 6 
may indicate RUNX2 has already played  its role in d ifferentiation and  gene 7 
expression, and  has shuttled  into the cytoplasm in its inactive form. 8 
However, some studies suggest this sub-nuclear localisation may be 9 
required  for maximal transcriptional activity (Sunhwa Kim et al. 2003b; 10 
Pockwinse et al. 2005). 11 
Expression of Parathyroid  hormone 1 receptor (PTH1R) was detected  in 12 
MSC and was also upregulated  earlier on Si-CaP on day 7 compared  to 13 
HA, indicating that cells on Si-CaP were d ifferentiating at an increased  rate.  14 
In hES-MP and ADMSC expression of osterix (OSX ) was analysed . OSX  is 15 
a transcription factor which acts dow nstream of RUNX2 it is essential for 16 
osteoblast d ifferentiation. In both cell types, OSX  levels were greater on Si- 17 
CaP compared  to HA, thus supporting the trend  of cells in Si-CaP 18 
d ifferentiating at greater rate. 19 
During osteoblast d ifferentiation RUNX2 and  OSX  upregulate osteoblast 20 
related  genes including COL1A1 and  BGLAP.  Collagen type I is the most 21 
abundant protein in bone, and  production of this type of collagen peaks as 22 
cells become mature extracellular matrix-producing osteoblasts (Anselme 23 
2000).  In MSC, hES-MP and ADMSC, COL1A1 gene expression on Si-CaP 24 
was upregulated  earlier and  to a greater extent to HA, and  on both 25 
substrates increased  gradually over time. In each cell type, collagen type I 26 
protein production reflected  COL1A1 gene expression; with the exception 27 
of MSC on Si-CaP: gene expression decreased  on days 14 and  21, yet 28 
protein detected  by immunocytochemistry, increased . This may be due to 29 
the level of translation and  posttranslational processing required  to 30 
produce stable collagen.  31 
 32 
ADMSC showed the most extensive production of collagen type I, and  on 33 
Si-CaP, and  covered  a greater area compared  to HA. The structure of the 34 
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collagen appeared  to be very d ifferent to that seen on PL+OS, which 1 
appeared  brighter and denser. This may be due to the presence of ascorbic 2 
acid  in the osteogenic media, which is thought to be required to crosslink 3 
and  stabilise the triple helix (Aronow et al. 1990; Franceschi et al. 2009). 4 
Osteocalcin or bone gamma-carboxyglutamic acid -containing protein 5 
(BGLAP) is a late stage osteoblast specific protein, produced only by 6 
mature osteoblasts prior to the onset of mineralisation (Marinucci et al. 7 
2010). In MSC and ADMSC, BGLAP gene expression was higher on Si-CaP 8 
compared  to HA. In hES-MP, BGLAP levels were slightly but not 9 
significantly higher on HA when compared  to Si-CaP. The protein encoded 10 
by the BGLAP gene (osteocalcin), was detected  in cells on both Si-CaP and  11 
HA, strong, cytoplasmic staining was seen, which closely reflected  gene 12 
expression. 13 
 14 
DMP1 gene expression was analysed  to determine whether cells were 15 
capable of terminal d ifferentiation along the osteoblast lineage into 16 
osteocytes. Osteocytes play a major role in bone remodeling, and  are 17 
therefore essential for the long-term success of a bone graft.  In each cell 18 
type DMP1 expression was detected  on both Si-CaP and HA. However, 19 
levels of DMP1 were higher on Si-CaP in both MSC, and  AMDSC, 20 
suggesting a greater number of osteocytes.  21 
  22 
Results from gene expression and  protein production demonstrate that 23 
cells were d ifferentiating into osteoblasts on Si-CaP and HA. However, Si- 24 
CaP upregulated  the osteoblast related  genes RUNX2, COL1A1 and  PTH1R 25 
earlier than HA and PL+OS, suggesting that cells cultured  on Si-CaP were 26 
d ifferentiating along the osteoblast lineage at a greater rate compared  to 27 
HA.  28 
 29 
Alkaline phosphatase (ALP) is a commonly used  early marker of osteoblast 30 
d ifferentiation. ALP was strongly expressed  in each cell type after culture 31 
on both Si-CaP and HA, suggesting both these substrates are capable of 32 
inducing d ifferentiation into osteoblasts. All cell types had  higher ALP 33 
activity on Si-CaP compared  with HA; this was most obvious in the case of 34 
MSC, where ALP activity was greater than 10% higher on Si-CaP than on 35 
HA.  36 
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Alkaline phosphatase plays a crucial role in mineralisation as it functions to 1 
provide a source of inorganic phosphate required  to form hydroxyapatite 2 
crystals (Bellows et al. 1991). For each cell type, the area of mineralisation 3 
was greater on Si-CaP to that on HA. In MSC and ADMSC levels of 4 
mineralisation were similar, whereas in hES-MP, the area of mineralisation 5 
was up to 10% greater on both Si-CaP and HA.  These results demonstrate 6 
that both calcium-based  materials initiated  the formation of a mineralised 7 
matrix.  Yet overall, Si-CaP was clearly shown to be more osteoinductive, 8 
initiating d ifferentiation at an increased  rate and  to a greater extent than 9 
HA.  10 
 11 
In the absence of soluble factors, multip otent stem cells cultured  on tissue 12 
culture plastic, hydroxyapatite and  silicate substituted  calcium phosphate 13 
showed very d ifferent responses.  14 
Tissue culture plastic (PL) is composed  of polystyrene, a benzene 15 
containing polymer that is commonly modified  to increase cell attachment 16 
(Steele et al. 1993). This can be achieved  through the addition of oxygen 17 
containing groups to the polymer, creating a hydrophilic, negatively 18 
charged  surface when medium is added (Ramsey et al. 1984; Amstein & 19 
Hartman 1975; M 1974). Treated  PL supports cell attachment and  20 
proliferation, and  is not designed  to promote d ifferentiation, as the results 21 
shown above demonstrate. 22 
However, some cells can d ifferentiate on PL without soluble factors, such 23 
as human embryonic stem cells (hES). In hES cultures, PL is com monly 24 
coated  with Matrigel, proteins or substrates that mimic the extracellular 25 
matrix in vivo, to prevent d ifferentiation. More recently, alternative coatings 26 
or treatments to apply to PL to maintain stem cell function have been the 27 
subject of investigation (Ramos-Ibeas et al. 2012; Rajaraman et al. 2012). 28 
These are designed  to mimic stem cell niches, where cells are maintained  in 29 
a multipotent or pluripotent state until d ifferentiation is required . 30 
Conversely, biomaterials to support cell growth and  d ifferentiation for 31 
organ repair aim to mimic the desired  tissue.  32 
 33 
Many studies have exploited  aspects of the desired  in vivo environment to 34 
produce materials to d irect cell fate without the need  for soluble factors. 35 
The use of engineered substrates for culturing and  d ifferentiating cells has 36 
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significant advantages over the use of supplemented  media, as it allows 1 
cell growth and  development to be tailored to a specific application without 2 
the need  to use expensive, or introduce potentially harmful chemicals into 3 
the body.  However, the in vivo environment is extremely complex, and  4 
cells may encounter a variety of surfaces with d ifferent compositions, 5 
topographies, and  nano-scale features, each of which has the potential to 6 
influence cell behavior and  function. To understand  how each of these 7 
factors can influence cell fate, a number of studies have designed  materials 8 
to examine specific parameters such as; altered  topography, defined  9 
surface chemistry, nano-scale features and  the influence of protein 10 
composition. 11 
Topography has been known to influence cells for over a century (Carrel & 12 
Burrows 1911) and  can alter cell morphology, adhesion, motility, 13 
proliferation  gene expression and  protein production (McNamara et al. 14 
2010). Due to advances in technology enabling precise manufacture and  15 
analysis of nano- patterned  surfaces, the extent to which topography can 16 
alter cell fate has been understood only recently (J. Y. Lim et al. 2011). 17 
The size and  shape of topographical patterns appear to be critical for 18 
controlling cell fate. Substrates composed  of poly (methyl methacrylate) 19 
with semi-d isordered pits, 120 nm diameter and  100 nm deep, induce 20 
osteogenic d ifferentiation of MSC (Dalby et al. 2007). Nanotubes between 21 
70-100 nm in d iameter enhanced  cytoskeletal stress and  induced  osteogenic 22 
d ifferentiation, when compared  to tubes of 30 nm, which promoted 23 
proliferation (S. Oh et al. 2009). These studies suggest the topography 24 
regulates cell d ifferentiation via controlled  adhesion and  enhanced  25 
cytoskeletal tension. 26 
 This theory was also examined in two separate studies, which utilised  27 
adhesive islands; cell fate was shown to be dependent upon the shape of 28 
island  to which each cell could  adhere. Star and  rectangle shapes, 29 
encouraged cell spreading, and  an increase in actin filament organisation 30 
promoted osteogenesis. Whereas shapes that promoted low contractility, 31 
such as flower-like or rounded shapes promoted  adipogenic d ifferentiation 32 
(McBeath et al. 2004; Kilian et al. 2010). Adipocytes are spherical in shape, 33 
as this provides the most efficient surface area to volume ratio 34 
for lipid  storage, the smaller, rounded islands minimise cell spreading and 35 
CHAPTER FIVE 
 179 
focal adhesion formation, and  as a result the preferential spherical 1 
phenotype is maintained  (S. Murphy et al. 2010). 2 
The d isordered  nano-patterned  substrates used  by Dalby et al in the study 3 
mentioned  above concluded that the extent of osteogenic d ifferentiation 4 
was determined  by the d isorder of the pattern produced (Dalby et al. 2007). 5 
Regularly spaced  pits or symmetrical patterns d id  not induce 6 
d ifferentiation to the same extent as slightly d isordered  patterns (Dalby et 7 
al. 2007). This is reflected  in the rate and  extent of d ifferentiation shown in 8 
this chapter, with Si-CaP promoting greater d ifferentiation compared  to 9 
HA, which could  be due to the substitution of silicate into Si-CaP creating a 10 
d isordered  surface containing areas of negative and  positive charge, 11 
whereas HA has a regular repeating pattern of calcium and phosphate ions. 12 
These topographical studies reflect the role of components of the native 13 
ECM, which is fibrillar and  contains specific d istributions of adhesive 14 
proteins. Although the surfaces of Si-CaP and HA discs do not contain 15 
significant areas of raised  or patterned  topography, a similar activation of 16 
osteogenic d ifferentiation was observed .  However, the surfaces of these 17 
substrates contain areas of both positive and  negative charge, known to 18 
influence the d istribution and  conformation of p roteins bound  to the 19 
surface, and  these may have a similar patterning effect as changes in 20 
surface topography.   21 
Surface chemistry can readily be controlled and  modified  and  has been 22 
shown to influence cell attachment (Tourniaire et al. 2006), d ifferentiation 23 
(Hay et al. 2011) and  to guide cell fate in vitro (Curran et al. 2006). Some 24 
studies have investigated  alternate ionic substitutions in hydroxyapatites, 25 
such as strontium, zinc and  magnesium with the aim to improve 26 
d issolution rates and  bioactivity (S R Kim et al. 2003a; Ramaswamy et al. 27 
2008; Fredholm et al. 2012). The silicon substitution in Si-CaP affects its 28 
surface charge, surface structure, and  solubility, which can, in turn, result 29 
in changes in the biological performance in vitro and  in vivo. The surface 30 
chemistry of HA and Si-CaP undergoes significant changes in vivo, as ions 31 
are released  through d issolution, creating a biomimetic apatite like layer, 32 
which is known to encourage protein adsorption and  osteogenic 33 
d ifferentiation.  34 
CHAPTER FIVE 
 180 
The surface energy of substrates can also d irectly influence protein 1 
adsorption and  determine their structural arrangement, with d ifferential 2 
protein adsorption detected  on surfaces with positively and  negativ ely 3 
charged  surfaces (Anselme 2000). 4 
 5 
The ECM is composed  of a variety of proteins, an important part of the 6 
cellular microenvironment and  plays a significant role in regulating cell 7 
adhesion, proliferation and  d ifferentiation (Mathews et al. 2012). As such 8 
significant effort has focused  of ECM based  scaffolds for bone repair. 9 
Studies have examined the effect of a variety of proteins on osteogenic 10 
d ifferentiation and  have utilised  peptides to create substrates with greater 11 
bioactivity, with promising results (García & Reyes 2005; Badylak et al. 12 
2009). Collagen type I and  vitronectin have profound influences on 13 
mesenchymal stem cells, reducing proliferation rates and  encouraging 14 
osteogenic d ifferentiation (Mathews et al. 2012).  Both of these proteins 15 
have been shown to bind  in vivo and  in vitro to HA and Si-CaP with high 16 
affinity (Botelho et al. 2011). 17 
 18 
Substrates designed  to induce osteogenic d ifferentiation, through 19 
topological variation, the use of adhesive islands, altered  surface chemistry 20 
and  adsorption of proteins or peptides provide valuable tools to study 21 
osteogenic d ifferentiation in vitro. However, they may not be suitable for 22 
clinical use in vivo. For example, it is relatively easy to manufacture in 2D 23 
nano-patterned  surfaces on a small scale, such as is required  for in vitro 24 
experiments, however producing large, complex 3D structures for major 25 
skeletal defects may not be cost effective or easy to manufacture 26 
(McMurray et al. 2011). However, recent advances in 3D printing may 27 
change this. 28 
 29 
Calcium phosphate based  substrates naturally incorporate a number of the 30 
desired  aspects of the in vivo environment, and  due to their similarity with 31 
the mineral phase of bone mimic the environment, which they aim to 32 
induce repair. As a result, these substrates have become clinically relevant.  33 
Whether combined  with autologous cells or implanted  alone, bo th HA and 34 
Si-CaP have the potential to d irect osteogenic d ifferentiation or multipotent 35 




Results shown above demonstrate cells from bone marrow, ad ipose tissue 2 
and  of embryonic origin are capable of osteogenic d ifferentiation. Despite 3 
the efficient d ifferentiation of hES-MP cells, there are still safety and  ethical 4 
issues regard ing the clinical use of these cells, which must be addressed  5 
before their clinical use. Bone marrow derived  MSC are currently used  as a 6 
source of multipotent cells for bone repair, however extraction is an 7 
invasive procedure, and  both volume of tissue and  number of multipotent 8 
cells obtained  are often limited .   9 
Adipose derived stem cells (ADMSC) showed comparable rates of 10 
attachment, d ifferentiation and  mineralisation to MSC, but demonstrated 11 
greater proliferation potential and  more extensive, mature protein 12 
production on both HA and Si-CaP. Furthermore, autologous supply is not 13 
nearly as limited , multipotent cells much more frequent, surgery is still 14 
invasive (but may be preferred) and  cells may be purified  and  stored  for 15 
later use if needed. As a result it is suggested  that ADMSC may represent a 16 
promising alternative source for cells for clinical bone repair. 17 
 18 
This study is the first to com pare the osteogenic d ifferentiation of these 19 
three cell types, on Si-CaP and  HA, in the absence of soluble osteogenic 20 
factors. The results clearly demonstrate these substrates are osteoinductive, 21 
and  are capable of d irecting cell fate in a manner comparable to, or greater 22 
than osteogenic supplementation. 23 
The implication of these findings for tissue engineering is clear, suggesting 24 
these substrates may be utilised  to control stem cell fate in vivo and  in vitro 25 





CHAPTER SIX: CELL SUBSTRATE INTERACTIONS 1 
 2 
6.1 Introduction 3 
 4 
The development of successful biomaterials for bone tissue engineering is 5 
shifting towards substrates that mimic the natural extracellular matrix 6 
(ECM). Substrates that actively drive cellular d ifferentiation and  accurately 7 
mimic natural repair of tissues or organs remove the need for the 8 
supplementation of expensive, potentially harmful soluble factors. 9 
In vivo cells interact closely with the extracellular matrix ECM, a 10 
heterogeneous milieu, a structu rally organised  network of biological 11 
macromolecules, which is subject to many physical forces (Nombela-Arrieta 12 
et al. 2011; Badylak et al. 2009; Kolf, Cho & Tuan 2007b; Chamberlain et al. 13 
2007; Crisan et al. 2008; Barry & J. M. Murphy 2004; Boyd et al. 2009; 14 
Haasters et al. 2009; Yoshimura et al. 2006; Pittenger 1999; Jack et al. 2002). 15 
Due to the complexity of the ECM it is inherently d ifficult to determine its 16 
impact on cell behavior. As a result studies have examined individual 17 
aspects of the ECM in an attempt to understand  its role in cell fate and 18 
d ifferentiation (Chamberlain et al. 2007; Fisher et al. 2010; Haasters et al. 19 
2009; Yoshimura et al. 2006; Pittenger 1999). Cell response to substrate 20 
compliance, composition, topography and physical forces have all been 21 
analysed  with fascinating results. For example, matrix elasticity has been 22 
shown to d ifferentiate mesenchymal stem cells into tissues that most closely 23 
resemble the mechanical properties of the polyacrylamide substrates to 24 
which they were attached  (Engler et al. 2006). Matrix composition has also 25 
been shown to stimulate d ifferentiation; when MSC adhered  to vitronectin 26 
and  collagen type I coated  plates, they were induced  to d ifferentiate along 27 
the osteoblast lineage without the need  for osteogenic supplementation  28 
(Salasznyk et al. 2004). Topography in the form of nano-patterned  substrates, 29 
adhesive islands, micro-textured  and  surface roughness and  physical forces 30 
including shear stress, mechanical loading and  compression have all been 31 
shown to positively influence osteogenic d ifferentiation  (McNamara et al. 32 
2010; Rosa et al. 2003; Kapur et al. 2003; Sun et al. 2012; Barrère et al. 2008). 33 
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These studies have provided  significant insight into how cells ‗sense‘ their 1 
environment and  transduce this information into complex cellular responses. 2 
A common factor in such stud ies is the requirement of cellular adhesion. 3 
Cells initially ‗attach‘ to surfaces and  over the longer term ‗adhere‘. The 4 
adhesion phase is characterised  by binding of integrins - the key receptor 5 
involved  in linking cells to the ECM. Since their d iscovery over 25 years ago 6 
(Hynes 1987) they have become one of the best understood cell adhesion 7 
receptors.  8 
Integrins are composed  of two glycoprotein subunits, namely the α chain and 9 
β chain, which are non-covalently bound. The mammalian set of integrins is 10 
composed  of 18 α and  8 β subunits, which assemble to form 24 d istinct 11 
integrins. Individually integrin binding to the ECM is relatively weak 12 
however, ligand binding activates clustering of multiple integrins, which 13 
form a larger signaling complex. Within this complex, a variety of adapter 14 
proteins connect integrins to the cytoskeleton. These large clusters of 15 
integrins and  signaling molecules form focal adhesion complexes, which are 16 
essential to cell adhesion (Eleniste & Bruzzaniti 2012). Shown below in 17 
Figure 71. 18 
Focal adhesions can d irectly couple to the actin cytoskeleton, and  allow 19 
information about the external environment to be transduced  into the cell, 20 
activating intracellular signaling pathways involved  in proliferation, 21 
migration, and  d ifferentiation (Giancotti 1999).   22 
In bone, cells are in intimate contact with bone mineral and  the variety of 23 
proteins secreted  by osteoblasts. Studies mimicking this natural ECM 24 
produced by osteoblasts have shown demonstrated  enhanced  osteoblast 25 
d ifferentiation and  even activation of osteogenic lineage in MSC (Mathews et 26 
al. 2012; Florence Barrère 2006). The mineral phase of bone, composed  of 27 
calcium phosphate in the form of hydroxyapatite, has also been shown to 28 
significantly impact cell behavior (Müller et al. 2007). However, cells are 29 
rarely in d irect contact with hydroxyapatite instead  interact with an 30 
adsorbed  protein layer (both in vivo and  in vitro) (Guth & Buckland 2005). 31 
The structure of calcium phosphates can be altered  via ionic substitutions 32 
and  these impact upon the type, amount and  conformation of protein 33 
adsorbed , whilst this has been well documented  (Botelho 2005), the 34 






Figure 71: Biophysical forces and interactions of a stem cell and the extracelluar 3 
matrix.  4 
Physical forces are written in blue and mechanical stimuli in red. Inset shows magnification 5 
of a focal adhesion, incuding a transmembrane heterodimeric integrin, paxillin (Pax), 6 
TALIN, focal adhesion kinase (FAK), vinculin (Vinc), ZYXIN, and vasodilator-stimulated 7 
phosphoprotein (VASP). Abbreviation: ECM, extracellular matrix. Adapted from (Sun et al. 8 
2012). 9 
 10 
This chapter aims to determine how multipotent stem cells interact with 11 
hydroxyapatite and  silicate substituted  calcium phosphate (and  the adsorbed 12 
protein layer) through morphological analysis of the actin cytoskeleton and 13 
focal adhesion formation during adhesion and  the expression of integrins 14 





6.2 Results  1 
6.2.1 Commitment signals 2 
 3 
To determine whether Si-CaP and HA were delivering d iscrete signals to 4 
d irect d ifferentiation along the osteogenic lineage or whether continuous 5 
contact with these substrates was required , the lineage capacity of cells 6 
(MSC) was analysed  after culture for 24 hours on each substrate.   7 
Cells were seeded  onto Si-CaP, HA and on PL+OS and  after 24 hours; non- 8 
adherent cells were removed and adherent cells re-plated  onto PL with 9 
ad ipogenic, chondrogenic or osteogenic d ifferentiation media. After 7, 14 and  10 
21 days mRNA was collected  and  analysed  for expression of lineage related 11 
genes. The results are shown below in  Figure 72.  12 
Cells that were cultured  on Si-CaP and HA did  not show expression of 13 
adipogenic transcription factor PPARG or the chondrogenic markers SOX9 14 
and  COL2A1. Whereas cells cu ltured  on PL+OS for 24 hours were not 15 
committed  to the osteoblast lineage: cells expressed  PPARG on days 7 and  21 16 
after culture in ad ipogenic media, and  SOX9 and  COL2A1 in chondrogenic 17 
d ifferentiation media.  Cells cultured  on all substrates showed  expression of 18 
osteogenic markers RUNX2 and  BGLAP. 19 
 20 
These results demonstrate that cells are committed  to the osteoblast lineage 21 
within 24 hours, when cultured  on Si-CaP and HA. This proves there must 22 
be a positive signalling event driving d ifferentiation within this short period 23 
of time. PL+OS is known to favour osteogenic d ifferentiation rather than 24 
actively induce it and  that commitment to the osteoblast lineage under these 25 
conditions does not occur within 24 hours. 26 
 27 
These results prompted  the investigation into changes in morphology and 28 






Figure 72: Commitment signals.  2 
Cells were cultured on Si-CaP, HA or PL+OS for 24 hours then replated onto PL with 3 
adipogenic, osteogenic or chondrogenic media and cultured for up to 21 days. Abbreviations: 4 
B2M; beta-2-microglobulin, PPARG; Peroxisome proliferator-activated receptor gamma, 5 
RUNX2; Runt-related transcription factor 2, BGLAP; bone gamma-carboxyglutamic acid- 6 
containing protein, SOX9; SRY (sex determining region Y)-box 9, and COL2A1; collagen 7 
type 2 alpha 1, +; positive control (cDNA from primary bone cartilage and fat) and -; 8 







6.2.2 MSC morphology 1 
 2 
To examine the cell morphology on each substrate, attached  cells were 3 
immunostained  for vinculin, a key protein in focal adhesions, and  with a 4 
phalloid in conjugate to detect filamentous actin. Representative images of 5 
MSC vinculin and  actin staining at 24 hours and  48 hours are shown in Figure 6 
73 and  Figure 74 respectively, where the vinuclin staining is shown in green 7 
and  phalloid in in red .  Cell nuclei were stained  with the DNA intercalating 8 
dye DAPI, which appears blue. 9 
 10 
At 24 hours MSC attached  to Si-CaP had  d iverse morphology, cells varied  in 11 
both size and  shape see Figure 73. Several cells had  defined  focal adhesions 12 
and  d isplayed  strong actin staining. Cells were evenly d ispersed  at 24 hours; 13 
however, by 48 hours cells were clustered  together. At this time, cells were 14 
more homogenous in size, yet cell shape was still varied , ranging from 15 
stellar-like to elongated  cells. Vinculin staining was brighter throughout the 16 
cell, and  the majority of cells had  multiple, well defined  focal adhesions. 17 
Actin staining was less intense than at 24 hours and  was located  around the 18 
edge of the cells. 19 
MSC attached  to HA at 24 hours were notably smaller than cells on Si-CaP, 20 
nonetheless there was still wide variation in cell shape. Focal adhesions were 21 
observed  in most cells, and  strong actin was detected  in roughly 50% of the 22 
cells. Similar to Si-CaP, cells were evenly d ispersed  at 24 hours. At 48 hours 23 
post seeding a greater number of cells were detected  and  were packed close 24 
together. Vinculin staining was seen in  multiple focal adhesions and  25 
filamentous actin fibers were observed  throughout many cells. Overall, cells 26 
were homogenous in size and  were morphologically similar to cells on Si- 27 




Figure 73: Actin and vinculin immunostaining of MSC on Si-CaP and HA, 24 and 48 2 
hours after seeding.  3 
(A) MSC on Si-CaP at 24 hours and (B) 48 hours, (C) MSC on HA at 24 hours and (D) 48 4 
hours. Immunstined with Actin (Red) and Vinculin (Green) DAPI (blue), scale bar 5 
represents 100 μm. 6 
 7 
Cells attached  to PL+OS at 24 hours were larger than the cells seen on Si-CaP 8 
and  HA at the same time see Figure 74. Prominent focal adhesions were 9 
detected  and  strong actin staining was seen around the cell edge. After 48 10 
hours cells were more flattened  and  the actin fibers more organised .  11 
At 24 hours post seeding on PL, most cells were small, fibroblast -like and 12 
had  numerous, small, focal adhesions. Actin fibers were localised  around the 13 
cell edge near the focal adhesions. Several cells were rou nded up, without 14 
mature focal adhesions. By 48 hours, cells were more flattened , and  cuboidal 15 
in shape, had  d istinct focal adhesions, and  strong actin staining was detected 16 
around the edge of cell. At 48 hours cells were notably smaller than on 17 
PL+OS, HA and si-CaP at the same time point. 18 
Morphology and  staining varied  between cells on each substrate. Cells were 19 
more flattened  and  hade d istinct focal adhesions on PL and  PL+OS at 24 20 
hours, compared  to cells on HA and Si-CaP. However, at 48 hours cells on Si- 21 
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CaP and HA were homogenous in shape and  size, and  on both substrates 1 
had  strong vinculin staining, in the form of focal adhesions.  2 
On PL and PL+OS at both time points cells were more heterogeneous in size 3 
and  shape and  d id  not change as significantly over  time, compared  to HA 4 
and  Si-CaP.  5 
 6 
 7 
Figure 74: Actin and vinculin immunostaining of MSC on PL and PL+OS, 24 and 48 8 
hours after seeding.  9 
(A) MSC on PL+OS at 24 hours and (B) 48 hours, (C) MSC on PL at 24 hours and (D) 48 10 
hours. Immunstined with Actin (Red) and Vinculin (Green) DAPI (blue), scale bar 11 
represents 100 μm. 12 
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6.2.3 hES-MP morphology 1 
 2 
hES-MP attached  to Si-CaP at 24 hours were heterogeneous in size and  3 
shape, some were elongated , fibroblast-like and  others were very small, as 4 
shown in Figure 75.  5 
Only a few cells appeared  to have focal adhesions however, actin staining 6 
was seen in the majority of the cells. At 48 hours, less actin was detected , and  7 
staining was observed  in few cells. Many cells had  focal ad hesion and 8 
appeared  to be more flattened  than at the previous time point. Cell size still 9 
varied  and  some very small cells were observed . Cells appeared  to be tightly 10 
packed forming clusters of cells. 11 
 12 
The majority of cells on HA, at 24 hours, were small, with multiple focal 13 
adhesion sites. Strong vinculin staining was detected  throughout the cells 14 
and  actin staining was seen, but d id  not appear organised  into fibrils. The 15 
cells morphology d id  not change significantly at 48 hours post seeding. The 16 
majority of hES-MP were small and  had  little actin staining, however there 17 
were several larger cells, which d isplayed  organised  actin fibrils and  18 






Figure 75: Actin and vinculin immunostaining of hES-MP on Si-CaP and HA, 24 2 
and 48 hours after seeding.  3 
(A) hES-MP on Si-CaP at 24 hours and (B) 48 hours, (C) hES-MP on HA at 24 hours and 4 
(D) 48 hours. Immunstined with Actin (Red) and Vinculin (Green) DAPI (blue), scale bar 5 
represents 100 μm. 6 
 7 
The size and  shape of cells on PL+OS was heterogeneous, see Figure 76; 8 
some cells were large and  irregular, whereas others were much smaller and 9 
more uniform in shape. Strong vinculin staining was detected  at the edge of 10 
many cells, and  also across the cell body. Actin fibers were well defined  and 11 
intensely stained . At 48 hours, cells were larger and  contained  more focal 12 
adhesions, throughout the cells, cells were wide and  flattened  but still varied 13 
in size and  shape. 14 
At 24 hours on PL, many cells were clustered  close together and  mostly 15 
elongated , and  fibroblastic in morphology. Vinculin staining was detected  16 
throughout the cells, but few small focal adhesions were seen. Actin was 17 
intensely stained  and  arranged around the edges of the cells. At 48 hours, 18 
post seeding, significantly more, larger focal adhesions were seen and  cells 19 
were slightly wider and  more flattened  out. Strong actin was seen near the 20 





Figure 76: Actin and vinculin immunostaining of hES-MP on PL and PL+OS, 24 and 3 
48 hours after seeding.  4 
(A) hES-MP on PL+OS at 24 hours and (B) 48 hours, (C) hES-MP on PL at 24 hours and 5 
(D) 48 hours. Immunstined with Actin (Red) and Vinculin (Green) DAPI (blue), scale bar 6 
















6.2.4 ADMSC morphology 1 
 2 
Cells on Si-Cap at 24 hours stained  intensely with actin - filamentous strands 3 
were clearly visible, see Figure 77. The majority of cells were elongated, 4 
fibroblast-like and  were homogenous in size, and  had  multiple small focal 5 
adhesions, as detected  by vinculin staining. By 48 hours post seed ing cells 6 
were wider and  more flattened  with larger, punctate focal adhesions. Cells 7 
showed d ifferential staining of actin, either staining widely of having very 8 
little. Cells on HA at 24 hours were similar to cells on Si-CaP, at 24 hours, 9 
d isplaying intense, widespread  actin staining. Cells also had  few, small focal 10 
adhesions, and  had  less vinculin staining throughout the cell. By 48 hours 11 
cells were wider, had  less actin staining, and  had  more, larger focal 12 
adhesions. Vinculin staining was also evident throughout the cells.  13 
 14 
Figure 77: Actin and vinculin immunostaining of ADMSC on Si-CaP and HA, 24 15 
and 48 hours after seeding.  16 
(A) ADMSC on Si-CaP at 24 hours and  (B) 48 hours, (C) ADMSC on HA at 24 17 
hours and  (D) 48 hours. Immunstined  with Actin (Red) and  Vinculin (Green) 18 
DAPI (blue), scale bar represents 100 μm  19 
At 24 hours on PL+OS cells were wide (Figure 78), flattened  and had  intense 20 
actin staining, as seen on Si-CaP and HA. However, vinuclin staining was 21 
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more evident and  larger focal adhesions were observed , in some case 1 
throughout the cell. At 48 hours post seeding, cells had  significantly more, 2 
larger, focal adhesions. Although not present in some cells, strong actin 3 
staining was detected  in other cells, closely related  to the focl adhesions. 4 
Cells were spread  out in a monolayer, and  d id  not appear to overlap as seen 5 
in HA and Si-CaP. 6 
Cells cultured  on PL for 24 hou rs, had  a wide, flattened  morphology. Cells 7 
were relatively homogenous, and  d isplayed  intense actin staining, with little 8 
to no vnculin staining detected . Very few focal adhesions were seen and 9 
were very faint. At 48 hours post seeding, cells still had  str ong actin staining, 10 
but had  larger, brighter focal adhesions, and  appeared  to grow in small 11 
clusters, unlike cells on PL+OS. 12 
 13 
Figure 78: Actin and vinculin immunostaining of ADMSC on Si-CaP and HA, 24 14 
and 48 hours after seeding.  15 
(A) ADMSC on Si-CaP at 24 hours and  (B) 48 hours, (C) ADMSC on HA at 24 16 
hours and  (D) 48 hours. Immunstined  with Actin (Red) and  Vinculin (Green) 17 





6.2.5 MSC integrin expression 1 
 2 
Integrin expression in MSC was analysed  over 21 days on each substrate and 3 
the relative expression of each subunit is shown in Figure 79 and  Figure 80. 4 
On Day 1, alpha 1 integrin (ITGA1) levels increased  on Si-CaP and HA 1.3- 5 
and  1.5-fold , and  expression remained  at similar levels on Day 7 (5.3 ± 0.05, 6 
and  4.0 ± 0.06 respectively). On Day 14, levels of ITGA1 on Si-CaP increased  7 
rapid ly to 5.7-fold  greater than PL and 3.0-fold  greater than HA, by Day 21 8 
levels of ITGA1 were highest on Si-CaP (29.3 ± 0.14). ITGA1 expression on 9 
HA also increased  slightly on Day 14, but was at its highest on Day 21 (23.8 ± 10 
0).  ITGA1 expression on PL+OS followed a similar trend , increasing over 11 
time and was highest on Day 21 (15.2 ± 2.2). ITGA1 expression on PL 12 
remained  constant, and  d id  not increase above (1.9 ± 0.03). 13 
On HA, alpha 2 integrin (ITGA2) expression increased  over time in a linear 14 
fashion until Day 7 (7.7 ± 0.08), after which it decreased  slightly but later 15 
increased  on Day 21 to 7.97 ± 3.04. On Si-CaP ITGA2 increased  at a similar 16 
rate to HA up to Day 14, when it was 5.5-fold  greater than PL+OS), on Day 17 
21 levels increased  to (20.5 ± 3.04) and  was 2.6-fold  greater than. ITGA2 on 18 
PL+OS increased  over time, dropping slightly on Day 7, an d  reaching its 19 
highest level on Day 21 (3.5 ± 0). On PL levels decreased  slightly after Day 1, 20 
and  remained  low throughout culture. 21 
Alpha 3 integrin (ITGA3) expression increased  rapid ly on Day 1 on HA and 22 
Si-CaP and  (13.5 ± 0, and  11.6 ± 0.06 respectively). On Si-CaP ITGA3 levels 23 
then decreased  to 4.5 ± 0.07 on Day 7 and  then further declined  on Day 21 to 24 
1.3 ± 0.01. On HA ITGA3 levels decreased  at a slower rate and  remained  2.4- 25 
fold  greater than Si-CaP on Day 7, after which expression levels decreased  to 26 
2.9 ± 0.01. On PL+OS expression of ITGA3 decreased  on Day 1 then increased  27 
over time and was highest on Day 21 at 4.6 ±0.4. On PL levels of ITGA3 28 
fluctuated  over time but remained  between 0.19 and  1.05 ± 0.01. 29 
On Si-CaP, alpha 4 integrin (ITGA4) increased  on Day 1 to 5.2 ± 0.08 and  then 30 
decreased  over time to 2.1 ± 0.02 on Day 21. On HA ITGA4 expression was 31 
highest on Day 7 (3.1-fold  less than Si-CaP) then decreased  over time to 0.5 ± 32 
0.02. On PL+OS ITGA4 expression fluctuated  between 0.5 and  1.1 ± 0.2. On 33 
PL ITGA4 expression remained  low at all time points and  d id  not increase 34 






Figure 79:MSC integrin expression.  
Data are mRNA levels of genes of interest and are represented as level of expression 
normalised to beta-2 microglobulin and to Day 0. Two donors were used, and each sample 
was run in duplicate 
 1 
On Si-CaP, alpha 5 integrin (ITGA5) expression increased  26-fold  on Day 1 to 2 
26.2 ± 0.51 and  then decreased  on days 7 and  14, by Day 21 levels increased 3 
slightly to 4.6 ± 0.05. On HA ITGA5 expression increased  gradually (7-fold) 4 
over 14 days and  on Day 21 was 11.9 ± 2.26. On PL+OS ITGA5 also increased  5 
gradually over 21 days, increasing sharply on Day 7 (11.5-fold) and  on Day 6 
21 reached 11.9 ± 0.05. ITGA5 expression on PL was highest on Day 1 (2.8 ± 7 
0.73) then decreased  over time.  8 
Alpha V integrin (ITGAV) expression on Si-CaP followed a similar trend  to 9 
ITGA5. ITGAV  on Si-CaP was highest on Day 1 (46.5 ± 1.14) then decreased 10 
until Day 14, after which levels increased  slightly to 12.0 ± 1.17 on Day 21. 11 
On HA, ITGAV  levels reached 34.8 ± 0.87 on Day 7 and  then decreased  until 12 
Day 21 where expression was 0.06 ± 0.006. ITGAV  expression on PL+OS was 13 
initially low (0.11 ± 0.005) then increased  rapid ly on days 14 and  21, reaching 14 
41.9 ± 1.02 on Day 21. On PL ITGAV  levels were less than 2.4 until Day 21 15 
where expression increased  2.8-fold  to 6.7 ± 0.13. 16 
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Expression of beta 1 integrin (ITGB1) on Si-CaP increased  25.6-fold  on Day 1 1 
and  continued  to increase to 54.8 ±0.27, on Day 14 where levels were highest, 2 
on Day 21 expression decreased  0.8-fold  to 48.7 ±0.23. On HA, ITGB1 3 
expression increased  8.1-fold  on Day 1, and  continued  to rise until Day 21 to 4 
22.9 ± 1.46. ITGB1 levels on PL+OS also increased  over time, reaching highest 5 
levels on Day 21 (30.5 ±0.74). ON PL, expression of ITGB1 remained  6 
relatively constant (between 0.33 and  1.04). 7 
On Si-CaP, HA and PL+OS expression of beta 3 integrin (ITGB3) increased  8 
over time. On both HA and Si-CaP, ITGB1 expression increased  in a similar 9 
manner, with the greatest increase seen on Day 7, (1.01- and  1.07-fold) , levels 10 
then increased  1.46- and  1.40 fold  on 14, and  finally increasing to 22.6 ±0.22 11 
and  22.4 ±0.44 Day 21. On PL+OS ITGB1 expression was relatively low until 12 
Day 7, where levels increased  5.5-fold  to reach 12.7 ± 1.62 on Day 14, after 13 
which increased  1.2-fold  and  reached 15.2 ± 0.22 on Day 21. On PL, ITGB3 14 
levels decreased  slightly (0.01-fold) on Day 1 and  remained  less than 0.02 15 

























Figure 80: MSC integrin expression.  
Data are mRNA levels of genes of interest and are represented as level of expression 
normalised to beta-2 microglobulin and to Day 0. Two donors were used, and each sample 
was run in duplicate 
 1 
 2 
6.2.6 hES-MP integrin expression 3 
 4 
ITGA1 expression on Si-CaP increased  greatly over 14 days, (64-fold) then 5 
remained  at a similar level on Day 21 (64.9 ± 3.81), shown in Figure 81. 6 
Expression of ITGA1 on HA also increased  over 21 days, and  was highest on 7 
Day 21 (53.3 ± 2.87), but remained  lower than Si-CaP at all time points. On 8 
PL+OS expression of ITGA1 was low on days 1 and  7, then increased  (15.2- 9 
fold) to 46.8 ± 0.23 then increased  further on Day 21 to 53.9 ± 0.53. On PL 10 
ITGA1 levels increased  gradually over time (reaching 4.4 ± 0.04), but were 11 
lower than on all other substrates at all time points. 12 
 13 
Expression of ITGA2 on Si-CaP increased  on Day 1 22.6-fold  and  continued 14 
to increase at a similar rate until Day 7, when levels were 1.04-fold  greater 15 
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than HA and 95.7-fold  greater than PL. On Day 14 ITGA2 expression on Si- 1 
CaP increased  to 44.6 ± 6.53 on Day 21 where levels were 1.18-fold  greater 2 
than all other substrates. On HA ITGA2 also increased  in a time dependent 3 
manner, initially at a slow rate on days 1 and  7 (1.2-fold) however, on Day 14 4 
expression increased  2.7-fold  to 35.0 ± 0.34. On PL+OS ITGA2 levels were 5 
low on Day 1 then increased  on Day 7 to 8.53 ± 1.21, expression remained  at 6 
a similar level on Day 14, then increased  again on Day 21 to 12.91 ± 0.13. 7 
Expression of ITGA2 on PL did  not vary over 21 days remaining less than 1. 8 
 9 
On HA, ITGA3 expression increased  4.6-fold  on Day 1 and  continued  to rise 10 
to 13.9 ± 0.41 on Day 7, where levels were greater than on any oth er 11 
substrate. On Day 14 ITGA3 decreased  to 7.4 ± 0.11 and  by Day 21 was 0.92 ± 12 
0.004. On Si-CaP ITGA3 increased  on days 1 and  7 (7.1-fold  higher than on 13 
PL), on Day 14 levels dropped to 7.5 ± 0.04, then decreased  further to 4.6 ± 14 
0.02 on Day 21 (5.1-fold  greater than HA). ITGA3 on PL+OS initially 15 
decreased  on Day 1 and  then increased  to 0.1 ± 0.01 on Day 7. By Day 14 16 
levels of ITGA3 decreased  and  then increased  on Day 21 to 4.7 ± 0. On PL 17 
ITGA3 expression decreased  slightly (0.0001-fold) on Day 1, and  remained  18 
low at all time points. 19 
 20 
ITGA4 levels on Si-CaP and HA increased  on Day 1 (4- and  4.6-fold  21 
respectively), and  at this point ITGA4 levels were at least 4-fold  greater than 22 
PL and PL+OS. On Day 7 ITGA4 expression on Si-CaP remained  the same 23 
but decreased  on HA (0.8-fold). ITGA4 expression on Si-CaP decreased 24 
slightly on Day 14 to 0.82-fold  less than on HA, after which levels of ITGA4 25 
on both Si-CaP and HA decreased . On PL+OS ITGA4 expression decreased 26 
initially, and  remained  low until Day 21 when levels increased  to 4.6 ± 0.06. 27 
On PL, ITGA4 expression decreased  on Day 1 and  remained  at similar levels 28 












Figure 81: hES-MP integrin expression.  
Data are mRNA levels of genes of interest and are represented as level of expression 
normalised to beta-2 microglobulin and to Day 0. Two donors were used, and each sample 
was run in duplicate 
 1 
 2 
ITGA5 levels on Si-CaP increased  on Day 1 to 25.4 ± 0.62, where expression 3 
was 136-fold  greater than on any other substrate shown in  Figure 82. 4 
Expression continued  to increase on Day 7 to 36.9 ± 0.90 and  then decreased  5 
on Day 14. By Day 21 levels of ITGA5 were similar to Day 0 (0.16 ±0.001). On 6 
HA ITGA5 d id  not increase until Day 7 (65.8-fold), after which levels 7 
increased  at a similar rate to 23.9 ± 0.31 on Day 14, by Day 21 ITGA5 levels 8 
decreased  to 0.84 ± 0.01.  On PL+OS ITGA5 expression remained  low, until 9 
Day 14, when it increased  to 22.9 ± 0.89, on Day 21, levels decreased  to 4.64 ± 10 
0.07, similar to levels of ITGA5 seen on Si-CaP and HA at this time. On PL 11 
expression increased  slightly on Day 7, to 1.48 ± 0.10 but remained  less than 12 
1 at all other time points. 13 
On Si-CaP and HA, levels of ITGAV  increased  over 14 days, reaching 48.7 ± 14 
0.24 and  32.5 ± 2.7 respectively. Initially levels on Si-CaP increased  at a 15 
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greater rate (21.3-fold) compared  to HA (3.9-fold). Throughout culture, levels 1 
of ITGAV  were consistently higher on Si-CaP than on HA. On Day 21, ITGAV  2 
on both HA and Si-CaP decreased , yet were both at least 10-fold  greater than 3 
on PL. On PL+OS ITGAV  expression initially, then increased  to 3-.4 ± 0.3 on 4 
Day 7, levels remained  high on Day 14 then increased  further to 33.8 ± 0.05 5 
on Day 21. On PL, ITGAV  increased  slightly on Day 7, but remained  less than 6 





Figure 82: hES-MP integrin expression.  
Data are mRNA levels of genes of interest and are represented as level of expression 
normalised to beta-2 microglobulin and to Day 0. Two donors were used, and each sample 
was run in duplicate 
 9 
 10 
ITGB1 expression increased  over time on PL+OS, Si-CaP and HA. On Si-Cap, 11 
levels of ITGB1 were consistently higher than on all other substrates 12 
including HA, and  by Day 21 Si-CaP was 1.43-fold  greater than HA, and 13 
19.9-fold  greater than PL. On PL+OS expression of ITGB1 was initially low 14 
(4.35 ± 0.03 until Day 7) then increased  sharply on Day 14 (5.2-fold), after 15 
which the rate of expression slowed  and was highest on Day 21 at 24.5 ± 0.48. 16 
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On PL, ITGB1 also remained  low until Day 14, where it increased  slightly to 1 
4.2 ± 0.02, but by Day 21 expression decreased  to 2.65 ± 0.03. 2 
ITGB3 expression on PL+OS increased  3.9-fold  on Day 7, by Day 14 levels 3 
were greater than on any other substrate 5.8 ± 0.09, levels of ITGB3 continued 4 
to increase, and  were highest on Day 21 9.65 ± 0.05. On Si-CaP expression 5 
was also initially low, and  decreased  to 0.78 ± 0.01 on Day 7, however levels 6 
increased  21.7-fold  on Day 14, and  reached  2.29 ± 0 on Day 21. On HA, 7 
ITGB3 decreased  on Day 1 to 0.16 ± 0.004 and  then increased , to 18-fold 8 
greater than Si-CaP on Day 7, by Day 14 levels of ITGB3 decreased  again 9 
then reached 6.08 ± 0.12 on Day 21. On PL, expression of ITGB3 decreased  on 10 
Day 1 and  remained  low thereafter. 11 
 12 
6.2.7 ADMSC integrin expression 13 
 14 
Expression of ITGA1 increased  in a linear fashion on Si-CaP on days 1 to 14, 15 
where levels reached 46.37 ± 0.23; on Day 21 expression decreased  to 45.73 ± 16 
0, shown in Figure 83. On HA ITGA1 expression was low (less than 0) until 17 
Day 14 when it increased  greatly to 18.07 ± 0.62. On Day 21 ITGA1 increased 18 
2.3-fold , but expression of ITGA1 on HA remained  lower than Si-CaP at all 19 
time points. A similar trend  in expression was seen on PL+OS, initially low 20 
until Day 14 (27.3 ± 1.47) after which it increased  to 63.14 ± 10.7 on Day 21, 21 
higher than on any other substrate. On PL expression of ITGA1 remained  less 22 
than 1 over 21 days. 23 
 24 
On both HA and Si-CaP ITGA2 expression increased  at similar rates over 21 25 
days, and  reached levels of 32.33 ± 0.15 and  24 ± 0 on Day 21 respectively. At 26 
all time points cells on Si-CaP showed greater expression of ITGA2 compared 27 
with HA and PL+OS. On PL+OS ITGA2 expression d id  not increase until 28 
Day 21, where it reached 10.05 ± 2. On PL ITGA2 expression increased  on 29 
days 7 and  14 reaching 3.83 ± 0.34, on Day 21 levels decreased  0. 30 
 31 
On PL expression of ITGA3 d id  not vary by more than 0.5 and  remained  less 32 
than 1 at all time points after Day 0. On HA, ITGA3 expression increased  5.1- 33 
fold  on Day 1 (15.6-fold  higher than any other substrate at this time). 34 
Expression levels decreased  to 0.02 ± 0.001 on Day 14 and  by Day 21 were 0. 35 
On Si-CaP ITGA3 expression decreased  initially to 0.33 ± 0.15, then increased 36 
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sharply on Day 7 to 10.53 ± 0.51 (1.8-fold  higher than PL+OS). On days 14 1 
and  21 expression decreased  to 1.54 ± 0.02 and  0.18 ± 0.02 respectively. On 2 
PL+OS expression decreased  on Day 1, then increased  on Day 7, 28-fold . By 3 
Day 14 levels of ITGA3 d ropped slightly and  then increased  to 13.22 ± 0.26 4 
on Day 21. 5 
 6 
ITGA4 expression on Si-CaP increased  on Day 1, 4.24-fold  then decreased  on 7 
Day 7 to 3.69 ± 0.05. On days 14 and  21 levels continued  to decrease and 8 
were 1.25 ± 0.05 on Day 21. On HA, ITGA4 expression followed a similar 9 
trend  but peaked later, on Day 7 (3.49 ± 0.05). Levels decreased  on Day 14, 10 
but were higher than on any other substrate at this time point, on Day 21 11 
expression levels dropped to 1.11 ± 0.02. On PL+OS, ITGA4 expression 12 
decreased  on days 1 and  7, then increased  to 0.95 ± 0.12 on Day 14, and 13 
peaked on Day 21 at 2.01 ± 0.11. ITGA4 expression on PL, was lower than on 14 
PL+OS, yet followed a similar trend , decreasing initially, then increasing to 15 

























Figure 83: ADMSC integrin expression.  
Data are mRNA levels of genes of interest and are represented as level of expression 
normalised to beta-2 microglobulin and to Day 0. Two donors were used, and each sample 
was run in duplicate 
 
 1 
ITGA5 expression on Si-CaP and HA increased  on Day 1 (25.5- and  6.7-fold), 2 
and  levels continued  to increase on Day 7, reaching 42.8 ± 1.04 and  21.5 ± 2.0 3 
respectively, shown in Figure 84. At this point cells on both substrates had 4 
4.17-fold  greater ITGA5 expression than PL and PL+OS. On Day 14 5 
expression decreased  to 5.8 ± 0.11 on HA and 10.7 ± 2.7 on Si-CaP. ITGA5 6 
expression on Day 21 decreased  on Si-CaP to 2.98 ± 0.03, but increased  on 7 
HA to 10.06 ± 0.19. On PL+OS expression initially increased  6-fold , then 8 
dropped to 5.83 ± 0.54 on Day 7. On Day 14 levels increased  7.3-fold  and  9 
continued  to increase to 25.19 ± 0.25 on Day 21. On PL expression of ITGA5 10 
fluctuated  increasing on days 1 and  14, but decreasing on Day 7; expression 11 




Expression of ITGAV  increased  35.9-fold  on Si-Cap on Day 1, and  then 1 
increased  to 58.2 ± 2.9 on Day 7 (1.12-fold  higher than on any substrates at 2 
any time point), on Day 14 levels decreased  to 13.23 ± 1.6 then increased  3 
slightly on Day 21 to 18.0 ± 0.44. On PL+OS expression followed a similar 4 
trend , increasing on days 1 and  7, reaching 51.93 ± 5.08, then decreasing 5 
sharply on Day 14 to 0.52 ± 0.002 and  then decreased  further on Day 21 to 0. 6 
On HA, expression increased  at a slower rate on Day 1 (3.75-fold) but 7 
increased  rapid ly on Day 7 to 49.87 ± 0.24.  On Day 14 levels of ITGAV  8 
decreased  to 10.41 ± 0.4 and  remained  at a similar level on Day 21. On PL 9 
ITGAV  expression increased  to 19.6 ± 0.1 on Day 7 then decreased  on Day 14 10 
to 2.0 ± 0.1, by Day 21 expression of ITGAV  increased  to 13.23. 11 
 12 
On PL and PL+OS expression of ITGB1 increased  over time, reaching 15.19 ± 13 
0.15 and  33.48 ± 0.32 respectively. On HA expression of ITGB1 increased 14 
3.95-fold  then increased  more gradually on days 7 and  14, to 13.55 ± 0.2 and  15 
21.48 ± 0.31 respectively. By Day 21 expression increased  slightly and  was 16 
1.58 –fold  greater than PL, but 0.72-fold  less than PL+OS. On Si-CaP 17 
expression increased  rapid ly (24.42-fold) on Day 1, then slowed to reach 18 
25.82 ± 0.5 on Day 7. By Day 14, expression decreased  to 17.45 ± 0.09, by Day 19 
21 ITGB1 expression increased  sharply and  reached 27.1 ± 0.13. 20 
 21 
On PL+OS, ITGAB3 expression d id  not increase until Day 7, when it 22 
increased  3.42-fold  to 5.08 ± 0.1. ITGAB3 levels continued  to increase at a 23 
similar rate and  by Day 21 reached 10.78 ± 1.26. On Si-Cap, ITGB3 expression 24 
increased  rapid ly, 12-fold  on Day 1 and  then increased  to 12.64 ±0.18, on Day 25 
7. By Day 14 levels reached were 12.295- and  2.23-fold  greater than PL and 26 
PL+OS respectively).the highest expression of ITGB3 was seen on Si-Cap on 27 
Day 21 (18.32 ± 0). On HA, expression increased  5.5-fold  on Day 1 and  by 28 
Day 7 levels of ITGB3 on HA were 1.13-fold  higher than on any other 29 
substrate at this time point. On Day 14 expression increased  to 16.25 ± 3.01, 30 
then decreased  to 13.98 ± 0.27 on Day 21. Expression of ITGB3 remained 31 









Figure 84: ADMSC integrin expression.  
Data are mRNA levels of genes of interest and are represented as level of expression 
normalised to beta-2 microglobulin and to Day 0. Two donors were used, and each sample 









6.3 Discussion 2 
 3 
Cell-substrate interactions are critical for the clinical success of a bone graft, 4 
as they determine integration with the host tissue. Early signals were shown 5 
to d irect d ifferentiation of uncommitted  cells within 24 hours upon Si-CaP 6 
and  HA. Further examination  of the interactions between mesenchymal stem 7 
cells and  these substrates demonstrated  that the cells were morphologically 8 
d istinct, and  showed d ifferential integrin expression profiles when compared 9 




Visualisation of cell morphology upon d ifferent substrates revealed  d istinct 14 
morphologies and  d ifferences in focal adhesion (FA) number, size, and  15 
d istribution (visualised  through vinculin staining) and  in cytoskeletal 16 
organisation (visualised  as actin staining). Whether in vivo or in vitro, cells are 17 
rarely in d irect contact with substrates, but instead  interact with an adsorbed 18 
protein layer. Nonetheless, the surface chemistry of the substrates 19 
determines the type, quantity and  conformation of protein adsorbed . As a 20 
result, d ifferences in adhesion and  morphology may be ultimately attributed 21 
to the substrates‘ structure and  composition. 22 
 23 
Cells adhere to the protein layer via integrins; these receptors bind  to specific 24 
motifs in proteins such as the RGD sequence found in fibronectin and  25 
collagen type I (Siebers et al. 2005).  Integrins that are not bound to ECM 26 
ligands are generally d istributed  d iffusely over the cell surface, and  27 
association with the actin cytoskeleton is only induced  upon binding to a 28 
ligand. Once bound to the ECM, integrins cluster together into focal contacts, 29 
which are composed  of cytoskeletal proteins, adapter molecules and  kinases. 30 
Vinculin is a key component of focal adhesions; along with other adapter 31 
proteins it links integrins to the actin cytoskeleton, and  functions to stabilse 32 
focal adhesions (Ziegler et al. 2006). 33 
Vinculin staining was detected  in all cell types on each  substrate, yet the size 34 
and  number of vinculin containing FAs varied  on d ifferent substrates 35 
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between each cell type.  MSC and hES-MP displayed  similar patterns of 1 
staining, whereas while ADMSC showed a similar morphology to the other 2 
MSC types, yet the pattern of staining was clearly d ifferent; with vinculin 3 
staining localised  to the cell periphery and  and  strong actin detected 4 
throughout the cells. In all cell types FA were smaller, and  more numerous 5 
on Si-CaP and HA when compared  to PL+OS and PL. Small FAs are 6 
indicative of motile cells (Anselme 2000) whereas larger more pronounced 7 
FAs, such as seen in ADMSC on PL+OS at 48 hours, suggest sessile cells.  8 
The size and  d istribution of FAs regulate cell shape and  spreading (C. S. 9 
Chen et al. 2003), which in turn have been shown to d irectly influence cell 10 
fate (Kilian et al. 2010; Sun et al. 2012). These results have been confirmed by 11 
several recent studies, which have manipulated  cell shape through 12 
controlling the size and  shape of adhesive islands. These studies 13 
demonstrated  multipotent cells on adhesive islands will p referentially 14 
d ifferentiate into osteoblasts if the island  promotes cell spreading, for 15 
example larger islands with defined  edges, whereas smaller islands with 16 
rounded edges induce an ad ipogenic phenotype (McBeath et al. 2004; Kilian 17 
et al. 2010). In vivo, ad ipocytes are spherical in shape, as this provides 18 
the most efficient surface area to volume ratio for  lipid  storage, the smaller, 19 
rounded islands minimise cell spreading and  focal adhesion formation, and 20 
as a result the preferential spherical phenotype is maintained  (S. Murphy et 21 
al. 2010).  22 
The substrates examined in this chapter d id  not contain cont rolled adhesive 23 
areas; instead , adsorption of adhesive proteins was purely determined  by the 24 
substrate‘s surface chemistry. Hydroxyapatite consists of a hexagonal 25 
arrangement of calcium (Ca2+) and  phosphate (PO4
3-) ions around columns of 26 
monovalent hydroxyl (OH -) ions. Whereas, the inclusion of silicate ions in 27 
silicate substituted  calcium phosphate (Si-CaP) alters this well organised 28 
structure, which has been shown to enhance its bioactivity through increased  29 
d issolution rates and  protein adsorption, which  are known to occur after 24 30 
hours in culture (Botelho 2005). 31 
 32 
Results shown above show clear d ifferences in cell morphology between 24 33 
and  48 hours after cell seeding.  Cell shape varied  on each substrate, and  at 34 
d ifferent time points but no substrate specific morphologies could  be 35 
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identified . hES-MP were larger on Si-CaP than on HA, yet this was less 1 
apparent in the other cell types.  Cells were notably larger and  more 2 
flattened  on Si-CaP and HA after 48 hours. However, on PL and PL+OS cells 3 
appeared  to be of similar size at both time points. 4 
The increased  number of FAs and  larger cells observed  on Si-CaP, compared 5 
to HA, indicate greater sites of ligand binding, which may be due to 6 
adsorption of protein in a preferential conformation or due a greater quantity 7 
of adsorbed  protein.  This is consistence with previous studies comparing 8 
protein adsorption on Si-CaP and HA (Guth et al. 2011; Guth & Buckland 9 
2005; Botelho et al. 2011; Guth, Campion, Buckland & Hing 2010a). 10 
Focal adhesions not only anchor cells to proteins or substrates but, when 11 
coupled  to the cytoskeleton, can also transfer force and  regulatory signals 12 
between the ECM and the cell.  13 
Cells transduce these signals through cell architecture, in a manner 14 
dependent upon tensional integrity or ‗tensegrity‘ (C. S. Chen & Ingber 15 
1999). A principal that is evident in the structural organisation of the 16 
musculoskeletal system and  its components, down to single cells (Ingber 17 
2010).   18 
Cells attached  to substrates via integrin clusters within FAs, these sites act as 19 
anchors, allowing cells to generate tension within the cytoskeleton through 20 
an actomysin filament slid ing mechanism (C. S. Chen & Ingber 1999). This 21 
increases cytoskeletal stress, which has been shown to influence cell fate 22 
(McBeath et al. 2004).  23 
In each cell type on Si-CaP and HA at 48 hours, cell morphology was similar; 24 
cells appeared  to be stretched  between areas of attachment, with areas of 25 
strong actin staining between focal adhesions. It is possible that the 26 
conformation of proteins, on HA and Si-CaP, are adsorbed  in a particular 27 
d istribution that encourages cells to generate cytoskeletal tension, acting as a 28 
regulator of transcription, driving cell fate. 29 
 30 
Integrin signalling 31 
Integrins represent a major family of transmembrane, cell-surface receptors, 32 
composed  of non-covalently bound α- and β-subunits (Ingber 2003). Each 33 
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subunit contains a large extracellular domain, a transmembrane region and  a 1 
small intracellular region. The extracellular domain interacts d irectly with 2 
ECM proteins, such as fibronectin, laminin, vitronectin and  collagen type I. 3 
The intracellular region interacts with signal transmission molecules and  4 
cytoskeletal proteins to regulate multiple cell functions, including; signal 5 
transduction, cytoskeletal remodeling, cell motility, migration, apoptosis, cell 6 
proliferation and  cell adhesion (Clark & J. S. J. Brugge 1995; Giancotti 1999). 7 
As the key receptors connecting the cytoskeleton to the extracellular matrix 8 
(ECM), integrins play a critical role in bone formation and  osteogenic 9 
d ifferentiation.  10 
Integrin expression in mesenchymal stem cells (Docheva et al. 2007) and  in 11 
mature osteoblasts (Anselme 2000) has been well documented , yet the 12 
expression of integrins during osteoblast d ifferentiation remains poorly 13 
understood. This is largely due to d ifferent detection methods resulting in 14 
contradictory results.  15 
Fluorescence activated  cell sorting (FACS) and  flow cytometry are commonly 16 
used , and  provide accurate and  rapid  results; immunocytochemistry and 17 
western blotting provide information regarding localisation and  quantity of 18 
expression however these techniques are often unsuitable to analyse 19 
expression over time courses in culture. Although few studies have relied  on 20 
RNA based  detection, PCR provides inexpensive, readily reproducible, clear 21 
insight into gene expression levels.  22 
Results from integrin gene expression analysis of 11 α and 8 β subunits (shown 23 
here) revealed  upregulation of α1, α2, α3, α4, α5, αV, β1 and  β3 subunits in all three 24 
cell types analysed . No change (defined  as a change of <1 relative expression 25 
units) was detected  in α6, α7, α8, α10, α11, β2, β4, β5, β6, β7 and  β8 integrins. 26 
 27 
Expression of integrins varied  between substrates, and  significant d ifferences 28 
were seen between expression on the calcium phosphate based  substrates 29 
and  on tissue culture plastic.  In general subunit expression on PL d id  not 30 
vary significantly, on PL+OS integrin expression appeared  lower and 31 
increased  later on when compared  to both Si-CaP and HA. Differences were 32 
also noted  between Si-CaP and HA and the expression of all subunits, with 33 
the exception of α3, was higher and  increased  earlier on Si-CaP.  The 34 
d iscrepancies observed  in expression levels between the calcium phosphate 35 
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based  substrates are of particular interest. The attachment of MSC is 1 
predominately mediated  by β1 (Docheva et al. 2007). Expression of β1 was 2 
significantly higher on Si-CaP compared  with HA up to day 7, which may 3 
explain the higher levels of attachment observed  on Si-CaP in the previous 4 
chapter. Differences in integrin expression have also been shown to affect the 5 
timing and  level of gene expression (Gronthos, Simmons, et al. 2001b; 6 
Hamidouche et al. 2009), which may explain the earlier, greater increase in 7 
osteoblast related  genes RUNX2 and COL1A1, on Si-CaP when compared  to 8 
HA.  9 
Integrin expression levels varied  significantly on Si-CaP and HA, yet the 10 
results from the previous chapter d id  not show such significant d iffer ences in 11 
levels of protein production or mineralisation.  This may be attributed  to the 12 
low sample number (n=2), however, expression in each cell type appeared 13 
very similar, suggesting these result may reflect true changes in integrin 14 
levels. 15 
The initial expression of intgerins on each substrate is likely to be determined 16 
by the type of protein adsorbed  onto the substrates surface. Both HA and Si- 17 
CaP have been shown to absorb fibronectin and  vitronectin from fetal bovine 18 
serum (FBS) in culture media, which are recognised  by α3β1, α4β1, α5β1 and αVβ3. 19 
Expression of these subunits were all upregulated  on day 1 on both Si-CaP 20 
and  HA, suggesting these proteins were adsorbed  onto the surface of these 21 
substrates, provid ing initial sites of attachment for cells.  The αVβ3 22 
heterodimer also recognises the RGD sequence within bone sialoprotein and 23 
osteopontin- proteins secreted  by osteoblasts. The expression of αV and β3 24 
increased  over time in each cell type, consistent with production of these 25 
osteoblast related  genes. Collagen type I is recognised  by α1β1 and α2β1, 26 
expression of these subunits also increased  over time and reached the 27 
greatest levels on day 21. Collagen type I is not found in FBS but is secreted 28 
by mature osteoblasts, the timing of expression of these integrins is  29 
consistent with collagen type I production shown in the previous chapter.  30 
Despite conflicting results from different studies, und ifferentiated  human 31 
MSC are generally thought to express α1, α2, α3, α4, α5, α6, α7, αv, β1, β3, and  β5 32 
whereas α1, α2, α3, α4, αv, β1, and  β3 have been detected  in osteoblasts. The 33 
results shown above are consistent with these results from other studies, and 34 
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although the β5 subunit was initially detected  in each cell type prior to 1 
d ifferentiation was not upregulated  on any substrate. 2 
Integrin expression is dynamic and  alters in response to variety of factors. 3 
The composition and  topography of orthopedic implants has been shown to 4 
impact cell adhesion and  expression of integrin subunits in osteoblasts.   5 
Osteoblast adhesion is greater on calcium phosphate based  materials such as 6 
HA, when compared  to on titanium (Kilpadi et al. 2001). Yet, integrin 7 
expression patterns on these substrates are quite similar: expression of α2, α3, 8 
α4, α6, αV, β1 and  β3 subunits have been shown on titanium based  alloys, 9 
whereas on cobalt-chrome-molybdenum alloys expression  of α3, α6 and  β3 10 
subunits were not detected  (R. K. Sinha & Tuan 1996). With the exception of 11 
α6 all of these subunits were detected  in MSC, hES-MP and ADMSC on both 12 
Si-CaP and HA. 13 
The surface topography of substrates is known to significantly affect cellular 14 
attachment, and  behavior as d iscussed  in the previous chapter. Yet, studies 15 
comparing integrin expression on surfaces with smooth and  rough 16 
topographies have conflicting results. Integrins α3 and α6 were not detected  in 17 
primary osteoblasts (R. K. Sinha & Tuan 1996), yet were found  on U2OS 18 
(human osteosarcoma cell line) cells on rough titanium  (P. J. ter Brugge, 19 
Dieudonne, et al. 2002a). In rat marrow cells α5 and  α6 were upregulated  (P. J. 20 
ter Brugge, Torensma, et al. 2002b) whereas in MG-63 (human osteosarcoma 21 
cell line) cells expression of α2, α3, α5, β1 and  β3 were seen yet α6 was not 22 
detected  (Lange et al. 2002). Difficulties in comparing expression in these 23 
studies arise from the use of d ifferent cell types, and  substrate compositions.  24 
Differential integrin expression involved  in cell attachment may also be 25 
attributed  to d ifferential protein adsorption , which can be influenced  by 26 
topography. For example, altered topography can cause changes in surface 27 
wettability, impacting d irectly upon protein adsorption (Siebers et al. 2005).  28 
Integrin expression is not only affected  by quantity of protein but also the 29 
conformation and  type of protein absorbed . On uncoated  polystyrene, 30 
osteoblasts express subunits α2, α4, α6, αV, β1 and  β3. When cultured  on 31 
fibronectin coated  polystyrene, α2, α6, and  αv expression is lost and  α3 and α5 32 
are expressed . Osteoblasts on collagen type I coated polystyrene, express 33 
subunit α3 instead  of subunit α6, and  on laminin coated  polystyrene α4, α6, αv, 34 
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and β1 subunits are expressed  (R. K. Sinha & Tuan 1996). 1 
These integrin subunits recognise specific sequences within these ECM 2 
proteins, and  can impact on cell adhesion, and  behavior. Irrespective of the 3 
composition of the substrate that is coated  (glass, titanium, titanium alloy, or 4 
tissue culture polystyrene) fibronectin consistently increases adhesion, 5 
proliferation and  d ifferentiation of osteoblasts (Cowles et al. 2000; Siebers et 6 
al. 2005). Conversely, coating titanium with collagen type I d id  not increase 7 
proliferation or d ifferentiation of osteoblasts (Becker et al. 2002). Whereas 8 
collagen type I coated  polystyrene increased  adhesion, spreading, and 9 
proliferation of osteoblasts and  d ifferentiation of MSC (Cowles et al. 2000; 10 
Salasznyk et al. 2004). Vitronectin has been shown to be a potent inducer of 11 
osteogenic d ifferentiation in MSC (Salasznyk et al. 2004), yet a decrease in 12 
adhesion was seen in osteoprogenitors on vitronectin when compared  to 13 
uncoated  polystyrene (Verrier et al. 2002).  14 
On Si-CaP and HA expression of integrin subunits that recognise fibronectin, 15 
vitronectin, laminin and  collagen type I were upregulated , consistent with 16 
previous studies, which have confirmed the adsorption of these proteins in 17 
vitro onto these substrates (Guth et al. 2011; Guth & Buckland 2005; Botelho 18 
et al. 2011; Guth, Campion, Buckland & Hing 2010a). 19 
Fibronectin, vitronectin, laminin and  collagen type I all contain a binding 20 
sequence recognised  by αvβ3, known as the RGD sequence. In collagen type I, 21 
however, this site is only exposed  after proteolytic processing (Davis 1992).  22 
The osteogenic effect of proteins containing the RGD sequence has been 23 
clearly shown, and  research has shown increased  biocompat ibility of 24 
orthopedic implants by coating substrates with short peptides containing this 25 
sequence (Huang et al. 2003; Hersel et al. 2003; Kantlehner et al. 2000; 26 
Schliephake et al. 2002; Ferris et al. 1999). However, the biological activity of 27 
these short peptides is less than that of the whole protein, and  over -coating 28 
of the substrates with peptides can lead  to impaired  motility (LeBaron & 29 
Athanasiou 2000). Therefore substrates such as Si-CaP and HA, that 30 
encourage adsorption of complete proteins onto their surfaces naturally, may 31 
be preferential to utilising such peptides. 32 
The majority of these results focused  on observational integrin expression in 33 
mature osteoblasts or cell lines. However, integrin expression can be highly 34 
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dynamic, changing as adsorbed  proteins are degraded  or replaced  by other 1 
proteins, secreted  by osteoblasts. Studies examining the requirement of 2 
certain integrins during osteogenic d ifferentiation have provided  more 3 
relevant data with regard  to improving and  understanding bioactivity of 4 
current bone graft substrates. 5 
A comprehensive study on MSC showed α5 was essential during 6 
dexamethasone induced  osteogenic d ifferentiation; forced  expression of α5 7 
promoted  d ifferentiation, while silencing of the ITGA5 gene prevented 8 
differentiation, and  priming of α5β1 was sufficient to drive osteogenic 9 
d ifferentiation (Hamidouche et al. 2010). However, others have shown that 10 
osteogenic d ifferentiation on calcium phosphate and  titanium based  11 
substrates is dependent upon expression of the α2β1 integrin heterodimer (Lu 12 
& Zreiqat 2010; Olivares-Navarrete et al. 2008).   13 
Possibly the most essential integrin subunit involved  in osteogen ic 14 
differentiation is β1, which is the major subunit involved  in both substrate 15 
driven and  osteogenic supplement driven d ifferentiation (Müller et al. 2007; 16 
R. K. Sinha & Tuan 1996; Anselme 2000).  17 
The significant increase in β1 on both Si-CaP and HA suggest it is likely the 18 
key integrin subunit involved  in initiating substrate driven d ifferentiation.   19 
To confirm the role of β1 in osteogenic differentiation, it could  then be 20 
blocked using a integrin neutralising antibody, such as the one used  by Lu 21 
and  Zreiquat (Lu & Zreiqat 2010). The α subunits known to form 22 
heterodimers with β1 could  also be overexpressed , blocked and  analysed  to 23 
determine the key combination of subunits involved . 24 
Once the key integrins involved  were identified  osteogenic d ifferentiation 25 
could  be initiated  through priming the integrins using a similar monoclonal 26 
antibody used  by Hamidouche et al (Hamidouche et al. 2009). 27 
Determining key integrins involved  in substrate driven d ifferentiation could 28 
enable better design of biomaterials for bone repair, through improved 29 
design of substrates or development of small molecules to activate the 30 
required  integrins. The use of such  substrates or molecules may be used  to 31 
promote d ifferentiation of MSC in skeletal d isorders or injuries where 32 










CHAPTER SEVEN: GENERAL CONCLUSIONS AND 1 
FUTURE DIRECTIONS  2 
 3 
This thesis examined  the hypothesis that the superior bone formation 4 
associated  with Si-CaP is a result of activating the osteogenic d ifferentiation 5 
of mesenchymal stem cells.  6 
 7 
Si-CaP and HA were used  for in vitro testing in the form of dense d iscs, 8 
which were manufactured  to eliminate porosity as a potential factor that 9 
may influence cell response; as a result the only significant variable 10 
between the materials was their d ifferent surface chemistr ies. The 11 
manufacture of dense d iscs was optimised  with regard  to multiple physical 12 
properties and  production yield . Several critical parameters determining 13 
the physical properties of dense d iscs were identified  includ ing (powder 14 
weight, pressure applied , calcination, lubrication and  sintering 15 
temperature). The recommended final parameters allowed d iscs to be 16 
manufactured  to be <0.16 % porous.. 17 
Mesenchymal stem cells from three d ifferent sources (bone marrow, 18 
embryonic stem cells, and  adipose tissue) were ch osen for analysis and  19 
although were shown to d isplay d ifferences in morphology, proliferation, 20 
heterogeneity, and  surface marker expression profiles, possessed  similar 21 
d ifferentiation capacities.  22 
 23 
Bone marrow derived MSC may represent the most biologically relevant 24 
stem cell to examine osteogenic d ifferentiation, however were limited  in 25 
number and  supply, had  relatively low proliferation capacity and 26 
detectable donor variability. Mesenchymal progenitors derived  from 27 
embryonic stem cells (hES-MP) represent a far more abundant supply of 28 
multipotent cells, with significant proliferation capacity yet may not be 29 
clinically relevant due to legal and  ethical issues. Furthermore, it was 30 
demonstrated  that hES-MP are heterogeneous; containing a subpopulation 31 
of committed  progenitor cells. Adipose derived  stem cells (ADMSC) 32 
d isplayed  similar characteristics to MSC, but possessed  greater expansion 33 
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potential, greater availability and  as such may represent an attractive 1 
clinical alternative to bone marrow derived  MSC. 2 
 3 
Si-CaP and HA were shown to support attachment, proliferation and  4 
induce osteogenic d ifferentiation of MSC, hES-MP and ADMSC in the 5 
absence of osteogenic supplementation. Rates of d ifferentiation were 6 
comparable to cells cu ltured  on tissue culture plastic with soluble factors 7 
known to drive osteogenic d ifferentiation. 8 
 9 
Each cell type d ifferentiated  along the osteoblast lineage as evidenced  by 10 
upregulation of osteoblast related  genes (RUNX2, OSX, COL1A1, BGLAP 11 
and  DMP1), increased  protein production (RUNX2, collagen type I, and  12 
osteocalcin), an increase in alkaline phosphatase activity, and  production of 13 
a mineralised  matrix. 14 
 15 
ADMSC showed comparable rates of attachment, d ifferentiation and  16 
mineralisation to MSC and hES-MP; but demonstrated  greater proliferation 17 
potential and  more extensive, mature protein production on both HA and 18 
Si-CaP. As a result it is suggested  that ADMSC are a promising source of 19 
multipotent cells for clinical bone repair. 20 
 21 
Greater attachment, proliferation, gene expression, protein produ ction 22 
alkaline phosphatase and  mineralisation were detected  on Si-CaP when 23 
compared  to HA, in each cell type. Suggesting the superior bone formation 24 
seen with Si-CaP in vivo may be a result of increased  rates of d ifferentiation 25 
of multipotent stem cells. 26 
 27 
The inclusion of silicate in the calcium phosphate lattice has been 28 
previously shown to enhance d issolution rates, and  encourage preferential 29 
adsorption of proteins when compared  to stoichiometric HA (Botelho 30 
2005). Cells adhere to these proteins adsorbed  onto bone grafts via 31 
integrins, which are known to regulate cell behavior through bi-d irectional 32 
signalling (Siebers et al. 2005).  33 
 34 
To determine whether Si-CaP and  HA were eliciting their ostogenic effect 35 
via these receptors, integrin expression was analysed .  An upregulation in 36 
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expression of α1, α2, α3, α4, α5, αV, β1 and  β3 subunits was detected . These 1 
subunits recognise binding sequences within fibronectin, vitronectin, 2 
laminin and  collagen type I, proteins known to positively influence 3 
osteogenic d ifferentiation (Salasznyk et al. 2004; Müller et al. 2007). These 4 
results suggest integrin signaling may be implicated  in the substrate driven 5 
d ifferentiation observed  on Si-CaP and HA. 6 
 7 
The intracellular signalling pathways involved  in substrate driven 8 
osteogenic d ifferentiation remain unclear, largely due to the lack of 9 
research in this area but also d ifferences in the proposed  pathways 10 
involved . 11 
The ERK1/ 2 pathways is known to be key mechanotransduction pathway 12 
in activating cellular responses to mechanical stimuli (Sun et al. 2012) and  13 
has been shown to be involved  in osteoblast survival, proliferation and  14 
d ifferentiation (Salazar & Ohneda 2012). 15 
 16 
Culture of cells upon substrates in the presence of selective MEK inhibitor 17 
U0126 (Favata 1998) may determine if the MAPK/ ERK pathway is 18 
involved . However, due to the complexity of signalling cascades, it is 19 
possible that one pathway may compensate for  inhibition of another. 20 
 21 
An alternative approach would  be to use a microarray designed  to detect 22 
known molecules involved  in intracellular signalling pathways or cell 23 
lineage specification (Arrayit Corporation ARYC - Pathways™ 1993).  24 
 25 
Protein adsorption on Si-CaP and HA has been previously examined in 26 
several comprehensive studies (Guth & Buckland 2005; Guth et al. 2011; 27 
Botelho et al. 2011; Botelho et al. 2004), and  as such was not examined in 28 
this thesis. However, it may be pertinent to analyse protein adsorption  with 29 
regard to integrin expression and  examine how proteins synthesised  by 30 
osteoblasts influence their subsequent behaviour.  31 
 32 
Topography in the form of porosity has been shown to impact upon 33 
protein adsorption and  significantly cell behavior (K A Hing 2005). As Si- 34 
CaP and HA are clinically used  in the form of porous micro-granules. It 35 
may also be relevant to examine the d ifferentiation of multipotent stem 36 
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cells upon these substrates in this porous form. However, several issues 1 
regard ing cell imaging and  detachment are likely to complicate analysis of 2 
the substrates in this format. 3 
 4 
Morphologically cells on Si-CaP and HA were very d ifferent to those 5 
cultured  on PL and PL+OS.  The presence of d irectionally aligned  actin 6 
fibers and  small focal adhesions on Si-CaP and HA suggests cell may be 7 
tensionally strained  upon these substrates.   8 
 9 
Increased  cellular tension is known to positively influence osteogenic 10 
d ifferentiation, and  can result from regulating adhesion (McBeath et al. 11 
2004; Kilian et al. 2010), shear stress, (Kapur et al. 2003) and mechanical 12 
loading (S.-M. Lim et al. 2012). 13 
 14 
In microgravity, such as in space flight, bone density is lost due to lack of 15 
mechanical loading (Bikle & Halloran 1999).  It would  be interesting to 16 
determine whether the d ifferentiation observed  on Si-CaP and  HA would  17 
be influenced  in microgravity. Examining the mechanism through which 18 
this tensional strain induces d ifferentiation may provide insight into 19 
improving bone health during space flight. 20 
 21 
In conclusion, the d irected  d ifferentiation observed  on Si-CaP and HA not 22 
only provides significant implications for improving bone graft design and  23 
subsequent repair, but also may hold the answers to questions further 24 









Macros used  to count cell number and  area of staining run on Image J   3 
A. Cell counter macro 4 
 5 
setAutoThreshold("Default dark"); 6 
/ / run("Threshold ..."); 7 
setThreshold(57, 255); 8 
run("Convert to Mask"); 9 
run("Analyze Particles...", "size=10-1000 circularity=0.00-1.00 10 
show=Ellipses d isplay summarize in_situ"); 11 
 12 
B. Area quantification macro 13 
 14 
run("8-bit"); 15 
/ / run("Threshold ..."); 16 
setAutoThreshold("Default dark"); 17 
setThreshold(0, 128); 18 
run("Convert to Mask"); 19 
run("Analyze Particles...", "size=0-Infinity circularity=0.00-1.00 20 
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